



**Admission blood glucose concentration; A more powerful predictor of mortality after acute myocardial infarction than diabetes diagnosis**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001596
Article Type:	Research
Date Submitted by the Author:	06-Jul-2012
Complete List of Authors:	Gholap, Nitin; University Hospitals of Leicester, Diabetes Research; University Of Leicester, Health Sciences Mehta, Rajnikant; University Of Leicester, Health Sciences Ng, Leong; University of Leicester, Cardiovascular Sciences Davies, Melanie; University of Leicester, Cardiovascular sciences Khunti, Kamlesh; University Of Leicester, Health Sciences Squire, Iain; Leicester Royal Infirmary, Cardiovascular Sciences
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Myocardial infarction < CARDIOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Admission blood glucose concentration; A more powerful predictor of mortality after acute**  
4  
5 **myocardial infarction than diabetes diagnosis**  
6  
7

8 Nitin N Gholap<sup>1</sup>, Rajnikant L Mehta<sup>1</sup>, Leong Ng<sup>2,3</sup>, Melanie J Davies<sup>2</sup>, Kamlesh Khunti<sup>1</sup>, Iain B Squire<sup>2,3</sup>  
9

10  
11 1. Department of Health Sciences, University of Leicester, Leicester, UK  
12

13 2. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK  
14

15 3. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK  
16  
17

18 **Address for correspondence:**  
19

20 Professor Iain B Squire  
21

22 Department of Cardiovascular Sciences  
23

24 Clinical Sciences Building  
25

26 Leicester Royal Infirmary  
27

28 Leicester LE2 7LX  
29

30 UK  
31

32 Tel: +44 116 252 3125  
33

34 Fax: +44 116 252 3108  
35

36 e-mail: [is11@le.ac.uk](mailto:is11@le.ac.uk)  
37  
38  
39  
40  
41  
42

43 **Keywords:** Acute myocardial infarction, diabetes, glucose  
44  
45

46 **Word count: 3029**  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT:**

**Objective:** To explore the relative impact of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI.

**Design:** Retrospective cohort study based on the Myocardial Ischaemia National Audit Project dataset.

**Setting:** Tertiary care centre.

**Participants:** 4111 (20.3% known diabetes) consecutive patients admitted with acute myocardial infarction (58.3% STEMI) between October 2002 and September 2008.

**Primary and secondary outcome measures:** All-cause mortality at 30-days and 1-year. The relative association of admission blood glucose and of antecedent diabetes with mortality was assessed using multivariate Cox regression analysis. Furthermore we compared these relationships in patients with STEMI to those with NSTEMI.

**Results:** By 30 days and 1 year, 409 (9.9%) and 677 (16.5%) of patients died. After adjusting for covariates, diabetes did not show independent association with mortality at any time point, in the entire cohort (HR 30 days 0.93 (CI 0.63 – 1.38); 1-year 1.00 (0.77 – 1.30)) or in subgroups of STEMI (HR 30days 1.03 (0.65 – 1.64); 1 year 1.08 (0.77 – 1.51)) and non-STEMI (HR 30-days 0.62 (0.26-1.50); 1-year 0.87(0.56 – 1.36)). In contrast, after adjusting for covariates, admission glucose showed robust and independent association with mortality in the entire cohort (HR: 30 days 1.07 (1.04 – 1.10); 1-year 1.05 (1.03 – 1.08)), and in the subgroup of STEMI (30-days 1.07 (1.03 – 1.10); 1-year 1.07 (1.04 – 1.10)), and NSTEMI (HR 30 days 1.07 (1.00 - 1.14); 1-year 1.02 (0.97 - 1.06)).

**Conclusion:** Admission glucose is strongly associated with mortality in all presentations of acute myocardial infarction (AMI), irrespective of established diabetes diagnosis. The increased risk is

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

maintained up to 1 year. Future studies are required to assess the impact of active management of elevated blood glucose in improving mortality in individuals admitted with AMI.

For peer review only

## INTRODUCTION

For patients with acute myocardial infarction (AMI) the risk of adverse outcome is increased by the concomitant diagnosis of diabetes mellitus (diabetes).(1, 2) In addition, elevated blood glucose concentration, a common finding at admission in patients with AMI, is also associated with increased risk of adverse outcome, irrespective of prior diabetes.(1-8). In some studies (4, 9) the association between admission blood glucose concentration and adverse outcome was more powerful in patients without, compared to those with, prior diabetes. Indeed we previously reported more powerful association with 30-day and 1-year mortality after STEMI for admission blood glucose concentration, compared to the diagnosis of diabetes.(9)

While a causal relationship is unproven, there are numerous potential pathophysiological mechanisms by which hyperglycaemia may impart toxicity during myocardial ischaemia.(10, 11) Indeed, observational data suggest that elevated blood glucose may contribute directly to adverse outcome after AMI. Prognosis is worse for patients in whom hyperglycaemia persists in the 24-48 hours after AMI compared to those in whom blood glucose normalises.(12, 13) In patients without prior diabetes, insulin-based treatment of hyperglycaemia after AMI is associated with improved prognosis.(14, 15) Further, in randomised, controlled trials (RCTs) of intensive, insulin-based blood glucose management during admission with AMI, survival benefit was evident only when intervention effectively lowered blood glucose concentration.(16, 17)

While the relationship between blood glucose concentration and outcome after AMI has largely been described in patients with STEMI, the majority of acute coronary syndromes in contemporary practice are non-ST elevation AMI (NSTEMI). The aim of the current analysis was to compare the relative strength of association with 30-day, and 1-year mortality of antecedent diabetes diagnosis and admission blood glucose concentration in patients with STEMI and with NSTEMI, and in those with and without a history of diabetes, in a multi-ethnic population. We also assessed the relevance

1  
2  
3 of blood glucose concentration, recorded soon after admission to hospital with AMI, to mortality in  
4  
5 patients surviving to discharge.  
6  
7  
8  
9

## 10 11 **METHODS**

12  
13  
14 Data were from consecutive admissions between 1st October 2002 – 30<sup>th</sup> September 2008, to the  
15  
16 two coronary care units (CCU) of a large teaching hospital serving the population of Leicestershire,  
17  
18 UK (approximately 946,000 residents in 2004). For all patients, as part of the hospital's mandatory  
19  
20 commitment to the Myocardial Ischaemia National Audit Project (MINAP),(18) we record clinical and  
21  
22 demographic data including information on diagnosis (STEMI/NSTEMI), electrocardiographic (ECG)  
23  
24 site of infarct, medical history, coronary heart disease risk-factors, and prescribed medication. Data  
25  
26 are record-linked to mortality information (19) and include self reported coding for ethnicity, for  
27  
28 which local coverage is thorough. Approximately 10% of the local population are of South Asian  
29  
30 ethnic origin, over twice the UK national average.  
31  
32

33  
34  
35 Patients were categorised as having a diagnosis of diabetes if this was self-reported by the patient,  
36  
37 or on the basis of medication prescribed prior to admission. The blood glucose measurement used  
38  
39 for the analysis was the first recorded at the time of the index admission, assayed in the hospital  
40  
41 laboratory as part of routine investigations. All diagnoses of AMI were verified prior to submission to  
42  
43 the national MINAP database; the diagnosis of AMI was made according to the joint  
44  
45 ESC/ACCF/AHA/WHF definition.(20) Patients were categorised as STEMI or NSTEMI, according to the  
46  
47 final discharge diagnosis recorded in the MINAP database. For patients with multiple AMI admissions  
48  
49 during the study period, we considered only the first event.  
50  
51

52  
53 Survival was measured from the date of first admission to the date of death or of censoring at 30<sup>th</sup>  
54  
55 September 2009. Mortality data are supplied to the hospital on a monthly basis via the UK Office for  
56  
57  
58  
59  
60

1  
2  
3 National Statistics. The pre-defined primary outcome measure was 30-day, and 1-year, all-cause  
4 mortality..  
5  
6

7  
8 The study was approved by the local research ethics committee. The data used in this analysis were  
9 gathered during routine care and as part of the MINAP (18) mandatory requirement for all acute  
10 hospitals in England and Wales to collect data pertaining to admission with AMI.  
11  
12  
13

### 14 **Statistical analysis**

15  
16  
17  
18  
19 Baseline characteristics were compared between groups using independent two-sample t-tests for  
20 continuous variables and chi-squared tests for categorical variables. Mortality at 30 days and at 1  
21 year, in the entire cohort, and in those patients surviving to discharge, was calculated.  
22  
23  
24

25  
26 We calculated mortality proportions for patients admitted from 1<sup>st</sup> October 2002 to 30<sup>th</sup> September  
27 2008 with follow-up censored at 30<sup>th</sup> September 2009. Survival probabilities were calculated using  
28 Kaplan-Meier [KM] analyses and patient groups compared using survival analysis log rank test.  
29  
30  
31  
32  
33 Relative risk of mortality, as a function of clinical variables, was examined using Cox proportional  
34 hazards techniques. We initially assessed the unadjusted, univariate association with outcome for  
35 admission blood glucose and for diabetes, and for other potentially relevant clinical and  
36 demographic variables (age, sex, ethnicity (white European, South Asian), smoking, type of AMI  
37 (STEMI, NSTEMI), prior history (hypertension, any coronary artery disease, cerebrovascular or  
38 peripheral vascular disease), admission systolic blood pressure and heart rate, estimated glomerular  
39 filtration rate (eGFR), coronary revascularisation during index admission, pre-admission and  
40 discharge drug therapy (anti-platelet, beta-blocker, statin, angiotensin converting enzyme inhibitor/  
41 angiotensin receptor blocker), and index loop diuretic use. An interaction term representing  
42 calendar year of admission was included to adjust for potential temporal changes in the  
43 management of acute coronary artery disease.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Demographic and clinical covariates with univariate association ( $p < 0.10$ ) with mortality at 30 days, or  
4  
5 1 year were entered into multivariate models (Cox proportional hazards). Statistical significance for  
6  
7 all comparisons was set at  $p < 0.05$  (2 sided). Data are presented as hazard ratio (HR) and 95%  
8  
9 confidence intervals (CI). We used fractional polynomials to model admission glucose to account  
10  
11 for any non-linearity and assessed its independent association with mortality in subgroups with and  
12  
13 without diabetes. Analyses were carried out using SPSS version 18.  
14  
15  
16  
17  
18  
19

## 20 RESULTS

21  
22  
23 The study population was the 4111 patients admitted between 1<sup>st</sup> October 2002 – 30<sup>th</sup> September  
24  
25 2008 with discharge diagnosis of AMI (STEMI 2397, 58.3%) and for whom a minimum of 365 days  
26  
27 follow-up was available from the date of admission. For this cohort, median follow up was 912 days  
28  
29 (range 0 to 2556) days; for 3792 (92.2%) patients surviving to discharge from the index admission,  
30  
31 median follow up was 1031 (range 1 to 2556) days.  
32  
33

34  
35 Demographic details of the study population are presented in Table 1. Prior diabetes was recorded  
36  
37 in 835 (20.3%) patients: compared to those without, patients with antecedent diabetes were on  
38  
39 average older (68.6 vs 65.8 years,  $p < 0.005$ ), more likely to be female (33.9% vs 28.9%,  $p = 0.022$ ) and  
40  
41 to have prior cardiovascular co-morbidities. Presentation with NSTEMI was more prevalent in cases  
42  
43 with (50.1%), compared to those without (39.6%), prior diabetes ( $p < 0.005$ ). Mean plasma glucose  
44  
45 was higher in patients with diabetes ( $12.0 \pm 5.5$  mmol/L) compared to those without ( $7.9 \pm 3.3$   
46  
47 mmol/L) ( $p < 0.005$ ). Mean peak CK was lower in patients with diabetes.  
48  
49

50  
51 During the index admission administration of loop diuretic was more frequent (52.7% vs 33.4%,  
52  
53  $p < 0.005$ ) and, for patients with STEMI, coronary reperfusion therapy less frequent (50.2% vs 60.9%,  
54  
55  $< 0.005$ ), in patients with diabetes. Other than for slightly less use of beta-blockers and aspirin in  
56  
57  
58  
59  
60



1  
2  
3 patients with diabetes, patterns of prescription of secondary prevention therapies at discharge were  
4  
5 similar in the two groups.  
6  
7

### 8 **Mortality – Univariate analysis**

9  
10  
11 Deaths during hospitalisation, over 30-days, 1-year and the entire period of follow-up numbered 319  
12 (7.8%), 409 (9.9%), 677 (16.5%) and 1041 (25.3%) respectively. Age, female sex, higher admission  
13 heart rate, higher eGFR, lower systolic blood pressure and presentation with STEMI (compared to  
14 NSTEMI), as well as prior smoking and hypertension, each showed univariate association with  
15 mortality risk over all time periods (Table 2). Loop diuretic was associated with a 3-4 fold increase in  
16 mortality during follow-up. Survival improved over the period of observation.  
17  
18

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Prior diabetes showed strong univariate association with mortality risk over all time periods: HR 30  
days 1.40 (1.12 - 1.75); 1 year 1.58 (1.33 - 1.86); all follow-up 1.66 (1.44 , 1.90)) (Table 2). The  
strength of association between glucose and mortality was consistent at 30-days and at 1-year, each  
mmol/L increase in admission glucose concentration being associated with a 6-7% increase in hazard  
of mortality over all time periods.

### 37 **Post-discharge mortality**

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In those surviving to discharge (N=3792), 106 (2.8%), 363 (9.6%) and 726 (19.1%) died by 30-days, 1-  
year and over all follow-up (Table 2A, Supplementary data). Univariate associations with mortality  
were similar to those in the entire population. Prior diabetes showed univariate association with  
increased risk of death at all times, although this was not statistically significant at 30 days (HR 1.36,  
(0.87 - 2.12)). For admission glucose, the strength of association with post-discharge mortality was  
very similar to that in the entire cohort, with 5-7% increase risk per mmol/L increase in glucose.  
(Table 2A, Supplementary Data).

### 56 **Mortality – Multivariate analysis**

1  
2  
3 Table 3 shows the results of multivariate analysis. Age, lower admission systolic blood pressure and  
4 higher heart rate, lower eGFR, prescription of loop diuretic, and STEMI (compared to NSTEMI) each  
5 retained independent association with mortality, as did prescription of individual discharge  
6 medications. After covariate adjustment, diabetes did not retain independent association with  
7 mortality at any time. In contrast, adjustment for covariates had little impact upon the risk of  
8 mortality associated with admission glucose concentration.  
9  
10  
11  
12  
13  
14  
15

### 16 17 **Post-discharge mortality**

18  
19  
20 For patients surviving to discharge, associations between clinical variables and the risk of mortality  
21 were similar to those seen in the entire cohort (Table 3A, Supplementary data). While there was no  
22 association between prior diabetes and risk of mortality at any time (HR 30 days 0.64 (0.31 – 1.300);  
23 1 year 0.91 (0.66 – 1.26); all follow-up 1.08 (0.86 – 1.36)), blood glucose retained powerful  
24 association with the primary endpoint. This was evident at 30 days (HR per mmol/L 1.10, 95% CI 1.05  
25 – 1.15), 1 year (1.05, 1.02 – 1.08), and over all follow-up (1.04, 1.02 – 1.06)).  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Admission glucose concentration – influence on mortality in patients with or without diabetes**

35  
36  
37 We repeated multivariate analysis including a term for interaction between diabetes diagnosis and  
38 admission glucose concentration. While numerically greater in individuals without diabetes (Figure  
39 1), there was no conventional statistically significant difference in the association between mortality  
40 and admission blood glucose for patients with and without diabetes (30 days HR 1.00, (CI 0.97 –  
41 1.03, p=0.95; 1 year 0.99, (0.97 – 1.02), p=0.66; entire follow-up 0.99, (0.97 – 1.01, p=0.42)).  
42  
43  
44  
45  
46  
47  
48

### 49 **Diabetes and glucose after AMI – influence on mortality in STEMI and NSTEMI**

50  
51  
52 After adjustment for covariates, diabetes showed no statistically significant association with  
53 mortality at any time period, either for STEMI or NSTEMI (Table 4). The strength of association  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 between blood glucose and mortality was very similar in the first 30 days after STEMI or NSTEMI.

4  
5 The strength of this relationship declined with time only after NSTEMI.  
6  
7  
8  
9

## 10 11 **DISCUSSION**

12  
13 It is well known that, both prior diabetes diagnosis, and admission blood glucose concentration, are  
14 associated with adverse outcome after AMI. In this report we compared the relative association of  
15 these two measures of dysglycaemia with survival after STEMI as well as NSTEMI. Irrespective of the  
16 type of AMI, the univariate association with mortality risk for antecedent diabetes (40% excess at 30  
17 days, 55-65% thereafter) was no longer apparent after adjustment for relevant covariates including  
18 admission glucose concentration. In contrast, the excess risk associated with increasing glucose was  
19 not reduced after adjustment, was similar in those with and without known diabetes, and remained  
20 relevant in patients discharged alive from the index event.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 In our previous report of over 4000 patients with STEMI, admitted in 1993-2004,(9) the 50% increase  
34 in 30-day and 1-year mortality risk associated with known diabetes was attenuated by half on  
35 covariate adjustment and removed completely when admission blood glucose concentration was  
36 included in the analysis. The current report confirms these observations and extends them to a  
37 contemporary period, and to patients with NSTEMI as well as STEMI, in whom the strength of  
38 association between admission blood glucose concentration and 30-day mortality risk was similar,  
39 and concentration dependent. Importantly, the excess risk, around 7% for each 1mmol/L increase in  
40 admission glucose concentration, was maintained up to and beyond 1 year from the index infarction.  
41  
42 Further, this phenomenon was attenuated with time only for patients with NSTEMI, and was evident  
43 even in those patients who survived to discharge from hospital, two potentially important clinical  
44 observations. These findings are in contrast to one previous report which reported the association  
45 between admission glucose and mortality to be confined to in-hospital deaths following either  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 STEMI or NSTEMI.(8) They are however in keeping with the vast majority of reports in this area.(1-7,  
4  
5 9, 11)  
6

7  
8 In contrast to most previous reports,(1-9, 11) we observed no independent association between  
9  
10 diabetes and mortality risk after AMI. However, to our knowledge and unlike the present report,  
11  
12 none of these studies adjusted for admission blood glucose, and each reported individual  
13  
14 relationships between mortality after AMI and either diabetes diagnosis (1, 2, 4, 8) or blood glucose  
15  
16 concentration.(3-8, 11-13, 21) The current analysis and our previous study (9) are the only reports to  
17  
18 compare the relative association with outcome of both diabetes and blood glucose concentration.  
19  
20 Both studies demonstrate a much stronger relationship between survival and blood glucose, and the  
21  
22 loss of association between mortality and diabetes when blood glucose is considered.  
23  
24

25  
26 These observations are of potential clinical significance. While admission blood glucose  
27  
28 concentration after AMI is on average higher in patients with, compared to those without, known  
29  
30 diabetes,(4, 8, 9) there is considerable overlap, as seen in the current report (Figure 1). While many  
31  
32 patients presenting with AMI will have previously undiagnosed diabetes,(22) blood glucose at the  
33  
34 time of admission with AMI is not a reliable indicator of the subsequent diagnosis of diabetes.(23,  
35  
36 24) In routine practice, the management of hyperglycaemia after AMI is influenced by the presence  
37  
38 of prior diabetes diagnosis.(5) In both European(14) and North American(6) settings, the majority  
39  
40 (>65%) of patients presenting with hyperglycaemia in the context of AMI, and not previously known  
41  
42 to have diabetes, do not receive active management of blood glucose. In the presence of a true,  
43  
44 direct toxic effect upon prognosis of elevated blood glucose, failure to correct hyperglycaemia may  
45  
46 represent suboptimal clinical care, and patients without known diabetes may be particularly  
47  
48 disadvantaged. In particular, our demonstration that the relationship between glucose  
49  
50 concentration and subsequent outcome is evident in NSTEMI as well as STEMI is of clear clinical  
51  
52 relevance in terms of the overall management of patients presenting with AMI.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The strength of association between diabetes and mortality risk after AMI has been reported to  
4 increase with time from the event.(25) While we observed such a trend on univariate analysis, this  
5 was attenuated in multivariate analysis, an observation which may relate to our inclusion of blood  
6 glucose as a covariate. A previous meta-analysis suggested a stronger association between  
7 admission blood glucose and adverse outcome.(4) While we could not demonstrate formal statistical  
8 evidence of such a phenomenon, our data show convincingly that the relationship between glucose  
9 and outcome is at least as powerful in patients without known diabetes. Blood glucose soon after  
10 admission represents an easily identified, clinically relevant marker of risk after AMI, which should  
11 be assessed routinely irrespective of diabetes status.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 An important observation from this study is the persisting association between admission blood  
24 glucose concentration and mortality risk in patients surviving to discharge, in both NSTEMI and  
25 STEMI. While in keeping with the possibility that blood glucose concentration at admission reflects  
26 the degree of individual physiological stress, or is a marker of the extent of infarction, our findings  
27 are as much in keeping with a direct, adverse influence on prognosis of acute hyperglycaemia. The  
28 mechanisms by which elevated glucose may be directly cardiotoxic have been summarised  
29 elsewhere (10) and include attenuation of ischaemic preconditioning, QT prolongation, increased  
30 thrombophilia, and endothelial dysfunction. Furthermore, clinical studies overwhelmingly support a  
31 possible causal link between hyperglycaemia and adverse prognosis after AMI. Hyperglycaemia  
32 persisting at 24 hours after admission is associated with adverse outcome,(12, 13, 17).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 While observational studies show consistently the adverse association between hyperglycaemia and  
47 outcomes post AMI, results of the RCTs of active management of blood glucose have been  
48 inconsistent.(16,17) However, in such trials, effective reduction in blood glucose with an  
49 intervention after AMI was associated with improved prognosis.(16) The guidelines from  
50 professional societies in this area differ in their recommendations.(27,28) In the North American  
51 guidelines, intensive glucose control is recommended in patients with AMI and significant  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hyperglycaemia (blood glucose levels > 10.0 mmol/L) admitted in an intensive care unit.(28) In  
4  
5 contrast, the National Institute for Health and Clinical Excellence guidance recommends against  
6  
7 routine use of intensive insulin therapy to manage hyperglycaemia (blood glucose levels > 11.0  
8  
9 mmol/L) in patients with acute coronary syndrome.(27) The latter guidelines highlighted a need for  
10  
11 randomised controlled trials addressing specific gaps in knowledge this area.  
12

13  
14  
15 Our report is subject to the limitations inherent in all observational cohort studies. Blood glucose  
16  
17 concentration used in this analysis was that first recorded for the index admission, and is likely to  
18  
19 have varied in timing relative to symptom onset. Our database lacks information on left ventricular  
20  
21 (LV) ejection fraction, evidence of heart failure, and a number of other potentially relevant variables.  
22  
23 Further, we have no information regarding the number of patients who were given a diagnosis of  
24  
25 diabetes during, or subsequent to, the index admission. However, if elevated glucose contributes  
26  
27 directly to prognosis, active management is likely to confer greater benefit when delivered as early  
28  
29 as possible, irrespective of subsequent diabetes status. Thus we suggest the first recorded blood  
30  
31 glucose concentration to be highly relevant to guiding appropriate management in individual  
32  
33 patients, irrespective of residual LV function. While we have no information on interventions or  
34  
35 changes to therapy after discharge, it is unlikely that these impacted on outcome in a major way, as  
36  
37 the strongest association between mortality and glucose was in the first 30 days.  
38  
39

40  
41  
42 In summary, admission blood glucose concentration is a powerful, routinely available marker of  
43  
44 mortality risk after AMI. After adjustment for admission blood glucose, known diabetes is not  
45  
46 associated with adverse outcome. The association between blood glucose concentration and  
47  
48 mortality risk is of similar magnitude in patients with and without known diabetes, is evident for  
49  
50 NSTEMI as well as STEMI, and persists beyond 1 year from the index event, including in patients  
51  
52 surviving to discharge. Future studies are merited of the impact of active management of blood  
53  
54 glucose in patients with all presentations of acute coronary artery disease, irrespective of diabetes  
55  
56 diagnosis.  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus

- Robust associations is seen for both measures of glycaemia - the diagnosis of diabetes, and elevated blood glucose levels on admission, with poor outcomes in patients with ST elevation myocardial infarction (STEMI).
- We explored the less known, relative association of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with STEMI and NSTEMI.

### Key Messages:

- In patients with both STEMI as well as NSTEMI, admission glucose is more strongly associated with mortality than is antecedent diabetes diagnosis.
- The increased risk associated with admission glucose is evident during the index admission, at 30 days, one year and beyond and is apparent in those surviving to discharge.
- Conversely, after multivariate adjustment for covariates, including admission glucose is not associated with mortality.

### Strengths and limitations of this study

- This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary clinical practice in a tertiary care centre.
- A statistically robust association was seen for admission glucose with both short and longer term mortality after adjusting for many important confounders.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Our data lacks information on glucose lowering intervention, patients with undiagnosed diabetes and other potentially relevant variables which were not considered in the analysis.

For peer review only



Table 1: Baseline characteristics at admission stratified by diabetes status

	All n=4111	Known DM n= 835 (20.3%)	Not Known DM n=3276 (79.7%)	P Value*	Missing Value (%)
<b>Demography</b>					
Age (years)	66.4 (13.3)	68.6 (11.8)	65.8 (13.6)	<0.005	0.0
Women (%)	1224 (29.8)	276 (33.1)	948 (28.9)	0.022	0.0
<b>Ethnicity (%)</b>					
White European	3381 (82.2%)	545 (16.1)	2836 (86.6)	<0.005	0.0
South Asian	730 ( 17.8%)	290 (39.7%)	440 (60.3%)		0.0
<b>Medical History (%)</b>					
Hypertension	2048 (50.3)	584 (70.0)	1464 (45.0)	<0.005	1.0
Current/Ex Smoker	1366 (35.7)	282 (36.8)	1084 (35.5)	0.527	7.1
Coronary Heart Disease§	491 (12.1)	149 (17.9)	342 (10.6)	<0.005	0.9
CVA	254 (6.3)	86 (10.3)	168 (5.2)	<0.005	1.2
PVD	154 (3.8)	42 (5.0)	112 (3.5)	0.041	1.2
Heart Failure	190 (4.7)	76 (9.1)	114 (3.5)	<0.005	1.2
<b>Type of Infarction (%)</b>					
STEMI	2397 (58.3)	417 (49.9)	1980 (60.4)	<0.005	0.0
nSTEMI	1714 (41.7)	418 (50.1)	1296 (39.6)		
<b>Physical Examination</b>					
Heart Rate (beats/min)	81.1 (24.3)	85.5 (25.3)	80.0 (24.0)	<0.005	1.5
SBP (mmHg)	136.5 (28.4)	137.7 (30.7)	136.2 (27.8)	0.202	1.0
<b>Biochemical Data</b>					
Peak CK (IU/L, Normal range < 200)	1113.5 (1810.4)	939.9 (1279.3)	1156.4 (1917)	<0.005	7.6
Creatinine (µmol/L)	116.4 (63.8)	128.8 (76.1)	113.1 (59.8)	<0.005	16.8
eGFR (mL/min)	63.0 (22.2)	57.7 (23.6)	64.4 (21.7)	<0.005	16.6
Total cholesterol (mmol/L)	5.1 (1.3)	4.4 (1.2)	5.2 (1.3)	<0.005	16.6
Haemoglobin (g/L)	13.7 (1.9)	13.0 (1.9)	13.9 (1.8)	<0.005	66.6
Plasma glucose (mmol/L)	8.8 (4.2)	12.0 (5.5)	7.9 (3.3)	<0.005	14.9
<b>Therapies (%)</b>					
<b>Prior to index admission</b>					
Aspirin	2671 (65.0)	622 (74.5)	2049 (62.5)	<0.005	0.0
Beta blocker	990 (25.6)	265 (33.2)	725 (23.6)	<0.005	6.0
ACEI or ARB	1097 (28.3)	407 (51.0)	690 (22.5)	<0.005	5.8
Statins	1083 (28.0)	389 (48.7)	694 (22.6)	<0.005	5.8
<b>In-hospital</b>					
Reperfusion therapy #	2414 (58.7)	419 (50.2)	1995 (60.9)	<0.005	0.0
Loop diuretics	1502 (37.4)	436 (52.7)	1066 (33.4)	<0.005	2.3
<b>At discharge</b>					
Aspirin	2701 (68.1)	529 (65.3)	2172 (68.8)	0.057	3.5
Beta blocker	2513 (63.3)	483 (59.6)	2030 (64.3)	0.013	3.5
ACEI or ARB	2493 (62.9)	495 (61.0)	1998 (63.4)	0.222	3.6
Statin	2704 (67.7)	537 (65.6)	2167 (68.2)	0.167	2.8

All values are mean (SD) or number (%). \* known diabetes vs not known diabetes. DM, Diabetes Mellitus; CVA, Cerebrovascular accidents; PVD, Peripheral Vascular Disease; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; SBP, Systolic blood pressure; CK, Creatinine Kinase; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

# thrombolysis or coronary intervention (PCI or CABG) or both

**Table 2:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals)

N=4111	Mortality, N (%)		
	30 days	1 Year	All (Median 912 days)
	409 (9.95)	677 (16.47)	1041 (25.32)
<b>Admission Demographic Variable</b>			
Gender (Female vs Male)	0.535 (0.439, 0.650)	0.515 (0.443, 0.600)	0.554 (0.490, 0.627)
Age (year)	1.068 (1.059, 1.078)	1.077 (1.069, 1.084)	1.084 (1.077, 1.090)
SBP (mmHg)	0.979 (0.976, 0.983)	0.987 (0.984, 0.990)	0.992 (0.990, 0.994)
Heart Rate (beat/min)	1.010 (1.006, 1.013)	1.012 (1.009, 1.014)	1.012 (1.010, 1.014)
Total Cholesterol (mmol/L)	0.732 (0.666, 0.806)	0.765 (0.712, 0.821)	0.744 (0.703, 0.788)
Admission plasma glucose (mmol/L)	1.072 (1.052, 1.084)	1.065 (1.055, 1.076)	1.059 (1.050, 1.068)
eGFR (mL/min)	0.956 (0.951, 0.961)	0.955 (0.951, 0.959)	0.959 (0.956, 0.962)
NSTEMI vs STEMI	0.504 (0.405, 0.627)	0.736 (0.629, 0.862)	0.939 (0.830, 1.063)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.909 (0.688, 1.200)	0.846 (0.681, 1.052)	0.919 (0.780, 1.082)
2005	0.591 (0.402, 0.870)	0.652 (0.491, 0.865)	0.702 (0.564, 0.873)
2006	0.830 (0.592, 1.164)	0.696 (0.529, 0.917)	0.716 (0.572, 0.897)
2007	0.759 (0.570, 1.010)	0.678 (0.541, 0.849)	0.679 (0.558, 0.826)
2008	0.485 (0.338, 0.696)	0.551 (0.424, 0.716)	0.531 (0.415, 0.680)
Test for Linear Trend (p-value)	<0.001	<0.001	<0.001
<b>Ethnicity</b> (South Asian vs. White European)	1.013 (0.786, 1.304)	0.909 (0.741, 1.114)	0.856 (0.725, 1.012)
<b>Medical History (Yes vs No)</b>			
Smoking	1.016 (0.819, 1.259)	1.049 (0.891, 1.235)	1.160 (1.019, 1.320)
Prior Diabetes	1.400 (1.121, 1.750)	1.576 (1.331, 1.865)	1.655 (1.445, 1.896)
Prior Coronary Heart Disease §	0.862 (0.628, 1.182)	0.998 (0.791, 1.258)	1.113 (0.931, 1.330)
Prior Hypertension	1.286 (1.056, 1.567)	1.437 (1.232, 1.676)	1.472 (1.300, 1.666)
<b>Pre-Admission Medication (Yes vs No)</b>			
Aspirin	0.746 (0.613, 0.909)	0.869 (0.744, 1.015)	0.913 (0.804, 1.036)
Beta Blocker	1.385 (1.116, 1.719)	1.577 (1.338, 1.859)	1.489 (1.301, 1.703)
Statin	0.994 (0.795, 1.245)	1.129 (0.953, 1.338)	1.194 (1.041, 1.370)
ACEI or ARB	1.242 (1.002, 1.540)	1.467 (1.247, 1.726)	1.621 (1.423, 1.847)
<b>Admission treatment (Yes vs No)</b>			
Initial Reperfusion	0.616 (0.507, 0.749)	0.540 (0.464, 0.629)	0.466 (0.411, 0.527)
Loop Diuretic	3.457 (2.807, 4.256)	4.348 (3.681, 5.136)	4.052 (3.556, 4.618)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.043 (0.029, 0.062)	0.227 (0.192, 0.269)	0.439 (0.386, 0.499)
Beta Blocker	0.038 (0.025, 0.058)	0.237 (0.199, 0.282)	0.406 (0.357, 0.461)
Statin	0.043 (0.029, 0.062)	0.196 (0.165, 0.233)	0.344 (0.303, 0.390)
ACEI or ARB	0.047 (0.031, 0.700)	0.236 (0.198, 0.281)	0.469 (0.412, 0.533)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Table 3:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals).

N=4111	Mortality, N (%)		
	30 days 409 (9.95)	1 Year 677 (16.5)	All (Median 912 days) 1041 (25.3)
<b>Admission Demographics</b>			
Gender (Female vs Male)	1.268 (0.885, 1.819)	1.094 (0.865, 1.383)	1.114 (0.931, 1.332)
Age (year)	1.059 (1.040, 1.078)	1.062 (1.048, 1.075)	1.073 (1.062, 1.083)
SBP (mmHg)	0.987 (0.981, 0.992)	0.991 (0.987, 0.995)	0.993 (0.990, 0.996)
Heart Rate (beat/min)	1.007 (1.001, 1.013)	1.006 (1.002, 1.010)	1.007 (1.005, 1.010)
Admission plasma glucose (mmol/L)	1.072 (1.042, 1.104)	1.059 (1.037, 1.081)	1.053 (1.036, 1.071)
eGFR (mL/min)	0.987 (0.978, 0.996)	0.983 (0.977, 0.990)	0.988 (0.983, 0.993)
<b>nSTEMI vs STEMI</b>	0.411 (0.282, 0.597)	0.558 (0.443, 0.704)	0.700 (0.587, 0.834)
<b>Ethnicity</b> (South Asian vs White European)	1.355 (0.893, 2.057)	1.155 (0.851, 1.568)	0.996 (0.779, 1.273)
<b>Medical History (Yes vs No)</b>			
Smoking	1.125 (0.788, 1.607)	0.953 (0.749, 1.213)	0.942 (0.786, 1.130)
Prior Diabetes	0.934 (0.631, 1.382)	1.001 (0.770, 1.300)	1.134 (0.927, 1.386)
Prior Coronary Heart Disease§	0.717 (0.402, 1.278)	0.898 (0.632, 1.277)	1.111 (0.864, 1.428)
Prior Hypertension	1.291 (0.903, 1.846)	1.155 (0.913, 1.461)	1.133 (0.949, 1.353)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.944 (0.667, 1.335)	0.989 (0.781, 1.252)	1.010 (0.842, 1.213)
Beta Blocker	1.288 (0.898, 1.849)	1.363 (1.067, 1.742)	1.173 (0.970, 1.418)
Statin	0.863 (0.579, 1.286)	0.877 (0.668, 1.150)	0.918 (0.743, 1.135)
ACEI or ARB	0.719 (0.497, 1.042)	0.932 (0.728, 1.194)	1.017 (0.840, 1.232)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.416 (0.993, 2.019)	1.703 (1.322, 2.195)	1.532 (1.268, 1.851)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.297 (0.157, 0.562)	0.656 (0.479, 0.897)	0.861 (0.676, 1.097)
Beta Blocker	0.257 (0.133, 0.494)	0.564 (0.423, 0.753)	0.671 (0.544, 0.828)
Statin	0.628 (0.295, 1.339)	0.683 (0.484, 0.963)	0.629 (0.490, 0.808)
ACEI or ARB	0.470 (0.229, 0.968)	0.610 (0.443, 0.839)	0.850 (0.668, 1.081)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 4:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the subgroups of patients with STEMI and NSTEMI. Data are hazard ratio (95% confidence intervals)

N=4111		Mortality, N (%)					
STEMI	NSTEMI	30 days		1 Year		All	
2397	1714	STEMI	NSTEMI	STEMI	NSTEMI	STEMI	NSTEMI
<b>Admission Demographics</b>							
Age (year)		1.055 (1.033 - 1.077)	1.073 (1.031 - 1.116)	1.061 (1.044 - 1.078)	1.056 (1.035 - 1.079)	1.077 (1.062 - 1.091)	1.061 (1.046 - 1.077)
SBP (mmHg)		0.988 (0.982 - 0.994)	0.983 (0.970 - 0.995)	0.992 (0.987 - 0.997)	0.988 (0.982 - 0.995)	0.993 (0.989 - 0.997)	0.994 (0.990 - 0.998)
Heart Rate (beat/min)		1.008 (1.001 - 1.015)	1.008 (0.997 - 1.02)	1.008 (1.002 - 1.013)	1.007 (1.001 - 1.013)	1.008 (1.004 - 1.012)	1.007 (1.002 - 1.011)
eGFR (mL/min)		0.986 (0.975 - 0.997)	0.987 (0.969 - 1.005)	0.982 (0.974 - 0.991)	0.978 (0.968 - 0.989)	0.986 (0.979 - 0.993)	0.987 (0.979 - 0.995)
Admission plasma glucose		1.070 (1.034 - 1.107)	1.074 (1.005 - 1.148)	1.071 (1.042 - 1.10)	1.021 (0.979 - 1.066)	1.076 (1.051 - 1.10)	1.014 (0.983 - 1.047)
Prior Diabetes		1.035 (0.652 - 1.641)	0.629 (0.264 - 1.502)	1.083 (0.772 - 1.518)	0.878 (0.566 - 1.36)	1.189 (0.907 - 1.559)	1.055 (0.773 - 1.44)
<b>Admission treatment (Yes vs No)</b>							
Loop Diuretic		1.330 (0.890 - 1.989)	1.66 (0.759 - 3.629)	1.706 (1.248 - 2.333)	1.988 (1.283 - 3.081)	1.365 (1.068 - 1.745)	2.03 (1.496 - 2.756)
<b>Discharge Medication (Yes vs No)</b>							
Aspirin		0.301 (0.135 - 0.672)	0.308 (0.088 - 1.076)	0.499 (0.322 - 0.773)	0.869 (0.523 - 1.433)	0.697 (0.501 - 0.970)	1.052 (0.711 - 1.557)
Beta Blocker		0.208 (0.095 - 0.455)	0.337 (0.094 - 1.207)	0.469 (0.320 - 0.687)	0.77(0.485 - 1.222)	0.520 (0.393 - 0.698)	0.939 (0.674 - 1.308)
Statin		1.046 (0.375 - 2.918)	0.255 (0.066 - 0.992)	0.551 (0.334 - 0.908)	0.745 (0.449 - 1.237)	0.615 (0.429 - 0.880)	0.65 (0.444 - 0.951)
ACEI or ARB		0.392 (0.153 - 1.006)	0.451 (0.121 - 1.673)	0.903 (0.545 - 1.496)	0.541 (0.348 - 0.841)	1.041 (0.712 - 1.523)	0.857 (0.616 - 1.194)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

1  
2  
3 **Contributors:** NG, IS, KK conceived the idea of the study and were responsible for the design of the  
4  
5 study. NG, RM were responsible for undertaking for the data analysis and produced the tables and  
6  
7 graphs. IS, KK, MJD provided input into the data analysis. The initial draft of the manuscript was  
8  
9 prepared by NG and IS and then circulated repeatedly amongst all authors for critical revision. IS was  
10  
11 responsible for the acquisition of the data and IS, NG, RM, KK and MJD contributed to the  
12  
13 interpretation of the results.  
14

15  
16  
17 **Funding:** This research received no specific grant from any funding agency in the public, commercial  
18  
19 or not-for-profit sectors. The work in this paper is part of the research portfolio supported by the  
20  
21 Leicester NIHR Biomedical Research Unit in Cardiovascular Disease. NG has received support by the  
22  
23 National Institute for Health Research, Collaboration for Leadership in Applied Health Research and  
24  
25 Care - Leicestershire, Northamptonshire and Rutland (NIHR CLAHRC for LNR) project for a PhD.  
26

27  
28  
29 **Competing interests:** None  
30

31  
32 **Ethical approval:** The study was approved by the local research ethics committee.  
33

34  
35 **Copyright/licence for publication:** The Corresponding Author has the right to grant on behalf of all  
36  
37 authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for  
38  
39 government employees) on a worldwide basis to the BMJ Group and co-owners or contracting  
40  
41 owning societies (where published by the BMJ group on their behalf), and its Licensees to permit this  
42  
43 article (if accepted) to be published in the Heart edition and any other BMJPG products and to  
44  
45 exploit all subsidiary rights, as set out in our licence.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Malmberg K, Yusuf S, Gerstein HC, *et al.* Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry. *Circulation* 2000;102:1014-1019.
2. McGuire DK, Emanuelsson H, Granger CB, *et al.* Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO IIb study. *Eur Heart J* 2000;21:1750-1758
3. Svensson A-M, McGuire DK, Abrahamsson P, *et al.* Association between hyper- and hypoglycaemia and 2-year all-cause mortality risk in diabetic patients with acute coronary events. *Eur Heart J* 2005;26:1255-1261
4. Capes SE, Hunt D, Malmberg K, *et al.* Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000;355:773-778
5. Wahab NN, Cowden EA, Pearce NJ, *et al.* Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? *J. Am. Coll. Cardiol* 2002;40:1748- 1754
6. Kosiborod M, Rathore SS, Inzucchi SE, *et al.* Admission glucose and mortality in elderly patients hospitalised with acute myocardial infarction. *Circulation* 2005;111:3078-3086
7. Cao JJ, Hudson M, Jankowski M, *et al.* Relation of chronic and acute glycaemic control on mortality in acute myocardial infarction with diabetes mellitus. *Am J Cardiol* 2005;96:183-186

- 1  
2  
3 8. Sinnaeve PR, Steg G, Fox KAA, *et al.* Association of fasting glucose with increased short-term  
4 and 6-month mortality in ST-elevation and non ST-elevation acute coronary syndromes. *Arch*  
5  
6  
7 *Int Med* 2009;169:402-409  
8  
9
- 10 9. Squire IB, Nelson CP, Ng LL, *et al.* Prognostic value of admission blood glucose concentration  
11 and diabetes diagnosis on survival after acute myocardial infarction; Results from 4702 index  
12 cases in routine practice. *Clin Sci (London)* 2010;118:527-535  
13  
14  
15  
16
- 17 10. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. *Eur Heart J*  
18 2001;26:328-331  
19  
20  
21  
22
- 23 11. De Caterina R, Madonna R, Sourij H, *et al.* Glycaemia control in acute coronary syndromes:  
24 prognostic value and therapeutic options. *Eur Heart J* 2010;31:1557-1564  
25  
26  
27
- 28 12. Ghoyal A, Mahaffey KW, Garg J, *et al.* Prognostic significance of the change in glucose level in  
29 the first 24h after acute myocardial infarction: results from the CARDINAL study. *Eur Heart J*  
30 2006;27:1289-1297  
31  
32  
33  
34  
35
- 36 13. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for  
37 long-term prognosis after myocardial infarction even in non-diabetic patients. *Diabetes Care*  
38 1999;22:1827-1831  
39  
40  
41  
42
- 43 14. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for  
44 hyperglycaemic patients without known diabetes who present with an acute coronary  
45 syndrome. *Heart* 2007;93:1542-1546  
46  
47  
48  
49
- 50 15. Schnell O, Schafer O, Kleybrink S, *et al.* Intensification of therapeutic approaches reduces  
51 mortality in diabetic patients with acute myocardial infarction: the Munich registry. *Diabetes*  
52 *Care* 2004;27:455-460.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Malmberg K, Ryden L, Efendic S, *et al*. Randomised trial of insulin-glucose infusion followed by  
4  
5 subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI  
6  
7 study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995;26:57-65  
8  
9
- 10 17. Malmberg K, Ryden L, Wedel H, *et al*; DIGAMI 2 Investigators. Intense metabolic control by  
11  
12 means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2):  
13  
14 effects on mortality and morbidity. *Eur Heart J* 2005;26:650-661  
15  
16
- 17 18. Herrett E, Smeeth L, Walker L, *et al*; MINAP Academic group. The Myocardial Ischaemia  
18  
19 National Audit Project (MINAP) Heart 2010;96:1264-67  
20  
21
- 22 19. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly  
23  
24 admitted to hospital with heart failure in the United Kingdom: historical cohort study. *BMJ*  
25  
26 2003; 327(7414):526-31  
27  
28
- 29 20. Thygesen K, Alpert JS, White HD. The Joint ESC/ACCF/AHA/WHF Task Force for the redefinition  
30  
31 of myocardial infarction. *Eur Heart J* 2007;28:2525-2538  
32  
33
- 34 21. Garber AJ, Moghissi ES, Bransome ED Jr, *et al*; American College of Endocrinology Task Force  
35  
36 on Inpatient Diabetes Metabolic Control. *Endocr Pract* 2004;10:77-82  
37  
38
- 39 22. Kosiborod M, Inzucchi SE, Krumholz HM *et al*. Glucometrics in patients hospitalized with acute  
40  
41 myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation*  
42  
43 2008;117:1018  
44  
45
- 46 23. Norhammar A, Tenerz A, Nilsson G, *et al*. Glucose metabolism in patients with acute  
47  
48 myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
*Lancet* 2002;359:2140-2144.




- 1  
2  
3 24. Tenerz A, Lonnberg I, Berne C, *et al.* Myocardial infarction and prevalence of diabetes  
4  
5 mellitus, Is increased casual blood glucose at admission a reliable criterion for the diagnosis of  
6  
7 diabetes? *Eur Heart J* 2001;22:1102–1110  
8  
9  
10 25. De Mulder M, Oemrawsingh RH, Stam F, *et al.* Comparison of diagnostic criteria to detect  
11  
12 undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. *Heart* 2011;  
13  
14 10.1136/heartjnl-2011-300163  
15  
16  
17 26. Melchior T, Kober L, Madsen CR, *et al.* Accelerating impact of diabetes mellitus on mortality in  
18  
19 the years following an acute myocardial infarction. *Eur Heart J* 1999;20:973-978  
20  
21  
22 27. National Institute for Health and Clinical Excellence. (2011) Hyperglycaemia in acute coronary  
23  
24 syndromes: management of hyperglycaemia in people with acute coronary syndromes. (CG  
25  
26 130). London: National Institute for Health and Clinical Excellence.  
27  
28  
29 28. Deedwaniap, Kosibirod M, Barrett E *et al.* Hyperglycaemia and acute coronary syndrome. A  
30  
31 scientific Statement from the American Heart Association Diabetes Committee of the Council  
32  
33 on Nutrition, Physical activity and Metabolism. *Circulation* 2008;117:1610-9.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE LEGENDS**

Figure 1: Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The bars represent the number of people at various glucose levels. Solid lines indicate odds ratios while dotted lines indicate 95% confidence intervals. Solid bars and black lines indicate patients with diabetes. Clear bars and red lines indicate patients without Diabetes.

For peer review only



**Figure 1:** Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The **bars** represent the number of people at various glucose levels. **Solid lines** indicate odds ratios while **dotted** lines indicate 95% confidence intervals. **Solid bars** and **black lines** indicate patients with diabetes. **Clear bars** and **red lines** indicate patients without Diabetes.

70x51mm (300 x 300 DPI)

For peer review only

**Supplementary Table 2A:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the survivors at discharge cohort. Data are hazard ratio (95% confidence intervals)

N= 3790	Mortality N(%)		
	30 days 106(2.80)	1 Year 363(9.60)	All 726(19.10)
<b>Admission Demographics Variables</b>			
Gender (Female vs Male)	0.585 (0.395 , 0.865)	0.520 (0.422 , 0.640)	0.577 (0.497 , 0.670)
Age (year)	1.059 (1.041 , 1.077)	1.080 (1.069 , 1.090)	1.088 (1.080 , 1.096)
SBP (mmHg)	0.985 (0.978 , 0.992)	0.995 (0.991 , 0.999)	0.998 (0.996 , 1.001)
Heart Rate (beats/min)	1.002 (0.994 , 1.010)	1.012 (1.008 , 1.015)	1.012 (1.010 , 1.015)
Total Cholesterol (mmol/L)	0.772 (0.646 , 0.922)	0.801 (0.730 , 0.879)	0.752 (0.703 , 0.803)
Admission plasma glucose (mmol/L)	1.069 (1.044 , 1.095)	1.060 (1.045 , 1.076)	1.054 (1.042 , 1.065)
eGFR (mL/min)	0.957 (0.947 , 0.967)	0.954 (0.949 , 0.959)	0.959 (0.955 , 0.963)
<b>nSTEMI vs STEMI</b>	0.558 (0.367 , 0.850)	1.015 (0.824 , 1.250)	1.213 (1.048 , 1.403)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.907 (0.551 , 1.494)	0.789 (0.590 , 1.054)	0.915 (0.757 , 1.105)
2005	0.490 (0.234 , 1.024)	0.670 (0.465 , 0.964)	0.727 (0.567 , 0.934)
2006	0.647 (0.334 , 1.252)	0.562 (0.382 , 0.827)	0.645 (0.489 , 0.850)
2007	0.402 (0.215 , 0.751)	0.517 (0.376 , 0.712)	0.560 (0.435 , 0.721)
2008	0.261 (0.115 , 0.589)	0.477 (0.333 , 0.682)	0.460 (0.331 , 0.639)
Test for Linear Trend (p-value)	0.002	<0.001	<0.001
<b>Ethnicity (South Asian vs. White European)</b>			
	1.172 (0.726 , 1.891)	0.881 (0.665 , 1.167)	0.824 (0.673 , 1.008)
<b>Medical History (Yes vs No)</b>			
Smoking	1.417 (0.945 , 2.124)	1.179 (0.950 , 1.464)	1.281 (1.101 , 1.491)
Prior Diabetes	1.363 (0.874 , 2.124)	1.736 (1.384 , 2.177)	1.782 (1.516 , 2.093)
Prior Coronary Heart Disease §	1.427 (0.848 , 2.402)	1.289 (0.965 , 1.722)	1.309 (1.071 , 1.601)
Prior Hypertension	1.987 (1.315 , 3.002)	1.752 (1.413 , 2.172)	1.646 (1.417 , 1.912)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.945 (0.633 , 1.412)	1.078 (0.865 , 1.344)	1.038 (0.889 , 1.211)
Beta Blocker	1.966 (1.306 , 2.960)	1.850 (1.484 , 2.305)	1.582 (1.348 , 1.857)
Statin	1.169 (0.759 , 1.799)	1.306 (1.042 , 1.638)	1.323 (1.125 , 1.556)
ACEI or ARB	1.174 (0.762 , 1.807)	1.708 (1.373 , 2.124)	1.833 (1.570 , 2.140)
<b>Admission treatment (Yes vs No)</b>			
Initial Reperfusion	1.154 (0.774 , 1.720)	0.570 (0.464 , 0.701)	0.449 (0.387 , 0.521)
Loop Diuretic	3.199 (2.129 , 4.806)	4.940 (3.922 , 6.221)	4.174 (3.573 , 4.877)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.165 (0.107 , 0.253)	0.582 (0.469 , 0.723)	0.908 (0.771 , 1.069)
Beta Blocker	0.138 (0.086 , 0.221)	0.557 (0.451 , 0.688)	0.729 (0.626 , 0.848)
Statin	0.166 (0.108 , 0.255)	0.458 (0.371 , 0.566)	0.624 (0.536 , 0.726)
ACEI or ARB	0.176 (0.112 , 0.276)	0.545 (0.441 , 0.673)	0.886 (0.759 , 1.036)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Supplementary Table 3A:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality subject to survival to discharge. Data are hazard ratio (95% confidence intervals)

N= 3792	Mortality, N (%)		
	30 days 106(2.80)	1 Year 363(9.60)	All 726(19.10)
<b>Admission Demographics</b>			
Gender (Female vs Male)	0.848 (0.467, 1.538)	1.026 (0.774, 1.360)	1.113 (0.912, 1.358)
Age (year)	1.077 (1.040,1.115)	1.058 (1.042, 1.075)	1.071 (1.059, 1.083)
SBP (mmHg)	0.981( 0.971, 0.990)	0.994 (0.989, 0.998)	0.996 (0.993, 0.999)
Heart Rate (beat/min)	0.998 (0.987,1.008)	1.004 (1.000, 1.009)	1.007 (1.004, 1.010)
Admission plasma glucose (mmol/L)	1.095 (1.047,1.146)	1.046 (1.017,1.077)	1.042 (1.021, 1.064)
eGFR (mL/min)	0.994 (0.977, 1.011)	0.978 (0.970, 0.987)	0.985 (0.980, 0.991)
nSTEMI vs STEMI	0.253 (0.125, 0.512)	0.643 (0.486, 0.852)	0.826 (0.679, 1.005)
<b>Year of Admission</b>	0.826 (0.701, 0.974)	0.956 (0.887, 1.030)	0.926 (0.873, 0.981)
<b>Ethnicity</b>			
(South Asian vs White European)	2.021 (0.932, 4.384)	1.118 (0.760, 1.643)	0.950 (0.718, 1.258)
<b>Medical History (Yes vs No)</b>			
Smoking	1.722 (0.934, 3.177)	0.949 (0.710, 1.270)	0.920 (0.752, 1.124)
Prior Diabetes	0.638 (0.313, 1.303)	0.907 (0.656, 1.255)	1.080 (0.860, 1.356)
Prior Coronary Heart Disease §	1.093 (0.467, 2.560)	1.117 (0.751, 1.661)	1.328 (1.015, 1.738)
Prior Hypertension	1.836 (0.985, 3.421)	1.152 (0.868, 1.529)	1.112 (0.914, 1.354)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.951 (0.509, 1.778)	1.088 (0.810, 1.462)	1.086 (0.883, 1.336)
Beta Blocker	1.707 (0.929, 3.136)	1.403 (1.045, 1.883)	1.127 (0.913, 1.392)
Statin	0.961 (0.463, 1.997)	0.974 (0.699, 1.358)	0.992 (0.782, 1.258)
ACEI or ARB	0.685 (0.351, 1.339)	1.059 (0.784, 1.429)	1.093 (0.883, 1.353)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.029 (0.568,1.867)	1.598 (1.172, 2.179)	1.484 (1.203, 1.830)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.543 (0.235,1.256)	1.027 (0.702, 1.503)	1.228 (0.925, 1.631)
Beta Blocker	0.357 (0.167, 0.763)	0.730 (0.529, 1.007)	0.795 (0.633, 0.997)
Statin	1.191 (0.448, 3.170)	0.844 (0.574, 1.240)	0.712 (0.542, 0.935)
ACEI or ARB	0.425 (0.176, 1.027)	0.673 (0.475, 0.955)	0.955 (0.734, 1.243)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

1  
2  
3 **Admission blood glucose concentration; A more powerful predictor of mortality after acute**  
4  
5 **myocardial infarction than diabetes diagnosis**  
6  
7

8 Nitin N Gholap<sup>1</sup>, Rajnikant L Mehta<sup>1</sup>, Leong Ng<sup>2,3</sup>, Melanie J Davies<sup>2</sup>, Kamlesh Khunti<sup>1</sup>, Iain B Squire<sup>2,3</sup>  
9  
10

11 1. Department of Health Sciences, University of Leicester, Leicester, UK  
12

13 2. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK  
14

15 3. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK  
16  
17

18 **Address for correspondence:**  
19

20 Professor Iain B Squire  
21

22 Department of Cardiovascular Sciences  
23

24 Clinical Sciences Building  
25

26 Leicester Royal Infirmary  
27

28 Leicester LE2 7LX  
29

30 UK  
31

32 Tel: +44 116 252 3125  
33

34 Fax: +44 116 252 3108  
35

36 e-mail: [is11@le.ac.uk](mailto:is11@le.ac.uk)  
37  
38  
39  
40  
41  
42

43 **Keywords:** Acute myocardial infarction, diabetes, glucose  
44  
45

46 **Word count:** ~~3029~~2938  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT:**

**Objective:** To explore the relative impact of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI.

**Design:** Retrospective cohort study [based on the Myocardial Ischaemia National Audit Project dataset.](#)

**Setting:** [Tertiary care centre.](#)

**Participants:** 4111 (20.3% known diabetes) consecutive patients admitted with acute myocardial infarction (58.3% STEMI) [between October 2002 and September 2008.](#)

**Primary and secondary outcome measures:** [All-cause mortality at 30-days and 1-year.](#) The relative association of admission blood glucose and of antecedent diabetes with mortality [was](#) assessed using multivariate Cox regression analysis. Furthermore we compared these relationships in patients with STEMI to those with NSTEMI.

**Results:** By 30 days and 1 year, 409 (9.9%) and 677 (16.5%) of patients died. After adjusting for covariates, diabetes did not show independent association with mortality at any time point, in the entire cohort (HR 30 days 0.93 (CI 0.63 – 1.38); 1-year 1.00 (0.77 – 1.30)) or in subgroups of STEMI (HR 30days 1.03 (0.65 – 1.64); 1 year 1.08 (0.77 – 1.51)) and non-STEMI (HR 30-days 0.62 (0.26-1.50); 1-year 0.87(0.56 – 1.36)). In contrast, after adjusting for covariates, admission glucose showed robust and independent association with mortality in the entire cohort (HR ~~per mmol/L increase;~~ 30 days 1.07 (1.04 – 1.10); 1-year 1.05 (1.03 – 1.08)), and in the subgroup of STEMI (30-days 1.07 (1.03 – 1.10); 1-year 1.07 (1.04 – 1.10)), and NSTEMI (HR 30 days 1.07 (1.00 - 1.14); 1-year 1.02 (0.97 - 1.06)).

1  
2  
3 **Conclusion:** Admission glucose is strongly associated with mortality in all presentations of acute  
4 myocardial infarction (AMI), irrespective of established diabetes diagnosis. The increased risk is  
5 maintained up to 1 year. Future studies are required to assess the impact of active management of  
6 elevated blood glucose in improving mortality in individuals admitted with AMI.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## INTRODUCTION

For patients with acute myocardial infarction (AMI) the risk of adverse outcome is increased by the concomitant diagnosis of diabetes mellitus (diabetes).(1, 2) In addition, elevated blood glucose concentration, a common finding at admission in patients with AMI, is also associated with increased risk of adverse outcome, irrespective of prior diabetes.(1-8). In some studies (4, 9) the association between admission blood glucose concentration and adverse outcome was more powerful in patients without, compared to those with, prior diabetes. Indeed we previously reported more powerful association with 30-day and 1-year mortality after STEMI for admission blood glucose concentration, compared to the diagnosis of diabetes.(9)

While a causal relationship is unproven, there are numerous potential pathophysiological mechanisms by which hyperglycaemia may impart toxicity during myocardial ischaemia.(10, 11) Indeed, observational data suggest that elevated blood glucose may contribute directly to adverse outcome after AMI. Prognosis is worse for patients in whom hyperglycaemia persists in the 24-48 hours after AMI compared to those in whom blood glucose normalises.(12, 13) In patients without prior diabetes, insulin-based treatment of hyperglycaemia after AMI is associated with improved prognosis.(14, 15) Further, in randomised, controlled trials (RCTs) of intensive, insulin-based blood glucose management during admission with AMI, survival benefit was evident only when intervention effectively lowered blood glucose concentration.(16, 17)

While the relationship between blood glucose concentration and outcome after AMI has largely been described in patients with STEMI, the majority of acute coronary syndromes in contemporary practice are non-ST elevation AMI (NSTEMI). The aim of the current analysis was to compare the relative strength of association with 30-day, and 1-year mortality of antecedent diabetes diagnosis and admission blood glucose concentration in patients with STEMI and with NSTEMI, and in those

1  
2  
3 with and without a history of diabetes, in a multi-ethnic population. We also assessed the relevance  
4  
5 of blood glucose concentration, recorded soon after admission to hospital with AMI, to mortality in  
6  
7 patients surviving to discharge.  
8  
9

## 10 11 12 13 **METHODS**

14  
15  
16 Data were from consecutive admissions between 1st October 2002 – 30<sup>th</sup> September 2008, to the  
17  
18 two coronary care units (CCU) of a large teaching hospital serving the population of Leicestershire,  
19  
20 UK (approximately 946,000 residents in 2004). For all patients, as part of the hospital's mandatory  
21  
22 commitment to the Myocardial Ischaemia National Audit Programme (MINAP),(18) we record  
23  
24 clinical and demographic data including information on diagnosis (STEMI/NSTEMI),  
25  
26 electrocardiographic (ECG) site of infarct, medical history, coronary heart disease risk-factors, and  
27  
28 prescribed medication. Data are record-linked to mortality information (19) and include self  
29  
30 reported coding for ethnicity, for which local coverage is thorough. Approximately 10% of the local  
31  
32 population are of South Asian ethnic origin, over twice the UK national average.  
33  
34  
35

36  
37 Patients were categorised as having a diagnosis of diabetes if this was self-reported by the patient,  
38  
39 or on the basis of medication prescribed prior to admission. The blood glucose measurement used  
40  
41 for the analysis was the first recorded at the time of the index admission, assayed in the hospital  
42  
43 laboratory as part of routine investigations. All diagnoses of AMI were verified prior to submission to  
44  
45 the national MINAP database; the diagnosis of AMI was made according to the joint  
46  
47 ESC/ACCF/AHA/WHF definition.(20) Patients were categorised as STEMI or NSTEMI, according to the  
48  
49 final discharge diagnosis recorded in the MINAP database. For patients with multiple AMI admissions  
50  
51 during the study period, we considered only the first event.  
52  
53  
54

55  
56 Survival was measured from the date of first admission to the date of death or of censoring at 30<sup>th</sup>  
57  
58 September 2009. Mortality data are supplied to the hospital on a monthly basis via the UK Office for  
59  
60

1  
2  
3 National Statistics. The pre-defined primary outcome measure was ~~the relative strength of~~  
4 ~~association with~~ 30-day, and 1-year, all-cause mortality, ~~for diabetes diagnosis and for admission~~  
5 ~~blood glucose concentration.~~  
6  
7  
8  
9

10 The study was approved by the local research ethics committee. The data used in this analysis were  
11 gathered during routine care and as part of the MINAP (18) mandatory requirement for all acute  
12 hospitals in England and Wales to collect data pertaining to admission with AMI.  
13  
14  
15

### 16 17 18 **Statistical analysis** 19

20  
21 Baseline characteristics were compared between groups using independent two-sample t-tests for  
22 continuous variables and chi-squared tests for categorical variables. Mortality at 30 days and at 1  
23 year, in the entire cohort, and in those patients surviving to discharge, ~~was~~ calculated.  
24  
25  
26  
27

28 We calculated mortality proportions for patients admitted from 1<sup>st</sup> October 2002 to 30<sup>th</sup> September  
29 2008 with follow-up censored at 30<sup>th</sup> September 2009. Survival probabilities were calculated using  
30 Kaplan-Meier [KM] analyses and patient groups compared using survival analysis log rank test.  
31  
32  
33  
34  
35 Relative risk of mortality, as a function of ~~explanatory~~ clinical variables, was examined using Cox  
36 proportional hazards techniques. We initially assessed the unadjusted, univariate association with  
37 outcome for admission blood glucose and for diabetes, and for other potentially relevant clinical and  
38 demographic variables (age, sex, ethnicity (white European, South Asian), smoking, type of AMI  
39 (STEMI, NSTEMI), prior history (hypertension, any coronary artery disease, cerebrovascular or  
40 peripheral vascular disease), admission systolic blood pressure and heart rate, estimated glomerular  
41 filtration rate (eGFR), coronary revascularisation during index admission, pre-admission and  
42 discharge drug therapy (anti-platelet, beta-blocker, statin, angiotensin converting enzyme inhibitor/  
43 angiotensin receptor blocker), and index loop diuretic use. An interaction term representing  
44 calendar year of admission was included to adjust for potential temporal changes in the  
45 management of acute coronary artery disease.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Demographic and clinical covariates with univariate association ( $p < 0.10$ ) with mortality at 30 days, or 1 year were entered into multivariate models (Cox proportional hazards). Statistical significance for all comparisons was set at  $p < 0.05$  (2 sided). Data are presented as hazard ratio (HR) and 95% confidence intervals (CI). We used fractional polynomials to model admission glucose to account for any non-linearity and assessed its independent association with mortality in subgroups with and without diabetes. Analyses were carried out using SPSS version 18.

## RESULTS

~~Between 1<sup>st</sup> October 2002 – 30<sup>th</sup> September 2009, we recorded 4640 admissions with discharge diagnosis of AMI.~~ The study population was the 4111 ~~(STEMI 2397, 58.3%)~~ patients admitted between 1<sup>st</sup> October 2002 – 30<sup>th</sup> September 2008 with discharge diagnosis of AMI (STEMI 2397, 58.3%) and for whom a minimum of 365 days follow-up was available from the date of admission.

For this cohort, median follow up was 912 days (range 0 to 2556) days; for 3792 (92.2%) patients surviving to discharge from the index admission, median follow up was 1031 (range 1 to 2556) days.

Demographic details of the study population are presented in Table 1. Prior diabetes was recorded in 835 (20.3%) patients: compared to those without, patients with antecedent diabetes were on average older (68.6 vs 65.8 years,  $p < 0.005$ ), more likely to be female (33.9% vs 28.9%,  $p = 0.022$ ) and to have prior cardiovascular co-morbidities. Presentation with NSTEMI was more prevalent in cases with (50.1%), compared to those without (39.6%), prior diabetes ( $p < 0.005$ ). Mean plasma glucose was higher in patients with diabetes ( $12.0 \pm 5.5$  mmol/L) compared to those without ( $7.9 \pm 3.3$  mmol/L) ( $p < 0.005$ ). Mean peak CK was lower in patients with diabetes.

During the index admission administration of loop diuretic was more frequent (52.7% vs 33.4%,  $p < 0.005$ ) and, for patients with STEMI, coronary reperfusion therapy less frequent (50.2% vs 60.9%,  $p < 0.005$ ), in patients with diabetes. Other than for slightly less use of beta-blockers and aspirin in

1  
2  
3 patients with diabetes, patterns of prescription of secondary prevention therapies at discharge were  
4  
5 similar in the two groups.  
6  
7

### 8 **Mortality – Univariate analysis**

9  
10  
11 Deaths during hospitalisation, over 30-days, 1-year and the entire period of follow-up numbered [319](#)  
12 [\(7.8%\)](#), 409 (9.9%), 677 (16.5%) and 1041 (25.3%) respectively. Age, female sex, higher admission  
13  
14 heart rate, higher eGFR, lower systolic blood pressure and presentation with STEMI (compared to  
15  
16 NSTEMI), as well as prior smoking and hypertension, each showed univariate association with  
17  
18 mortality risk over all time periods (Table 2). Loop diuretic was associated with a 3-4 fold increase in  
19  
20 mortality during follow-up. Survival improved over the period of observation.  
21  
22  
23

24  
25 Prior diabetes showed strong univariate association with mortality risk over all time periods: HR 30  
26  
27 days 1.40 (1.12 - 1.75); 1 year 1.58 (1.33 - 1.86); all follow-up 1.66 (1.44 , 1.90)) (Table 2). The  
28  
29 strength of association between glucose and mortality was consistent at 30-days and at 1-year, each  
30  
31 mmol/L increase in admission glucose concentration being associated with a 6-7% increase in hazard  
32  
33 of mortality over all time periods.  
34  
35

### 36 **Post-discharge mortality**

37  
38  
39 In those surviving to discharge (N=3792), 106 (2.8%), 363 (9.6%) and 726 (19.1%) died by 30-days, 1-  
40  
41 year and over all follow-up (Table 2A, Supplementary data). Univariate associations with mortality  
42  
43 were similar to those in the entire population. Prior diabetes showed univariate association with  
44  
45 increased risk of death at all times, although this was not statistically significant at 30 days (HR 1.36,  
46  
47 (0.87 - 2.12)). For admission glucose, the strength of association with post-discharge mortality was  
48  
49 very similar to that in the entire cohort, with 5-7% increase risk per mmol/L increase in glucose.  
50  
51 (Table 2A, Supplementary Data).  
52  
53  
54

### 55 **Mortality – Multivariate analysis**

1  
2  
3 Table 3 shows the results of multivariate analysis. Age, lower admission systolic blood pressure and  
4 higher heart rate, lower eGFR, prescription of loop diuretic, and STEMI (compared to NSTEMI) each  
5 retained independent association with mortality, as did prescription of individual discharge  
6 medications. After covariate adjustment, diabetes did not retain independent association with  
7 mortality at any time. In contrast, adjustment for covariates had little impact upon the risk of  
8 mortality associated with admission glucose concentration.  
9  
10  
11  
12  
13  
14  
15

### 16 17 **Post-discharge mortality**

18  
19  
20 For patients surviving to discharge, associations between clinical variables and the risk of mortality  
21 were similar to those seen in the entire cohort (Table 3A, Supplementary data). While there was no  
22 association between prior diabetes and risk of mortality at any time (HR 30 days 0.64 (0.31 – 1.300);  
23 1 year 0.91 (0.66 – 1.26); all follow-up 1.08 (0.86 – 1.36)), blood glucose retained powerful  
24 association with the primary endpoint. This was evident at 30 days (HR per mmol/L 1.10, 95% CI 1.05  
25 – 1.15), 1 year (1.05, 1.02 – 1.08), and over all follow-up (1.04, 1.02 – 1.06)).  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Admission glucose concentration – influence on mortality in patients with or without diabetes**

35  
36  
37 We repeated multivariate analysis including a term for interaction between diabetes diagnosis and  
38 admission glucose concentration. While numerically greater in individuals without diabetes (Figure  
39 1), there was no conventional statistically significant difference in the association between mortality  
40 and admission blood glucose for patients with and without diabetes (30 days HR 1.00, (CI 0.97 –  
41 1.03, p=0.95; 1 year 0.99, (0.97 – 1.02), p=0.66; entire follow-up 0.99, (0.97 – 1.01, p=0.42)).  
42  
43  
44  
45  
46  
47  
48

### 49 **Diabetes and glucose after AMI – influence on mortality in STEMI and NSTEMI**

50  
51  
52 After adjustment for covariates, diabetes showed no statistically significant association with  
53 mortality at any time period, either for STEMI or NSTEMI (Table 4). The strength of association  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 between blood glucose and mortality was very similar in the first 30 days after STEMI or NSTEMI.

4  
5 The strength of this relationship declined with time only after NSTEMI.  
6  
7  
8  
9

## 10 11 DISCUSSION

12  
13  
14 It is well known that, both prior diabetes diagnosis, and admission blood glucose concentration, are  
15 associated both have well recognised association with adverse outcome after AMI. In this. This is the  
16 first report were compared the relative association of these two measures of dysglycaemia with  
17 survival after AMI in a population of STEMI as well as NSTEMI. Irrespective of the type of AMI, the  
18 univariate association with mortality risk for antecedent diabetes (40% excess at 30 days, 55-65%  
19 thereafter) was no longer apparent after adjustment for relevant covariates including admission  
20 glucose concentration. In contrast, the excess risk associated with increasing glucose was not  
21 reduced after adjustment, was similar in those with and without known diabetes, and remained  
22 relevant in patients discharged alive from the index event.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34  
35 In our previous report of over 4000 patients with STEMI, admitted in 1993-2004,(9) the 50% increase  
36 in 30-day and 1-year mortality risk associated with known diabetes was attenuated by half on  
37 covariate adjustment and removed completely when admission blood glucose concentration was  
38 included in the analysis. The current report confirms these observations and extends them to a  
39 contemporary period, and to patients with NSTEMI as well as STEMI, in whom the strength of  
40 association between admission blood glucose concentration and 30-day mortality risk was similar,  
41 and concentration dependent. Importantly, the excess risk, around 7% for each 1mmol/L increase in  
42 admission glucose concentration, was maintained up to and beyond 1 year from the index infarction.  
43  
44 Further, this phenomenon was attenuated with time only for patients with NSTEMI, and was evident  
45 even in those patients who survived to discharge from hospital, two potentially important clinical  
46 observations. These findings are in contrast to one previous report which reported the association  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 between admission glucose and mortality to be confined to in-hospital deaths following either  
4  
5 STEMI or NSTEMI.(8) They are however in keeping with the vast majority of reports in this area.(1-7,  
6  
7 9, 11)  
8  
9

10 In contrast to most previous reports,(1-9, 11) we observed no independent association between  
11  
12 diabetes and mortality risk after AMI. However, to our knowledge and unlike the present report,  
13  
14 none of these studies adjusted for admission blood glucose, and each reported individual  
15  
16 relationships between mortality after AMI and either diabetes diagnosis (1, 2, 4, 8) or blood glucose  
17  
18 concentration.(3-8, 11-13, 21) The current analysis and our previous study (9) are the only reports to  
19  
20 compare the relative association with outcome of both diabetes and blood glucose concentration.  
21  
22 Both studies demonstrate a much stronger relationship between survival and blood glucose, and the  
23  
24 loss of association between mortality and diabetes when blood glucose is considered.  
25  
26  
27

28 These observations are of potential clinical significance. While admission blood glucose  
29  
30 concentration after AMI is on average higher in patients with, compared to those without, known  
31  
32 diabetes,(4, 8, 9) there is considerable overlap, as seen in the current report (Figure 1). While many  
33  
34 patients presenting with AMI will have previously undiagnosed diabetes,(22) blood glucose at the  
35  
36 time of admission with AMI is not a reliable indicator of the subsequent diagnosis of diabetes.(23,  
37  
38 24) In routine practice, the management of hyperglycaemia after AMI is influenced by the presence  
39  
40 of prior diabetes diagnosis.(5) In both European(14) and North American(6) settings, the majority  
41  
42 (>65%) of patients presenting with hyperglycaemia in the context of AMI, and not previously known  
43  
44 to have diabetes, do not receive active management of blood glucose. In the presence of a true,  
45  
46 direct toxic effect upon prognosis of elevated blood glucose, failure to correct hyperglycaemia may  
47  
48 represent suboptimal clinical care, and patients without known diabetes may be particularly  
49  
50 disadvantaged. In particular, our demonstration that the relationship between glucose  
51  
52 concentration and subsequent outcome is evident in NSTEMI as well as STEMI is of clear clinical  
53  
54 relevance in terms of the overall management of patients presenting with AMI.  
55  
56  
57  
58  
59  
60



1  
2  
3 The strength of association between diabetes and mortality risk after AMI has been reported to  
4  
5 increase with time from the event.(25) ~~We observed no such trend, an observation which may relate~~  
6  
7 ~~to methodological differences among studies, including our inclusion of blood glucose as a covariate~~  
8  
9 While we observed such a trend on univariate analysis, this was attenuated in multivariate analysis,  
10  
11 an observation which may relate to our inclusion of blood glucose as a covariate. A previous meta-  
12  
13 analysis suggested a stronger association between admission blood glucose and adverse  
14  
15 outcome.(4) While we could not demonstrate formal statistical evidence of such a phenomenon, our  
16  
17 data show convincingly that the relationship between glucose and outcome is at least as powerful in  
18  
19 patients without known diabetes. Blood glucose soon after admission represents an easily identified,  
20  
21 clinically relevant marker of risk after AMI, which should be assessed routinely irrespective of  
22  
23 diabetes status.  
24  
25

26  
27  
28 An important observation from this study is the persisting association between admission blood  
29  
30 glucose concentration and mortality risk in patients surviving to discharge, in both NSTEMI and  
31  
32 STEMI. While in keeping with the possibility that blood glucose concentration at admission reflects  
33  
34 the degree of individual physiological stress, or is a marker of the extent of infarction, our findings  
35  
36 are as much in keeping with a direct, adverse influence on prognosis of acute hyperglycaemia. The  
37  
38 mechanisms by which elevated glucose may be directly cardiotoxic have been summarised  
39  
40 elsewhere (10) and include attenuation of ischaemic preconditioning, QT prolongation, increased  
41  
42 thrombophilia, and endothelial dysfunction. Furthermore, clinical studies overwhelmingly support a  
43  
44 possible causal link between hyperglycaemia and adverse prognosis after AMI, ~~and also the benefit~~  
45  
46 ~~of active lowering of glucose in this setting.~~ Hyperglycaemia persisting at 24 hours after admission is  
47  
48 associated with adverse outcome,(12, 13, 17) ~~and in controlled trials of the active management of~~  
49  
50 ~~blood glucose effective reduction in blood glucose after AMI was associated with improved~~  
51  
52 ~~prognosis.(16, 17)~~  
53  
54  
55  
56  
57  
58  
59  
60

While observational studies show consistently the adverse association between hyperglycaemia and outcomes post AMI, results of the RCTs of active management of blood glucose have been inconsistent.(16,17) However, in such trials, effective reduction in blood glucose with an intervention after AMI was associated with improved prognosis.(16) The guidelines from professional societies in this area differ in their recommendations.(27,28) In the North American guidelines, intensive glucose control is recommended in patients with AMI and significant hyperglycaemia (blood glucose levels > 10.0 mmol/L) admitted in an intensive care unit.(28) In contrast, the National Institute for Health and Clinical Excellence guidance recommends against routine use of intensive insulin therapy to manage hyperglycaemia (blood glucose levels > 11.0 mmol/L) in patients with acute coronary syndrome.(27) The latter guidelines highlighted a need for randomised controlled trials addressing specific gaps in knowledge this area.

Our report is subject to the limitations inherent in all observational cohort studies. Blood glucose concentration used in this analysis was that first recorded for the index admission, and is likely to have varied in timing relative to symptom onset. Our database lacks information on left ventricular (LV) ejection fraction, evidence of heart failure, and a number of other potentially relevant variables. Further, we have no information regarding the number of patients who were given a diagnosis of diabetes during, or subsequent to, the index admission. However, if elevated glucose contributes directly to prognosis, active management is likely to confer greater benefit when delivered as early as possible, irrespective of subsequent diabetes status. Thus we suggest the first recorded blood glucose concentration to be highly relevant to guiding appropriate management in individual patients, irrespective of residual LV function. While we have no information on interventions or changes to therapy after discharge, it is unlikely that these impacted on outcome in a major way, as the strongest association between mortality and glucose was in the first 30 days.

In summary, admission blood glucose concentration is a powerful, routinely available marker of mortality risk after AMI. After adjustment for admission blood glucose, known diabetes is not

1  
2  
3 associated with adverse outcome. The association between blood glucose concentration and  
4 mortality risk is of similar magnitude in patients with and without known diabetes, is evident for  
5 NSTEMI as well as STEMI, and persists beyond 1 year from the index event, including in patients  
6 surviving to discharge. Future studies are merited of the impact of active management of blood  
7 glucose in patients with all presentations of acute coronary artery disease, irrespective of diabetes  
8 diagnosis.

## 14 15 16 17 **ARTICLE SUMMARY**

### 18 19 **Article focus**

- 20  
21  
22  
23 • Robust associations is seen for both measures of glycaemia - the diagnosis of diabetes, and  
24 elevated blood glucose levels on admission, with poor outcomes in patients with ST  
25 elevation myocardial infarction (STEMI).
- 26  
27  
28  
29 • We explored the less known, relative association of admission blood glucose levels and  
30 antecedent diabetes on early and long term survival in a contemporary UK population of  
31 patients with STEMI and NSTEMI.

### 32 33 **Key Messages:**

- 34  
35  
36  
37 • In patients with both STEMI as well as NSTEMI, admission glucose is more strongly  
38 associated with mortality than is antecedent diabetes diagnosis.
- 39  
40  
41  
42 • The increased risk associated with admission glucose is evident during the index admission,  
43 at 30 days, one year and beyond and is apparent in those surviving to discharge.
- 44  
45  
46  
47 • Conversely, after multivariate adjustment for covariates, including admission glucose is not  
48 associated with mortality.

### 49 50 51 52 **Strengths and limitations of this study**

- This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary clinical practice in a tertiary care centre.
- A statistically robust association was seen for admission glucose with both short and longer term mortality after adjusting for many important confounders.
- Our data lacks information on glucose lowering intervention, patients with undiagnosed diabetes and other potentially relevant variables which were not considered in the analysis.

For peer review only

Table 1: Baseline characteristics at admission stratified by diabetes status

	All n=4111	Known DM n= 835 (20.3%)	Not Known DM n=3276 (79.7%)	P Value*	Missing Value (%)
<b>Demography</b>					
Age (years)	66.4 (13.3)	68.6 (11.8)	65.8 (13.6)	<0.005	0.0
Women (%)	1224 (29.8)	276 (33.1)	948 (28.9)	0.022	0.0
<b>Ethnicity (%)</b>					
White European	3381 (82.2%)	545 (16.1)	2836 (86.6)	<0.005	0.0
South Asian	730 ( 17.8%)	290 (39.7%)	440 (60.3%)		0.0
<b>Medical History (%)</b>					
Hypertension	2048 (50.3)	584 (70.0)	1464 (45.0)	<0.005	1.0
Current/Ex Smoker	1366 (35.7)	282 (36.8)	1084 (35.5)	0.527	7.1
Coronary Heart Disease§	491 (12.1)	149 (17.9)	342 (10.6)	<0.005	0.9
CVA	254 (6.3)	86 (10.3)	168 (5.2)	<0.005	1.2
PVD	154 (3.8)	42 (5.0)	112 (3.5)	0.041	1.2
Heart Failure	190 (4.7)	76 (9.1)	114 (3.5)	<0.005	1.2
<b>Type of Infarction (%)</b>					
STEMI	2397 (58.3)	417 (49.9)	1980 (60.4)	<0.005	0.0
nSTEMI	1714 (41.7)	418 (50.1)	1296 (39.6)		
<b>Physical Examination</b>					
Heart Rate (beats/min)	81.1 (24.3)	85.5 (25.3)	80.0 (24.0)	<0.005	1.5
SBP (mmHg)	136.5 (28.4)	137.7 (30.7)	136.2 (27.8)	0.202	1.0
<b>Biochemical Data</b>					
Peak CK (IU/L, Normal range < 200)	1113.5 (1810.4)	939.9 (1279.3)	1156.4 (1917)	<0.005	7.6
Creatinine (µmol/L)	116.4 (63.8)	128.8 (76.1)	113.1 (59.8)	<0.005	16.8
eGFR (mL/min)	63.0 (22.2)	57.7 (23.6)	64.4 (21.7)	<0.005	16.6
Total cholesterol (mmol/L)	5.1 (1.3)	4.4 (1.2)	5.2 (1.3)	<0.005	16.6
Haemoglobin (g/L)	13.7 (1.9)	13.0 (1.9)	13.9 (1.8)	<0.005	66.6
Plasma glucose (mmol/L)	8.8 (4.2)	12.0 (5.5)	7.9 (3.3)	<0.005	14.9
<b>Therapies (%)</b>					
<b>Prior to index admission</b>					
Aspirin	2671 (65.0)	622 (74.5)	2049 (62.5)	<0.005	0.0
Beta blocker	990 (25.6)	265 (33.2)	725 (23.6)	<0.005	6.0
ACEI or ARB	1097 (28.3)	407 (51.0)	690 (22.5)	<0.005	5.8
Statins	1083 (28.0)	389 (48.7)	694 (22.6)	<0.005	5.8
<b>In-hospital</b>					
Reperfusion therapy #	2414 (58.7)	419 (50.2)	1995 (60.9)	<0.005	0.0
Loop diuretics	1502 (37.4)	436 (52.7)	1066 (33.4)	<0.005	2.3
<b>At discharge</b>					
Aspirin	2701 (68.1)	529 (65.3)	2172 (68.8)	0.057	3.5
Beta blocker	2513 (63.3)	483 (59.6)	2030 (64.3)	0.013	3.5
ACEI or ARB	2493 (62.9)	495 (61.0)	1998 (63.4)	0.222	3.6
Statin	2704 (67.7)	537 (65.6)	2167 (68.2)	0.167	2.8

All values are mean (SD) or number (%). \* known diabetes vs not known diabetes. DM, Diabetes Mellitus; CVA, Cerebrovascular accidents; PVD, Peripheral Vascular Disease; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; SBP, Systolic blood pressure; CK, Creatinine Kinase; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

# thrombolysis or coronary intervention (PCI or CABG) or both

**Table 2:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals)

N=4111	Mortality, N (%)		
	30 days 409 (9.95)	1 Year 677 (16.47)	All (Median 912 days) 1041 (25.32)
<b>Admission Demographic Variable</b>			
Gender (Female vs Male)	0.535 (0.439, 0.650)	0.515 (0.443, 0.600)	0.554 (0.490, 0.627)
Age (year)	1.068 (1.059, 1.078)	1.077 (1.069, 1.084)	1.084 (1.077, 1.090)
SBP (mmHg)	0.979 (0.976, 0.983)	0.987 (0.984, 0.990)	0.992 (0.990, 0.994)
Heart Rate (beat/min)	1.010 (1.006, 1.013)	1.012 (1.009, 1.014)	1.012 (1.010, 1.014)
Total Cholesterol (mmol/L)	0.732 (0.666, 0.806)	0.765 (0.712, 0.821)	0.744 (0.703, 0.788)
Admission plasma glucose (mmol/L)	1.072 (1.052, 1.084)	1.065 (1.055, 1.076)	1.059 (1.050, 1.068)
eGFR (mL/min)	0.956 (0.951, 0.961)	0.955 (0.951, 0.959)	0.959 (0.956, 0.962)
NSTEMI vs STEMI	0.504 (0.405, 0.627)	0.736 (0.629, 0.862)	0.939 (0.830, 1.063)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.909 (0.688, 1.200)	0.846 (0.681, 1.052)	0.919 (0.780, 1.082)
2005	0.591 (0.402, 0.870)	0.652 (0.491, 0.865)	0.702 (0.564, 0.873)
2006	0.830 (0.592, 1.164)	0.696 (0.529, 0.917)	0.716 (0.572, 0.897)
2007	0.759 (0.570, 1.010)	0.678 (0.541, 0.849)	0.679 (0.558, 0.826)
2008	0.485 (0.338, 0.696)	0.551 (0.424, 0.716)	0.531 (0.415, 0.680)
Test for Linear Trend (p-value)	<0.001	<0.001	<0.001
<b>Ethnicity</b> (South Asian vs. White European)	1.013 (0.786, 1.304)	0.909 (0.741, 1.114)	0.856 (0.725, 1.012)
<b>Medical History</b> (Yes vs No)			
Smoking	1.016 (0.819, 1.259)	1.049 (0.891, 1.235)	1.160 (1.019, 1.320)
Prior Diabetes	1.400 (1.121, 1.750)	1.576 (1.331, 1.865)	1.655 (1.445, 1.896)
Prior Coronary Heart Disease §	0.862 (0.628, 1.182)	0.998 (0.791, 1.258)	1.113 (0.931, 1.330)
Prior Hypertension	1.286 (1.056, 1.567)	1.437 (1.232, 1.676)	1.472 (1.300, 1.666)
<b>Pre -Admission Medication</b> (Yes vs No)			
Aspirin	0.746 (0.613, 0.909)	0.869 (0.744, 1.015)	0.913 (0.804, 1.036)
Beta Blocker	1.385 (1.116, 1.719)	1.577 (1.338, 1.859)	1.489 (1.301, 1.703)
Statin	0.994 (0.795, 1.245)	1.129 (0.953, 1.338)	1.194 (1.041, 1.370)
ACEI or ARB	1.242 (1.002, 1.540)	1.467 (1.247, 1.726)	1.621 (1.423, 1.847)
<b>Admission treatment</b> (Yes vs No)			
Initial Reperfusion	0.616 (0.507, 0.749)	0.540 (0.464, 0.629)	0.466 (0.411, 0.527)
Loop Diuretic	3.457 (2.807, 4.256)	4.348 (3.681, 5.136)	4.052 (3.556, 4.618)
<b>Discharge Medication</b> (Yes vs No)			
Aspirin	0.043 (0.029, 0.062)	0.227 (0.192, 0.269)	0.439 (0.386, 0.499)
Beta Blocker	0.038 (0.025, 0.058)	0.237 (0.199, 0.282)	0.406 (0.357, 0.461)
Statin	0.043 (0.029, 0.062)	0.196 (0.165, 0.233)	0.344 (0.303, 0.390)
ACEI or ARB	0.047 (0.031, 0.0700)	0.236 (0.198, 0.281)	0.469 (0.412, 0.533)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Table 3:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals).

N=4111	Mortality, N (%)		
	30 days 409 (9.95)	1 Year 677 (16.5)	All (Median 912 days) 1041 (25.3)
<b>Admission Demographics</b>			
Gender (Female vs Male)	1.268 (0.885, 1.819)	1.094 (0.865, 1.383)	1.114 (0.931, 1.332)
Age (year)	1.059 (1.040, 1.078)	1.062 (1.048, 1.075)	1.073 (1.062, 1.083)
SBP (mmHg)	0.987 (0.981, 0.992)	0.991 (0.987, 0.995)	0.993 (0.990, 0.996)
Heart Rate (beat/min)	1.007 (1.001, 1.013)	1.006 (1.002, 1.010)	1.007 (1.005, 1.010)
Admission plasma glucose (mmol/L)	1.072 (1.042, 1.104)	1.059 (1.037, 1.081)	1.053 (1.036, 1.071)
eGFR (mL/min)	0.987 (0.978, 0.996)	0.983 (0.977, 0.990)	0.988 (0.983, 0.993)
<b>nSTEMI vs STEMI</b>	0.411 (0.282, 0.597)	0.558 (0.443, 0.704)	0.700 (0.587, 0.834)
<b>Ethnicity</b> (South Asian vs White European)	1.355 (0.893, 2.057)	1.155 (0.851, 1.568)	0.996 (0.779, 1.273)
<b>Medical History (Yes vs No)</b>			
Smoking	1.125 (0.788, 1.607)	0.953 (0.749, 1.213)	0.942 (0.786, 1.130)
Prior Diabetes	0.934 (0.631, 1.382)	1.001 (0.770, 1.300)	1.134 (0.927, 1.386)
Prior Coronary Heart Disease§	0.717 (0.402, 1.278)	0.898 (0.632, 1.277)	1.111 (0.864, 1.428)
Prior Hypertension	1.291 (0.903, 1.846)	1.155 (0.913, 1.461)	1.133 (0.949, 1.353)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.944 (0.667, 1.335)	0.989 (0.781, 1.252)	1.010 (0.842, 1.213)
Beta Blocker	1.288 (0.898, 1.849)	1.363 (1.067, 1.742)	1.173 (0.970, 1.418)
Statin	0.863 (0.579, 1.286)	0.877 (0.668, 1.150)	0.918 (0.743, 1.135)
ACEI or ARB	0.719 (0.497, 1.042)	0.932 (0.728, 1.194)	1.017 (0.840, 1.232)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.416 (0.993, 2.019)	1.703 (1.322, 2.195)	1.532 (1.268, 1.851)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.297 (0.157, 0.562)	0.656 (0.479, 0.897)	0.861 (0.676, 1.097)
Beta Blocker	0.257 (0.133, 0.494)	0.564 (0.423, 0.753)	0.671 (0.544, 0.828)
Statin	0.628 (0.295, 1.339)	0.683 (0.484, 0.963)	0.629 (0.490, 0.808)
ACEI or ARB	0.470 (0.229, 0.968)	0.610 (0.443, 0.839)	0.850 (0.668, 1.081)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 4:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the subgroups of patients with STEMI and NSTEMI. Data are hazard ratio (95% confidence intervals)

N=4111		Mortality, N (%)					
STEMI	NSTEMI	30 days		1 Year		All	
2397	1714	STEMI	NSTEMI	STEMI	NSTEMI	STEMI	NSTEMI
<b>Admission Demographics</b>							
Age (year)		1.055 (1.033 - 1.077)	1.073 (1.031 - 1.116)	1.061 (1.044 - 1.078)	1.056 (1.035 - 1.079)	1.077 (1.062 - 1.091)	1.061 (1.046 - 1.077)
SBP (mmHg)		0.988 (0.982 - 0.994)	0.983 (0.970 - 0.995)	0.992 (0.987 - 0.997)	0.988 (0.982 - 0.995)	0.993 (0.989 - 0.997)	0.994 (0.990 - 0.998)
Heart Rate (beat/min)		1.008 (1.001 - 1.015)	1.008 (0.997 - 1.02)	1.008 (1.002 - 1.013)	1.007 (1.001 - 1.013)	1.008 (1.004 - 1.012)	1.007 (1.002 - 1.011)
eGFR (mL/min)		0.986 (0.975 - 0.997)	0.987 (0.969 - 1.005)	0.982 (0.974 - 0.991)	0.978 (0.968 - 0.989)	0.986 (0.979 - 0.993)	0.987 (0.979 - 0.995)
Admission plasma glucose		1.070 (1.034 - 1.107)	1.074 (1.005 - 1.148)	1.071 (1.042 - 1.10)	1.021 (0.979 - 1.066)	1.076 (1.051 - 1.10)	1.014 (0.983 - 1.047)
Prior Diabetes		1.035 (0.652 - 1.641)	0.629 (0.264 - 1.502)	1.083 (0.772 - 1.518)	0.878 (0.566 - 1.36)	1.189 (0.907 - 1.559)	1.055 (0.773 - 1.44)
<b>Admission treatment (Yes vs No)</b>							
Loop Diuretic		1.330 (0.890 - 1.989)	1.66 (0.759 - 3.629)	1.706 (1.248 - 2.333)	1.988 (1.283 - 3.081)	1.365 (1.068 - 1.745)	2.03 (1.496 - 2.756)
<b>Discharge Medication (Yes vs No)</b>							
Aspirin		0.301 (0.135 - 0.672)	0.308 (0.088 - 1.076)	0.499 (0.322 - 0.773)	0.869 (0.523 - 1.433)	0.697 (0.501 - 0.970)	1.052 (0.711 - 1.557)
Beta Blocker		0.208 (0.095 - 0.455)	0.337 (0.094 - 1.207)	0.469 (0.320 - 0.687)	0.77(0.485 - 1.222)	0.520 (0.393 - 0.698)	0.939 (0.674 - 1.308)
Statin		1.046 (0.375 - 2.918)	0.255 (0.066 - 0.992)	0.551 (0.334 - 0.908)	0.745 (0.449 - 1.237)	0.615 (0.429 - 0.880)	0.65 (0.444 - 0.951)
ACEI or ARB		0.392 (0.153 - 1.006)	0.451 (0.121 - 1.673)	0.903 (0.545 - 1.496)	0.541 (0.348 - 0.841)	1.041 (0.712 - 1.523)	0.857 (0.616 - 1.194)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker



1  
2  
3 **Contributors:** NG, IS, KK conceived the idea of the study and were responsible for the design of the  
4  
5 study. NG, RM were responsible for undertaking for the data analysis and produced the tables and  
6  
7 graphs. IS, KK, MJD provided input into the data analysis. The initial draft of the manuscript was  
8  
9 prepared by NG and IS and then circulated repeatedly amongst all authors for critical revision. IS was  
10  
11 responsible for the acquisition of the data and IS, NG, RM, KK and MJD contributed to the  
12  
13 interpretation of the results.  
14

15  
16  
17 **Funding:** This research received no specific grant from any funding agency in the public, commercial  
18  
19 or not-for-profit sectors. The work in this paper is part of the research portfolio supported by the  
20  
21 Leicester NIHR Biomedical Research Unit in Cardiovascular Disease. NG has received support by the  
22  
23 National Institute for Health Research, Collaboration for Leadership in Applied Health Research and  
24  
25 Care - Leicestershire, Northamptonshire and Rutland (NIHR CLAHRC for LNR) project for a PhD .  
26

27  
28  
29 **Competing interests:** None  
30

31  
32 **Ethical approval:** The study was approved by the local research ethics committee.  
33

34  
35 **Copyright/licence for publication:** The Corresponding Author has the right to grant on behalf of all  
36  
37 authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for  
38  
39 government employees) on a worldwide basis to the BMJ Group and co-owners or contracting  
40  
41 owning societies (where published by the BMJ group on their behalf), and its Licensees to permit this  
42  
43 article (if accepted) to be published in the Heart edition and any other BMJPG products and to  
44  
45 exploit all subsidiary rights, as set out in our licence.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Malmberg K, Yusuf S, Gerstein HC, *et al.* Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry. *Circulation* 2000;102:1014-1019.
2. McGuire DK, Emanuelsson H, Granger CB, *et al.* Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO IIb study. *Eur Heart J* 2000;21:1750-1758
3. Svensson A-M, McGuire DK, Abrahamsson P, *et al.* Association between hyper- and hypoglycaemia and 2-year all-cause mortality risk in diabetic patients with acute coronary events. *Eur Heart J* 2005;26:1255-1261
4. Capes SE, Hunt D, Malmberg K, *et al.* Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000;355:773-778
5. Wahab NN, Cowden EA, Pearce NJ, *et al.* Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? *J. Am. Coll. Cardiol* 2002;40:1748- 1754
6. Kosiborod M, Rathore SS, Inzucchi SE, *et al.* Admission glucose and mortality in elderly patients hospitalised with acute myocardial infarction. *Circulation* 2005;111:3078-3086
7. Cao JJ, Hudson M, Jankowski M, *et al.* Relation of chronic and acute glycaemic control on mortality in acute myocardial infarction with diabetes mellitus. *Am J Cardiol* 2005;96:183-186

- 1  
2  
3 8. Sinnaeve PR, Steg G, Fox KAA, *et al.* Association of fasting glucose with increased short-term  
4  
5 and 6-month mortality in ST-elevation and non ST-elevation acute coronary syndromes. *Arch*  
6  
7 *Int Med* 2009;169:402-409  
8  
9
- 10 9. Squire IB, Nelson CP, Ng LL, *et al.* Prognostic value of admission blood glucose concentration  
11  
12 and diabetes diagnosis on survival after acute myocardial infarction; Results from 4702 index  
13  
14 cases in routine practice. *Clin Sci (London)* 2010;118:527-535  
15  
16
- 17 10. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. *Eur Heart J*  
18  
19 2001;26:328-331  
20  
21
- 22 11. De Caterina R, Madonna R, Sourij H, *et al.* Glycaemia control in acute coronary syndromes:  
23  
24 prognostic value and therapeutic options. *Eur Heart J* 2010;31:1557-1564  
25  
26  
27
- 28 12. Ghoyal A, Mahaffey KW, Garg J, *et al.* Prognostic significance of the change in glucose level in  
29  
30 the first 24h after acute myocardial infarction: results from the CARDINAL study. *Eur Heart J*  
31  
32 2006;27:1289-1297  
33  
34  
35
- 36 13. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for  
37  
38 long-term prognosis after myocardial infarction even in non-diabetic patients. *Diabetes Care*  
39  
40 1999;22:1827-1831  
41  
42
- 43 14. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for  
44  
45 hyperglycaemic patients without known diabetes who present with an acute coronary  
46  
47 syndrome. *Heart* 2007;93:1542-1546  
48  
49
- 50 15. Schnell O, Schafer O, Kleybrink S, *et al.* Intensification of therapeutic approaches reduces  
51  
52 mortality in diabetic patients with acute myocardial infarction: the Munich registry. *Diabetes*  
53  
54 *Care* 2004;27:455-460.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Malmberg K, Ryden L, Efendic S, *et al*. Randomised trial of insulin-glucose infusion followed by  
4 subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI  
5 study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995;26:57-65  
6  
7  
8  
9  
10  
11 17. Malmberg K, Ryden L, Wedel H, *et al*; DIGAMI 2 Investigators. Intense metabolic control by  
12 means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2):  
13 effects on mortality and morbidity. *Eur Heart J* 2005;26:650-661  
14  
15  
16  
17  
18 18. [Herrett E, Smeeth L, Walker L, \*et al\*; MINAP Academic group. The Myocardial Ischaemia](#)  
19 [National Audit Project \(MINAP\) \*Heart\* 2010;96:1264-67](#)  
20  
21  
22  
23 19. ~~Birkhead JS, Walker L, Pearson M, *et al*. Improving care for patients with acute coronary~~  
24 ~~syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP).~~  
25 ~~*Heart* 2004;90:1004-9~~  
26  
27  
28  
29  
30  
31 ~~20-19.~~ Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly  
32 admitted to hospital with heart failure in the United Kingdom: historical cohort study. *BMJ*  
33 2003; 327(7414):526-31  
34  
35  
36  
37  
38 ~~21-20.~~ Thygesen K, Alpert JS, White HD. The Joint ESC/ACCF/AHA/WHF Task Force for the  
39 redefinition of myocardial infarction. *Eur Heart J* 2007;28:2525-2538  
40  
41  
42  
43  
44 ~~22-21.~~ Garber AJ, Moghissi ES, Bransome ED Jr, *et al*; American College of Endocrinology Task Force  
45 on Inpatient Diabetes Metabolic Control. *Endocr Pract* 2004;10:77-82  
46  
47  
48  
49 ~~23-22.~~ Kosiborod M, Inzucchi SE, Krumholz HM *et al*. Glucometrics in patients hospitalized with  
50 acute myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation*  
51 2008;117:1018  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 | [24-23.](#) Norhammar A, Tenerz A, Nilsson G, *et al.* Glucose metabolism in patients with acute  
4 myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.  
5  
6 *Lancet* 2002;359:2140-2144.  
7  
8

9  
10 | [25-24.](#) Tenerz A, Lonnberg I, Berne C, *et al.* Myocardial infarction and prevalence of diabetes  
11 mellitus, Is increased casual blood glucose at admission a reliable criterion for the diagnosis of  
12 diabetes? *Eur Heart J* 2001;22:1102–1110  
13  
14  
15

16  
17 | [26-25.](#) De Mulder M, Oemrawsingh RH, Stam F, *et al.* Comparison of diagnostic criteria to detect  
18 undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. *Heart* 2011;  
19  
20 10.1136/heartjnl-2011-300163  
21  
22  
23

24  
25 | [26.](#) Melchior T, Kober L, Madsen CR, *et al.* Accelerating impact of diabetes mellitus on mortality in  
26 the years following an acute myocardial infarction. *Eur Heart J* 1999;20:973-978  
27  
28  
29

30  
31 | [27.](#) National Institute for Health and Clinical Excellence. (2011) [Hyperglycaemia in acute coronary](#)  
32 [syndromes: management of hyperglycaemia in people with acute coronary syndromes. \(CG](#)  
33 [130\).](#) London: National Institute for Health and Clinical Excellence.  
34  
35  
36

37  
38 | [27-28.](#) Deedwaniap, Kosibirod M, Barrett E *et al.* [Hyperglycaemia and acute coronary syndrome. A](#)  
39 [scientific Statement from the American Heart Association Diabetes Committee of the Council](#)  
40 [on Nutrition, Physical activity and Metabolism. \*Circulation\* 2008;117:1610-9.](#)  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE LEGENDS**

Figure 1: Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The bars represent the number of people at various glucose levels. Solid lines indicate odds ratios while dotted lines indicate 95% confidence intervals. Solid bars and black lines indicate patients with diabetes. Clear bars and red lines indicate patients without Diabetes. ~~Solid lines indicate odds ratios while dotted lines indicate 95% confidence intervals.~~

For peer review only



**Is blood glucose concentration a more powerful predictor of mortality after acute myocardial infarction than diabetes diagnosis? A retrospective cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001596.R1
Article Type:	Research
Date Submitted by the Author:	27-Jul-2012
Complete List of Authors:	Gholap, Nitin; University Hospitals of Leicester, Diabetes Research; University Of Leicester, Health Sciences Mehta, Rajnikant; University Of Leicester, Health Sciences Ng, Leong; University of Leicester, Cardiovascular Sciences Davies, Melanie; University of Leicester, Cardiovascular sciences Khunti, Kamlesh; University Of Leicester, Health Sciences Squire, Iain; Leicester Royal Infirmary, Cardiovascular Sciences
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Myocardial infarction < CARDIOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Is admission blood glucose concentration a more powerful predictor of mortality after myocardial**  
4 **infarction than diabetes diagnosis? : A retrospective cohort study.**  
5  
6

7  
8 Nitin N Gholap<sup>1</sup>, Rajnikant L Mehta<sup>1</sup>, Leong Ng<sup>2,3</sup>, Melanie J Davies<sup>2</sup>, Kamlesh Khunti<sup>1</sup>, Iain B Squire<sup>2,3</sup>  
9

10  
11 1. Department of Health Sciences, University of Leicester, Leicester, UK  
12

13 2. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK  
14

15 3. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK  
16  
17

18 **Address for correspondence:**  
19

20 Professor Iain B Squire  
21

22 Department of Cardiovascular Sciences  
23

24 Clinical Sciences Building  
25

26 Leicester Royal Infirmary  
27

28 Leicester LE2 7LX  
29

30 UK  
31

32 Tel: +44 116 252 3125  
33

34 Fax: +44 116 252 3108  
35

36 e-mail: [is11@le.ac.uk](mailto:is11@le.ac.uk)  
37  
38  
39  
40  
41  
42

43 **Keywords:** Acute myocardial infarction, diabetes, glucose  
44

45  
46 **Word count: 3277**  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**ABSTRACT:**

**Objective:** To explore the relative association of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI.

**Design:** Retrospective cohort study based on the Myocardial Ischaemia National Audit Project dataset.

**Setting:** Tertiary care centre.

**Participants:** 4111 (20.3% known diabetes) consecutive patients admitted with acute myocardial infarction (58.3% STEMI) between October 2002 and September 2008.

**Primary and secondary outcome measures:** All-cause mortality at 30-days and 1-year. The relative association of admission blood glucose and of antecedent diabetes with mortality was assessed using multivariate Cox regression analysis. Furthermore we compared these relationships in patients with STEMI to those with NSTEMI.

**Results:** By 30 days and 1 year, 409 (9.9%) and 677 (16.5%) of patients died. After adjusting for covariates, diabetes did not show independent association with mortality at any time point, in the entire cohort (HR 30 days 0.93 (CI 0.63 – 1.38); 1-year 1.00 (0.77 – 1.30)) or in subgroups of STEMI (HR 30days 1.03 (0.65 – 1.64); 1 year 1.08 (0.77 – 1.51)) and non-STEMI (HR 30-days 0.62 (0.26-1.50); 1-year 0.87(0.56 – 1.36)). In contrast, after adjusting for covariates, admission glucose showed robust and independent association with mortality in the entire cohort (HR: 30 days 1.07 (1.04 – 1.10); 1-year 1.05 (1.03 – 1.08)), and in the subgroup of STEMI (30-days 1.07 (1.03 – 1.10); 1-year 1.07 (1.04 – 1.10)), and NSTEMI (HR 30 days 1.07 (1.00 - 1.14); 1-year 1.02 (0.97 - 1.06)).

**Conclusion:** Admission glucose is strongly associated with mortality in all presentations of acute myocardial infarction (AMI), irrespective of established diabetes diagnosis. The increased risk is

1  
2  
3 maintained up to 1 year. Future studies are required to assess the impact of active management of  
4  
5 elevated blood glucose in improving mortality in individuals admitted with AMI.  
6  
7  
8  
9

## 10 11 ARTICLE SUMMARY

### 12 13 Article focus

- 14  
15 • Robust associations is seen for both measures of glycaemia - the diagnosis of diabetes, and  
16  
17 elevated blood glucose levels on admission, with poor outcomes in patients with ST elevation  
18  
19 myocardial infarction (STEMI).  
20  
21 • We explored the less known, relative association of admission blood glucose levels and antecedent  
22  
23 diabetes on early and long term survival in a contemporary UK population of patients with STEMI  
24  
25 and NSTEMI.  
26  
27  
28  
29

### 30 31 Key Messages:

- 32  
33 • In patients with both STEMI as well as NSTEMI, admission glucose is more strongly associated with  
34  
35 mortality than is antecedent diabetes diagnosis.  
36  
37 • The increased risk associated with admission glucose is evident during the index admission, at 30  
38  
39 days, one year and beyond and is apparent in those surviving to discharge.  
40  
41 • Conversely, after multivariate adjustment for covariates, including admission glucose is not  
42  
43 associated with mortality.  
44  
45  
46  
47  
48

### 49 50 Strengths and limitations of this study

- 51  
52 • This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary  
53  
54 clinical practice in a tertiary care centre.  
55  
56 • A statistically robust association was seen for admission glucose with both short and loner term  
57  
58 mortality after adjusting for many important confounders.  
59  
60

- 1  
2  
3 • Our data lacks information on glucose lowering intervention, patients with undiagnosed diabetes  
4  
5 and other potentially relevant variables which were not considered in the analysis.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **INTRODUCTION**

49  
50  
51  
52 For patients with acute myocardial infarction (AMI) the risk of adverse outcome is increased by the  
53 concomitant diagnosis of diabetes mellitus (diabetes).(1, 2) In addition, elevated blood glucose  
54 concentration, a common finding at admission in patients with AMI, is also associated with increased  
55  
56  
57  
58  
59  
60

1  
2  
3 risk of adverse outcome, irrespective of prior diabetes.(1-8). In some studies (4, 9) the association  
4  
5 between admission blood glucose concentration and adverse outcome was more powerful in  
6  
7 patients without, compared to those with, prior diabetes. Indeed we previously reported more  
8  
9 powerful association with 30-day and 1-year mortality after STEMI for admission blood glucose  
10  
11 concentration, compared to the diagnosis of diabetes.(9)  
12

13  
14 While a causal relationship is unproven, there are numerous potential pathophysiological  
15  
16 mechanisms by which hyperglycaemia may impart toxicity during myocardial ischaemia.(10, 11)  
17  
18 Indeed, observational data suggest that elevated blood glucose may contribute directly to adverse  
19  
20 outcome after AMI. Prognosis is worse for patients in whom hyperglycaemia persists in the 24-48  
21  
22 hours after AMI compared to those in whom blood glucose normalises.(12, 13) In patients without  
23  
24 prior diabetes, insulin-based treatment of hyperglycaemia after AMI is associated with improved  
25  
26 prognosis.(14, 15) Further, in randomised, controlled trials (RCTs) of intensive, insulin-based blood  
27  
28 glucose management during admission with AMI, survival benefit was evident only when  
29  
30 intervention effectively lowered blood glucose concentration.(16, 17)  
31  
32

33  
34 While the relationship between blood glucose concentration and outcome after AMI has largely  
35  
36 been described in patients with STEMI, the majority of acute coronary syndromes in contemporary  
37  
38 practice are non-ST elevation AMI (NSTEMI). The aim of the current analysis was to compare the  
39  
40 relative strength of association with 30-day, and 1-year mortality of antecedent diabetes diagnosis  
41  
42 and admission blood glucose concentration in patients with STEMI and with NSTEMI, and in those  
43  
44 with and without a history of diabetes, in a multi-ethnic population. We also assessed the relevance  
45  
46 of blood glucose concentration, recorded soon after admission to hospital with AMI, to mortality in  
47  
48 patients surviving to discharge.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

Data were from consecutive admissions between 1st October 2002 – 30<sup>th</sup> September 2008, to the two coronary care units (CCU) of a large teaching hospital serving the population of Leicestershire, UK (approximately 946,000 residents in 2004). For all patients, as part of the hospital's mandatory commitment to the Myocardial Ischaemia National Audit Project (MINAP),(18) we record clinical and demographic data including information on diagnosis (STEMI/NSTEMI), electrocardiographic (ECG) site of infarct, medical history, coronary heart disease risk-factors, and prescribed medication. Data are record-linked to mortality information (19) and include self reported coding for ethnicity, for which local coverage is thorough. Approximately 10% of the local population are of South Asian ethnic origin, over twice the UK national average.

Patients were categorised as having a diagnosis of diabetes if this was self-reported by the patient, or on the basis of medication prescribed prior to admission. All patients with AMI routinely underwent blood glucose measurement, in most cases within first 12 hours after admission with their blood samples assayed in the hospital laboratory. We used such first recorded admission glucose levels for this analysis. All diagnoses of AMI were verified prior to submission to the national MINAP database; the diagnosis of AMI was made according to the joint ESC/ACCF/AHA/WHF definition.(20) Patients were categorised as STEMI or NSTEMI, according to the final discharge diagnosis recorded in the MINAP database. For patients with multiple AMI admissions during the study period, we considered only the first event. The number of cases admitted with AMI during the study period determined the sample size.

Survival was measured from the date of first admission to the date of death or of censoring at 30<sup>th</sup> September 2009. Mortality data are supplied to the hospital on a monthly basis via the UK Office for National Statistics. Follow-up data on mortality was available for all the patients. The pre-defined primary outcome measure was 30-day, and 1-year, all-cause mortality..

1  
2  
3 The study was approved by the local research ethics committee (LNR Research Ethics  
4  
5 Committee 1, Ref 09/H0406/71 for database analysis study). The data used in this  
6  
7 analysis were gathered during routine care and as part of the MINAP (18) mandatory requirement  
8  
9 for all acute hospitals in England and Wales to collect data pertaining to admission with AMI.  
10

### 11 12 **Statistical analysis**

13  
14  
15 Baseline characteristics were compared between groups using independent two-sample t-tests for  
16  
17 continuous variables and chi-squared tests for categorical variables. Mortality at 30 days and at 1  
18  
19 year, in the entire cohort, and in those patients surviving to discharge, was calculated.  
20  
21

22  
23 We calculated mortality proportions for patients admitted from 1<sup>st</sup> October 2002 to 30<sup>th</sup> September  
24  
25 2008 with follow-up censored at 30<sup>th</sup> September 2009. Survival probabilities were calculated using  
26  
27 Kaplan-Meier [KM] analyses and patient groups compared using survival analysis log rank test.  
28  
29 Relative risk of mortality, as a function of clinical variables, was examined using Cox proportional  
30  
31 hazards techniques. We initially assessed the unadjusted, univariate association with outcome for  
32  
33 admission blood glucose and for diabetes, and for other potentially relevant clinical and  
34  
35 demographic variables (age, sex, ethnicity (white European, South Asian), smoking, type of AMI  
36  
37 (STEMI, NSTEMI), prior history (hypertension, any coronary artery disease, cerebrovascular or  
38  
39 peripheral vascular disease), admission systolic blood pressure and heart rate, estimated glomerular  
40  
41 filtration rate (eGFR), coronary revascularisation during index admission, pre-admission and  
42  
43 discharge drug therapy (anti-platelet, beta-blocker, statin, angiotensin converting enzyme inhibitor/  
44  
45 angiotensin receptor blocker), and index loop diuretic use. An interaction term representing  
46  
47 calendar year of admission was included to adjust for potential temporal changes in the  
48  
49 management of acute coronary artery disease.  
50  
51  
52

53  
54 Demographic and clinical covariates with univariate association ( $p < 0.10$ ) with mortality at 30 days, or  
55  
56 1 year were entered into multivariate models (Cox proportional hazards). All quantitative variables  
57  
58  
59  
60

1  
2  
3 were entered as continuous variables into the model. Patients with missing data (Table 1) were not  
4  
5 excluded but their values were set as missing. Statistical significance for all comparisons was set at  
6  
7  $p < 0.05$  (2 sided). Data are presented as hazard ratio (HR) and 95% confidence intervals (CI). We used  
8  
9 fractional polynomials to model admission glucose to account for any non-linearity and assessed its  
10  
11 independent association with mortality in subgroups with and without diabetes. Analyses were  
12  
13 carried out using SPSS version 18.  
14  
15

## 20 RESULTS

21  
22  
23 The study population was the 4111 patients admitted between 1<sup>st</sup> October 2002 – 30<sup>th</sup> September  
24  
25 2008 with discharge diagnosis of AMI (STEMI 2397, 58.3%) and for whom a minimum of 365 days  
26  
27 follow-up was available from the date of admission. For this cohort, median follow up was 912 days  
28  
29 (range 0 to 2556) days; for 3792 (92.2%) patients surviving to discharge from the index admission,  
30  
31 median follow up was 1031 (range 1 to 2556) days.  
32  
33

34  
35 Demographic details of the study population are presented in Table 1. Prior diabetes was recorded  
36  
37 in 835 (20.3%) patients: compared to those without, patients with antecedent diabetes were on  
38  
39 average older (68.6 vs 65.8 years,  $p < 0.005$ ), more likely to be female (33.9% vs 28.9%,  $p = 0.022$ ) and  
40  
41 to have prior cardiovascular co-morbidities. Presentation with NSTEMI was more prevalent in cases  
42  
43 with (50.1%), compared to those without (39.6%), prior diabetes ( $p < 0.005$ ). Mean plasma glucose  
44  
45 was higher in patients with diabetes ( $12.0 \pm 5.5$  mmol/L) compared to those without ( $7.9 \pm 3.3$   
46  
47 mmol/L) ( $p < 0.005$ ). Mean peak CK was lower in patients with diabetes.  
48  
49

50  
51 During the index admission administration of loop diuretic was more frequent (52.7% vs 33.4%,  
52  
53  $p < 0.005$ ) and, for patients with STEMI, coronary reperfusion therapy less frequent (50.2% vs 60.9%,  
54  
55  $p < 0.005$ ), in patients with diabetes. Other than for slightly less use of beta-blockers and aspirin in  
56  
57  
58  
59  
60

1  
2  
3 patients with diabetes, patterns of prescription of secondary prevention therapies at discharge were  
4  
5 similar in the two groups.  
6  
7

### 8 **Mortality – Univariate analysis**

9  
10  
11 Deaths during hospitalisation, over 30-days, 1-year and the entire period of follow-up numbered 319  
12 (7.8%), 409 (9.9%), 677 (16.5%) and 1041 (25.3%) respectively. Age, female sex, higher admission  
13 heart rate, higher eGFR, lower systolic blood pressure and presentation with STEMI (compared to  
14 NSTEMI), as well as prior smoking and hypertension, each showed univariate association with  
15 mortality risk over all time periods (Table 2). Loop diuretic was associated with a 3-4 fold increase in  
16 mortality during follow-up. Survival improved over the period of observation.  
17  
18

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Prior diabetes showed strong univariate association with mortality risk over all time periods: HR 30  
days 1.40 (1.12 - 1.75); 1 year 1.58 (1.33 - 1.86); all follow-up 1.66 (1.44, 1.90)) (Table 2). The  
strength of association between glucose and mortality was consistent at 30-days and at 1-year, each  
mmol/L increase in admission glucose concentration being associated with a 6-7% increase in hazard  
of mortality over all time periods.

### 37 **Post-discharge mortality**

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In those surviving to discharge (N=3792), 106 (2.8%), 363 (9.6%) and 726 (19.1%) died by 30-days, 1-  
year and over all follow-up (Table 2A, Supplementary data). Univariate associations with mortality  
were similar to those in the entire population. Prior diabetes showed univariate association with  
increased risk of death at all times, although this was not statistically significant at 30 days (HR 1.36,  
(0.87 - 2.12)). For admission glucose, the strength of association with post-discharge mortality was  
very similar to that in the entire cohort, with 5-7% increase risk per mmol/L increase in glucose.  
(Table 2A, Supplementary Data).

### 56 **Mortality – Multivariate analysis**



1  
2  
3 Table 3 shows the results of multivariate analysis. Age, lower admission systolic blood pressure and  
4 higher heart rate, lower eGFR, prescription of loop diuretic, and STEMI (compared to NSTEMI) each  
5 retained independent association with mortality, as did prescription of individual discharge  
6 medications. After covariate adjustment, diabetes did not retain independent association with  
7 mortality at any time. In contrast, adjustment for covariates had little impact upon the risk of  
8 mortality associated with admission glucose concentration.  
9  
10  
11  
12  
13  
14  
15

### 16 17 **Post-discharge mortality**

18  
19  
20 For patients surviving to discharge, associations between clinical variables and the risk of mortality  
21 were similar to those seen in the entire cohort (Table 3A, Supplementary data). While there was no  
22 association between prior diabetes and risk of mortality at any time (HR 30 days 0.64 (0.31 – 1.300);  
23 1 year 0.91 (0.66 – 1.26); all follow-up 1.08 (0.86 – 1.36)), blood glucose retained powerful  
24 association with the primary endpoint. This was evident at 30 days (HR per mmol/L 1.10, 95% CI 1.05  
25 – 1.15), 1 year (1.05, 1.02 – 1.08), and over all follow-up (1.04, 1.02 – 1.06)).  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Admission glucose concentration – influence on mortality in patients with or without diabetes**

35  
36  
37 We repeated multivariate analysis including a term for interaction between diabetes diagnosis and  
38 admission glucose concentration. While numerically greater in individuals without diabetes (Figure  
39 1), there was no conventional statistically significant difference in the association between mortality  
40 and admission blood glucose for patients with and without diabetes (30 days HR 1.00, (CI 0.97 –  
41 1.03, p=0.95; 1 year 0.99, (0.97 – 1.02), p=0.66; entire follow-up 0.99, (0.97 – 1.01, p=0.42)).  
42  
43  
44  
45  
46  
47  
48

### 49 **Diabetes and glucose after AMI – influence on mortality in STEMI and NSTEMI**

50  
51  
52 After adjustment for covariates, diabetes showed no statistically significant association with  
53 mortality at any time period, either for STEMI or NSTEMI (Table 4). The strength of association  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 between blood glucose and mortality was very similar in the first 30 days after STEMI or NSTEMI.  
4  
5 The strength of this relationship declined with time only after NSTEMI.  
6  
7  
8  
9

## 10 11 **DISCUSSION**

12  
13  
14 It is well known that, both prior diabetes diagnosis, and admission blood glucose concentration, are  
15 associated with adverse outcome after AMI. In this report we compared the relative association of  
16 these two measures of dysglycaemia with survival after STEMI as well as NSTEMI. Irrespective of the  
17 type of AMI, the univariate association with mortality risk for antecedent diabetes (40% excess at 30  
18 days, 55-65% thereafter) was no longer apparent after adjustment for relevant covariates including  
19 admission glucose concentration. In contrast, the excess risk associated with increasing glucose was  
20 not reduced after adjustment, was similar in those with and without known diabetes, and remained  
21 relevant in patients discharged alive from the index event.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 In our previous report of over 4000 patients with STEMI, admitted in 1993-2004,(9) the 50% increase  
34 in 30-day and 1-year mortality risk associated with known diabetes was attenuated by half on  
35 covariate adjustment and removed completely when admission blood glucose concentration was  
36 included in the analysis. The current report confirms these observations and extends them to a  
37 contemporary period, and to patients with NSTEMI as well as STEMI, in whom the strength of  
38 association between admission blood glucose concentration and 30-day mortality risk was similar,  
39 and concentration dependent. Importantly, the excess risk, around 7% for each 1mmol/L increase in  
40 admission glucose concentration, was maintained up to and beyond 1 year from the index infarction.  
41 Further, this phenomenon was attenuated with time only for patients with NSTEMI, and was evident  
42 even in those patients who survived to discharge from hospital, two potentially important clinical  
43 observations. These findings are in contrast to one previous report which reported the association  
44 between admission glucose and mortality to be confined to in-hospital deaths following either  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 STEMI or NSTEMI.(8) They are however in keeping with the vast majority of reports in this area.(1-7,  
4  
5 9, 11)  
6  
7

8  
9 In contrast to most previous reports,(1-9, 11) we observed no independent association between  
10  
11 diabetes and mortality risk after AMI. However, to our knowledge and unlike the present report,  
12  
13 none of these studies adjusted for admission blood glucose, and each reported individual  
14  
15 relationships between mortality after AMI and either diabetes diagnosis (1, 2, 4, 8) or blood glucose  
16  
17 concentration.(3-8, 11-13, 21) The current analysis and our previous study (9) are the only reports to  
18  
19 compare the relative association with outcome of both diabetes and blood glucose concentration.  
20  
21 Both studies demonstrate a much stronger relationship between survival and blood glucose, and the  
22  
23 loss of association between mortality and diabetes when blood glucose is considered. Due to  
24  
25 incomplete data and lack of power, we could not assess whether outcomes varied by diabetes  
26  
27 therapies. However previous studies have reported an independent association of admission blood  
28  
29 glucose with mortality regardless of diabetic therapy used.(2,5,7)  
30  
31

32  
33 These observations are of potential clinical significance. While admission blood glucose  
34  
35 concentration after AMI is on average higher in patients with, compared to those without, known  
36  
37 diabetes,(4, 8, 9) there is considerable overlap, as seen in the current report (Figure 1). While many  
38  
39 patients presenting with AMI will have previously undiagnosed diabetes,(22) blood glucose at the  
40  
41 time of admission with AMI is not a reliable indicator of the subsequent diagnosis of diabetes.(23,  
42  
43 24) In routine practice, the management of hyperglycaemia after AMI is influenced by the presence  
44  
45 of prior diabetes diagnosis.(5) In both European(14) and North American(6) settings, the majority  
46  
47 (>65%) of patients presenting with hyperglycaemia in the context of AMI, and not previously known  
48  
49 to have diabetes, do not receive active management of blood glucose. In the presence of a true,  
50  
51 direct toxic effect upon prognosis of elevated blood glucose, failure to correct hyperglycaemia may  
52  
53 represent suboptimal clinical care, and patients without known diabetes may be particularly  
54  
55 disadvantaged. In particular, our demonstration that the relationship between glucose  
56  
57  
58  
59  
60

1  
2  
3 concentration and subsequent outcome is evident in NSTEMI as well as STEMI is of clear clinical  
4  
5 relevance in terms of the overall management of patients presenting with AMI.  
6  
7

8  
9 The strength of association between diabetes and mortality risk after AMI has been reported to  
10  
11 increase with time from the event.(25) While we observed such a trend on univariate analysis, this  
12  
13 was attenuated in multivariate analysis, an observation which may relate to our inclusion of blood  
14  
15 glucose as a covariate. A previous meta-analysis suggested a stronger association between  
16  
17 admission blood glucose and adverse outcome.(4) While we could not demonstrate formal statistical  
18  
19 evidence of such a phenomenon, our data show convincingly that the relationship between glucose  
20  
21 and outcome is at least as powerful in patients without known diabetes. Blood glucose soon after  
22  
23 admission represents an easily identified, clinically relevant marker of risk after AMI, which should  
24  
25 be assessed routinely irrespective of diabetes status.  
26  
27

28  
29 An important observation from this study is the persisting association between admission blood  
30  
31 glucose concentration and mortality risk in patients surviving to discharge, in both NSTEMI and  
32  
33 STEMI. While in keeping with the possibility that blood glucose concentration at admission reflects  
34  
35 the degree of individual physiological stress, or is a marker of the extent of infarction, our findings  
36  
37 are as much in keeping with a direct, adverse influence on prognosis of acute hyperglycaemia. The  
38  
39 mechanisms by which elevated glucose may be directly cardiotoxic have been summarised  
40  
41 elsewhere (10) and include attenuation of ischaemic preconditioning, QT prolongation, increased  
42  
43 thrombophilia, and endothelial dysfunction. Furthermore, clinical studies overwhelmingly support a  
44  
45 possible causal link between hyperglycaemia and adverse prognosis after AMI. Hyperglycaemia  
46  
47 persisting at 24 hours after admission is associated with adverse outcome,(12, 13, 17).  
48  
49

50  
51 While observational studies show consistently the adverse association between hyperglycaemia and  
52  
53 outcomes post AMI, results of the RCTs of active management of blood glucose have been  
54  
55 inconsistent.(16,17) However, in such trials, effective reduction in blood glucose with an  
56  
57 intervention after AMI was associated with improved prognosis.(16) The guidelines from  
58  
59  
60

1  
2  
3 professional societies in this area differ in their recommendations.(27,28) In the North American  
4  
5 guidelines, intensive glucose control is recommended in patients with AMI and significant  
6  
7 hyperglycaemia (blood glucose levels > 10.0 mmol/L) admitted in an intensive care unit.(28) In  
8  
9 contrast, the National Institute for Health and Clinical Excellence guidance recommends against  
10  
11 routine use of intensive insulin therapy to manage hyperglycaemia (blood glucose levels > 11.0  
12  
13 mmol/L) in patients with acute coronary syndrome.(27) The latter guidelines highlighted a need for  
14  
15 randomised controlled trials addressing specific gaps in knowledge this area.  
16  
17

18  
19 Our report is subject to the limitations inherent in all observational cohort studies. Our results are  
20  
21 from a single-centre study. In the early years of the MINAP project, data on only STEMI were  
22  
23 collected. Furthermore, data collected for MINAP was gathered mainly from a setting of coronary  
24  
25 care unit. Selection bias could be the reason behind the overall low numbers of AMI cases (4111)  
26  
27 recruited in our study over a six year period in a catchment population of 1 million. However  
28  
29 baseline and clinical outcome parameters in our study are similar to previous studies. Selection bias  
30  
31 could also explain relatively high proportion of patients with STEMI (58.4%) compared to NSTEMI in  
32  
33 our cohort. We therefore conducted subgroup analysis for people with STEMI and NSTEMI and  
34  
35 compared their outcomes. Blood glucose concentration used in this analysis was that first recorded  
36  
37 for the index admission, and is likely to have varied in timing relative to symptom onset. Our  
38  
39 database lacks information on left ventricular (LV) ejection fraction, evidence of heart failure, and a  
40  
41 number of other potentially relevant variables. Information on body mass index, an indicator of  
42  
43 underlying metabolic syndrome and associated dysglycaemia, was not available. Further, we have  
44  
45 no information regarding the number of patients who were given a diagnosis of diabetes during, or  
46  
47 subsequent to, the index admission. However, if elevated glucose contributes directly to prognosis,  
48  
49 active management is likely to confer greater benefit when delivered as early as possible,  
50  
51 irrespective of subsequent diabetes status. Thus we suggest the first recorded blood glucose  
52  
53 concentration to be highly relevant to guiding appropriate management in individual patients,  
54  
55 irrespective of residual LV function. While we have no information on interventions or changes to  
56  
57  
58  
59  
60

1  
2  
3 therapy after discharge, it is unlikely that these impacted on outcome in a major way, as the  
4  
5 strongest association between mortality and glucose was in the first 30 days. Findings of our study  
6  
7 based on real-life practice are applicable to other populations treated in similar setting.  
8  
9

10  
11 In summary, admission blood glucose concentration is a powerful, routinely available marker of  
12  
13 mortality risk after AMI. After adjustment for admission blood glucose, known diabetes is not  
14  
15 associated with adverse outcome. The association between blood glucose concentration and  
16  
17 mortality risk is of similar magnitude in patients with and without known diabetes, is evident for  
18  
19 NSTEMI as well as STEMI, and persists beyond 1 year from the index event, including in patients  
20  
21 surviving to discharge. Future studies are merited of the impact of active management of blood  
22  
23 glucose in patients with all presentations of acute coronary artery disease, irrespective of diabetes  
24  
25 diagnosis.  
26  
27  
28  
29  
30  
31

## 32 **ARTICLE SUMMARY**

### 33 **Article focus**

- 34  
35  
36  
37  
38 • Robust associations is seen for both measures of glycaemia - the diagnosis of diabetes, and  
39  
40 elevated blood glucose levels on admission, with poor outcomes in patients with ST  
41  
42 elevation myocardial infarction (STEMI).  
43  
44
- 45  
46 • We explored the less known, relative association of admission blood glucose levels and  
47  
48 antecedent diabetes on early and long term survival in a contemporary UK population of  
49  
50 patients with STEMI and NSTEMI.  
51

### 52 **Key Messages:**

- In patients with both STEMI as well as NSTEMI, admission glucose is more strongly associated with mortality than is antecedent diabetes diagnosis.
- The increased risk associated with admission glucose is evident during the index admission, at 30 days, one year and beyond and is apparent in those surviving to discharge.
- Conversely, after multivariate adjustment for covariates, including admission glucose is not associated with mortality.

#### **Strengths and limitations of this study**

- This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary clinical practice in a tertiary care centre.
- A statistically robust association was seen for admission glucose with both short and longer term mortality after adjusting for many important confounders.
- Our data lacks information on glucose lowering intervention, patients with undiagnosed diabetes and other potentially relevant variables which were not considered in the analysis.

Table 1: Baseline characteristics at admission stratified by diabetes status

	All n=4111	Known DM n= 835 (20.3%)	Not Known DM n=3276 (79.7%)	P Value*	Missing Value (%)
<b>Demography</b>					
Age (years)	66.4 (13.3)	68.6 (11.8)	65.8 (13.6)	<0.005	0.0
Women (%)	1224 (29.8)	276 (33.1)	948 (28.9)	0.022	0.0
<b>Ethnicity (%)</b>					
White European	3381 (82.2%)	545 (16.1)	2836 (86.6)	<0.005	0.0
South Asian	730 ( 17.8%)	290 (39.7%)	440 (60.3%)		0.0
<b>Medical History (%)</b>					
Hypertension	2048 (50.3)	584 (70.0)	1464 (45.0)	<0.005	1.0
Current/Ex Smoker	1366 (35.7)	282 (36.8)	1084 (35.5)	0.527	7.1
Coronary Heart Disease§	491 (12.1)	149 (17.9)	342 (10.6)	<0.005	0.9
CVA	254 (6.3)	86 (10.3)	168 (5.2)	<0.005	1.2
PVD	154 (3.8)	42 (5.0)	112 (3.5)	0.041	1.2
Heart Failure	190 (4.7)	76 (9.1)	114 (3.5)	<0.005	1.2
<b>Type of Infarction (%)</b>					
STEMI	2397 (58.3)	417 (49.9)	1980 (60.4)	<0.005	0.0
nSTEMI	1714 (41.7)	418 (50.1)	1296 (39.6)		
<b>Physical Examination</b>					
Heart Rate (beats/min)	81.1 (24.3)	85.5 (25.3)	80.0 (24.0)	<0.005	1.5
SBP (mmHg)	136.5 (28.4)	137.7 (30.7)	136.2 (27.8)	0.202	1.0
<b>Biochemical Data</b>					
Peak CK (IU/L, Normal range < 200)	1113.5 (1810.4)	939.9 (1279.3)	1156.4 (1917)	<0.005	7.6
Creatinine (µmol/L)	116.4 (63.8)	128.8 (76.1)	113.1 (59.8)	<0.005	16.8
eGFR (mL/min)	63.0 (22.2)	57.7 (23.6)	64.4 (21.7)	<0.005	16.6
Total cholesterol (mmol/L)	5.1 (1.3)	4.4 (1.2)	5.2 (1.3)	<0.005	16.6
Haemoglobin (g/L)	13.7 (1.9)	13.0 (1.9)	13.9 (1.8)	<0.005	66.6
Plasma glucose (mmol/L)	8.8 (4.2)	12.0 (5.5)	7.9 (3.3)	<0.005	14.9
<b>Therapies (%)</b>					
<b>Prior to index admission</b>					
Aspirin	2671 (65.0)	622 (74.5)	2049 (62.5)	<0.005	0.0
Beta blocker	990 (25.6)	265 (33.2)	725 (23.6)	<0.005	6.0
ACEI or ARB	1097 (28.3)	407 (51.0)	690 (22.5)	<0.005	5.8
Statins	1083 (28.0)	389 (48.7)	694 (22.6)	<0.005	5.8
<b>In-hospital</b>					
Reperfusion therapy #	2414 (58.7)	419 (50.2)	1995 (60.9)	<0.005	0.0
Loop diuretics	1502 (37.4)	436 (52.7)	1066 (33.4)	<0.005	2.3
<b>At discharge</b>					
Aspirin	2701 (68.1)	529 (65.3)	2172 (68.8)	0.057	3.5
Beta blocker	2513 (63.3)	483 (59.6)	2030 (64.3)	0.013	3.5
ACEI or ARB	2493 (62.9)	495 (61.0)	1998 (63.4)	0.222	3.6
Statin	2704 (67.7)	537 (65.6)	2167 (68.2)	0.167	2.8

All values are mean (SD) or number (%). \* known diabetes vs not known diabetes. DM, Diabetes Mellitus; CVA, Cerebrovascular accidents; PVD, Peripheral Vascular Disease; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; SBP, Systolic blood pressure; CK, Creatinine Kinase; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

# thrombolysis or coronary intervention (PCI or CABG) or both



**Table 2:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals)

N=4111	Mortality, N (%)		
	30 days	1 Year	All (Median 912 days)
	409 (9.95)	677 (16.47)	1041 (25.32)
<b>Admission Demographic Variable</b>			
Gender (Female vs Male)	0.535 (0.439, 0.650)	0.515 (0.443, 0.600)	0.554 (0.490, 0.627)
Age (year)	1.068 (1.059, 1.078)	1.077 (1.069, 1.084)	1.084 (1.077, 1.090)
SBP (mmHg)	0.979 (0.976, 0.983)	0.987 (0.984, 0.990)	0.992 (0.990, 0.994)
Heart Rate (beat/min)	1.010 (1.006, 1.013)	1.012 (1.009, 1.014)	1.012 (1.010, 1.014)
Total Cholesterol (mmol/L)	0.732 (0.666, 0.806)	0.765 (0.712, 0.821)	0.744 (0.703, 0.788)
Admission plasma glucose (mmol/L)	1.072 (1.052, 1.084)	1.065 (1.055, 1.076)	1.059 (1.050, 1.068)
eGFR (mL/min)	0.956 (0.951, 0.961)	0.955 (0.951, 0.959)	0.959 (0.956, 0.962)
NSTEMI vs STEMI	0.504 (0.405, 0.627)	0.736 (0.629, 0.862)	0.939 (0.830, 1.063)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.909 (0.688, 1.200)	0.846 (0.681, 1.052)	0.919 (0.780, 1.082)
2005	0.591 (0.402, 0.870)	0.652 (0.491, 0.865)	0.702 (0.564, 0.873)
2006	0.830 (0.592, 1.164)	0.696 (0.529, 0.917)	0.716 (0.572, 0.897)
2007	0.759 (0.570, 1.010)	0.678 (0.541, 0.849)	0.679 (0.558, 0.826)
2008	0.485 (0.338, 0.696)	0.551 (0.424, 0.716)	0.531 (0.415, 0.680)
Test for Linear Trend (p-value)	<0.001	<0.001	<0.001
<b>Ethnicity</b> (South Asian vs. White European)	1.013 (0.786, 1.304)	0.909 (0.741, 1.114)	0.856 (0.725, 1.012)
<b>Medical History (Yes vs No)</b>			
Smoking	1.016 (0.819, 1.259)	1.049 (0.891, 1.235)	1.160 (1.019, 1.320)
Prior Diabetes	1.400 (1.121, 1.750)	1.576 (1.331, 1.865)	1.655 (1.445, 1.896)
Prior Coronary Heart Disease §	0.862 (0.628, 1.182)	0.998 (0.791, 1.258)	1.113 (0.931, 1.330)
Prior Hypertension	1.286 (1.056, 1.567)	1.437 (1.232, 1.676)	1.472 (1.300, 1.666)
<b>Pre-Admission Medication (Yes vs No)</b>			
Aspirin	0.746 (0.613, 0.909)	0.869 (0.744, 1.015)	0.913 (0.804, 1.036)
Beta Blocker	1.385 (1.116, 1.719)	1.577 (1.338, 1.859)	1.489 (1.301, 1.703)
Statin	0.994 (0.795, 1.245)	1.129 (0.953, 1.338)	1.194 (1.041, 1.370)
ACEI or ARB	1.242 (1.002, 1.540)	1.467 (1.247, 1.726)	1.621 (1.423, 1.847)
<b>Admission treatment (Yes vs No)</b>			
Initial Reperfusion	0.616 (0.507, 0.749)	0.540 (0.464, 0.629)	0.466 (0.411, 0.527)
Loop Diuretic	3.457 (2.807, 4.256)	4.348 (3.681, 5.136)	4.052 (3.556, 4.618)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.043 (0.029, 0.062)	0.227 (0.192, 0.269)	0.439 (0.386, 0.499)
Beta Blocker	0.038 (0.025, 0.058)	0.237 (0.199, 0.282)	0.406 (0.357, 0.461)
Statin	0.043 (0.029, 0.062)	0.196 (0.165, 0.233)	0.344 (0.303, 0.390)
ACEI or ARB	0.047 (0.031, 0.700)	0.236 (0.198, 0.281)	0.469 (0.412, 0.533)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Table 3:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals).

N=4111	Mortality, N (%)		
	30 days 409 (9.95)	1 Year 677 (16.5)	All (Median 912 days) 1041 (25.3)
<b>Admission Demographics</b>			
Gender (Female vs Male)	1.268 (0.885, 1.819)	1.094 (0.865, 1.383)	1.114 (0.931, 1.332)
Age (year)	1.059 (1.040, 1.078)	1.062 (1.048, 1.075)	1.073 (1.062, 1.083)
SBP (mmHg)	0.987 (0.981, 0.992)	0.991 (0.987, 0.995)	0.993 (0.990, 0.996)
Heart Rate (beat/min)	1.007 (1.001, 1.013)	1.006 (1.002, 1.010)	1.007 (1.005, 1.010)
Admission plasma glucose (mmol/L)	1.072 (1.042, 1.104)	1.059 (1.037, 1.081)	1.053 (1.036, 1.071)
eGFR (mL/min)	0.987 (0.978, 0.996)	0.983 (0.977, 0.990)	0.988 (0.983, 0.993)
<b>nSTEMI vs STEMI</b>	0.411 (0.282, 0.597)	0.558 (0.443, 0.704)	0.700 (0.587, 0.834)
<b>Ethnicity</b> (South Asian vs White European)	1.355 (0.893, 2.057)	1.155 (0.851, 1.568)	0.996 (0.779, 1.273)
<b>Medical History (Yes vs No)</b>			
Smoking	1.125 (0.788, 1.607)	0.953 (0.749, 1.213)	0.942 (0.786, 1.130)
Prior Diabetes	0.934 (0.631, 1.382)	1.001 (0.770, 1.300)	1.134 (0.927, 1.386)
Prior Coronary Heart Disease§	0.717 (0.402, 1.278)	0.898 (0.632, 1.277)	1.111 (0.864, 1.428)
Prior Hypertension	1.291 (0.903, 1.846)	1.155 (0.913, 1.461)	1.133 (0.949, 1.353)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.944 (0.667, 1.335)	0.989 (0.781, 1.252)	1.010 (0.842, 1.213)
Beta Blocker	1.288 (0.898, 1.849)	1.363 (1.067, 1.742)	1.173 (0.970, 1.418)
Statin	0.863 (0.579, 1.286)	0.877 (0.668, 1.150)	0.918 (0.743, 1.135)
ACEI or ARB	0.719 (0.497, 1.042)	0.932 (0.728, 1.194)	1.017 (0.840, 1.232)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.416 (0.993, 2.019)	1.703 (1.322, 2.195)	1.532 (1.268, 1.851)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.297 (0.157, 0.562)	0.656 (0.479, 0.897)	0.861 (0.676, 1.097)
Beta Blocker	0.257 (0.133, 0.494)	0.564 (0.423, 0.753)	0.671 (0.544, 0.828)
Statin	0.628 (0.295, 1.339)	0.683 (0.484, 0.963)	0.629 (0.490, 0.808)
ACEI or ARB	0.470 (0.229, 0.968)	0.610 (0.443, 0.839)	0.850 (0.668, 1.081)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Table 4:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the subgroups of patients with STEMI and NSTEMI. Data are hazard ratio (95% confidence intervals)

N=4111		Mortality, N (%)					
STEMI	NSTEMI	30 days		1 Year		All	
2397	1714	STEMI	NSTEMI	STEMI	NSTEMI	STEMI	NSTEMI
<b>Admission Demographics</b>							
Age (year)		1.055 (1.033 - 1.077)	1.073 (1.031 - 1.116)	1.061 (1.044 - 1.078)	1.056 (1.035 - 1.079)	1.077 (1.062 - 1.091)	1.061 (1.046 - 1.077)
SBP (mmHg)		0.988 (0.982 - 0.994)	0.983 (0.970 - 0.995)	0.992 (0.987 - 0.997)	0.988 (0.982 - 0.995)	0.993 (0.989 - 0.997)	0.994 (0.990 - 0.998)
Heart Rate (beat/min)		1.008 (1.001 - 1.015)	1.008 (0.997 - 1.02)	1.008 (1.002 - 1.013)	1.007 (1.001 - 1.013)	1.008 (1.004 - 1.012)	1.007 (1.002 - 1.011)
eGFR (mL/min)		0.986 (0.975 - 0.997)	0.987 (0.969 - 1.005)	0.982 (0.974 - 0.991)	0.978 (0.968 - 0.989)	0.986 (0.979 - 0.993)	0.987 (0.979 - 0.995)
Admission plasma glucose		1.070 (1.034 - 1.107)	1.074 (1.005 - 1.148)	1.071 (1.042 - 1.10)	1.021 (0.979 - 1.066)	1.076 (1.051 - 1.10)	1.014 (0.983 - 1.047)
Prior Diabetes		1.035 (0.652 - 1.641)	0.629 (0.264 - 1.502)	1.083 (0.772 - 1.518)	0.878 (0.566 - 1.36)	1.189 (0.907 - 1.559)	1.055 (0.773 - 1.44)
<b>Admission treatment (Yes vs No)</b>							
Loop Diuretic		1.330 (0.890 - 1.989)	1.66 (0.759 - 3.629)	1.706 (1.248 - 2.333)	1.988 (1.283 - 3.081)	1.365 (1.068 - 1.745)	2.03 (1.496 - 2.756)
<b>Discharge Medication (Yes vs No)</b>							
Aspirin		0.301 (0.135 - 0.672)	0.308 (0.088 - 1.076)	0.499 (0.322 - 0.773)	0.869 (0.523 - 1.433)	0.697 (0.501 - 0.970)	1.052 (0.711 - 1.557)
Beta Blocker		0.208 (0.095 - 0.455)	0.337 (0.094 - 1.207)	0.469 (0.320 - 0.687)	0.77 (0.485 - 1.222)	0.520 (0.393 - 0.698)	0.939 (0.674 - 1.308)
Statin		1.046 (0.375 - 2.918)	0.255 (0.066 - 0.992)	0.551 (0.334 - 0.908)	0.745 (0.449 - 1.237)	0.615 (0.429 - 0.880)	0.65 (0.444 - 0.951)
ACEI or ARB		0.392 (0.153 - 1.006)	0.451 (0.121 - 1.673)	0.903 (0.545 - 1.496)	0.541 (0.348 - 0.841)	1.041 (0.712 - 1.523)	0.857 (0.616 - 1.194)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

1  
2  
3 **Contributors:** NG, IS, KK conceived the idea of the study and were responsible for the design of the  
4  
5 study. NG, RM were responsible for undertaking for the data analysis and produced the tables and  
6  
7 graphs. IS, KK, MJD provided input into the data analysis. The initial draft of the manuscript was  
8  
9 prepared by NG and IS and then circulated repeatedly amongst all authors for critical revision. IS was  
10  
11 responsible for the acquisition of the data and IS, NG, RM, KK and MJD contributed to the  
12  
13 interpretation of the results.  
14

15  
16  
17 **Funding:** This research received no specific grant from any funding agency in the public, commercial  
18  
19 or not-for-profit sectors. The work in this paper is part of the research portfolio supported by the  
20  
21 Leicester NIHR Biomedical Research Unit in Cardiovascular Disease. NG has received support by the  
22  
23 National Institute for Health Research, Collaboration for Leadership in Applied Health Research and  
24  
25 Care - Leicestershire, Northamptonshire and Rutland (NIHR CLAHRC for LNR) project for a PhD.  
26  
27

28  
29 **Competing interests:** None  
30

31  
32 **Ethical approval:** The study was approved by the local research ethics committee (LNR Research  
33  
34 Ethics Committee 1, Ref 09/H0406/71 for database analysis study).  
35  
36

37 **Copyright/licence for publication:** The Corresponding Author has the right to grant on behalf of all  
38  
39 authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for  
40  
41 government employees) on a worldwide basis to the BMJ Group and co-owners or contracting  
42  
43 owning societies (where published by the BMJ group on their behalf), and its Licensees to permit this  
44  
45 article (if accepted) to be published in the Heart edition and any other BMJPG products and to  
46  
47 exploit all subsidiary rights, as set out in our licence.  
48  
49

50  
51  
52  
53  
54  
55  
56  
57 **REFERENCES**  
58  
59  
60

- 1  
2  
3 1. Malmberg K, Yusuf S, Gerstein HC, *et al.* Impact of diabetes on long-term prognosis in patients  
4  
5 with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry.  
6  
7 *Circulation* 2000;102:1014-1019.  
8  
9
- 10 2. McGuire DK, Emanuelsson H, Granger CB, *et al.* Influence of diabetes mellitus on clinical  
11  
12 outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO IIb  
13  
14 study. *Eur Heart J* 2000;21:1750-1758  
15  
16
- 17 3. Svensson A-M, McGuire DK, Abrahamsson P, *et al.* Association between hyper- and  
18  
19 hypoglycaemia and 2-year all-cause mortality risk in diabetic patients with acute coronary  
20  
21 events. *Eur Heart J* 2005;26:1255-1261  
22  
23
- 24 4. Capes SE, Hunt D, Malmberg K, *et al.* Stress hyperglycaemia and increased risk of death after  
25  
26 myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet*  
27  
28 2000;355:773-778  
29  
30
- 31 5. Wahab NN, Cowden EA, Pearce NJ, *et al.* Is blood glucose an independent predictor of  
32  
33 mortality in acute myocardial infarction in the thrombolytic era ? *J. Am. Coll. Cardiol*  
34  
35 2002;40:1748- 1754  
36  
37
- 38 6. Kosiborod M, Rathore SS, Inzucchi SE, *et al.* Admission glucose and mortality in elderly patients  
39  
40 hospitalised with acute myocardial infarction. *Circulation* 2005;111:3078-3086  
41  
42
- 43 7. Cao JJ, Hudson M, Jankowski M, *et al.* Relation of chronic and acute glycaemic control on  
44  
45 mortality in acute myocardial infarction with diabetes mellitus. *Am J Cardiol* 2005;96:183-186  
46  
47
- 48 8. Sinnaeve PR, Steg G, Fox KAA, *et al.* Association of fasting glucose with increased short-term  
49  
50 and 6-month mortality in ST-elevation and non ST-elevation acute coronary syndromes. *Arch*  
51  
52 *Int Med* 2009;169:402-409  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 9. Squire IB, Nelson CP, Ng LL, *et al.* Prognostic value of admission blood glucose concentration  
4  
5 and diabetes diagnosis on survival after acute myocardial infarction; Results from 4702 index  
6  
7 cases in routine practice. *Clin Sci (London)* 2010;118:527-535  
8  
9
- 10  
11 10. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. *Eur Heart J*  
12  
13 2001;26:328-331  
14
- 15  
16 11. De Caterina R, Madonna R, Sourij H, *et al.* Glycaemia control in acute coronary syndromes:  
17  
18 prognostic value and therapeutic options. *Eur Heart J* 2010;31:1557-1564  
19  
20
- 21  
22 12. Ghoyal A, Mahaffey KW, Garg J, *et al.* Prognostic significance of the change in glucose level in  
23  
24 the first 24h after acute myocardial infarction: results from the CARDINAL study. *Eur Heart J*  
25  
26 2006;27:1289-1297  
27
- 28  
29 13. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for  
30  
31 long-term prognosis after myocardial infarction even in non-diabetic patients. *Diabetes Care*  
32  
33 1999;22:1827-1831  
34  
35
- 36  
37 14. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for  
38  
39 hyperglycaemic patients without known diabetes who present with an acute coronary  
40  
41 syndrome. *Heart* 2007;93:1542-1546  
42
- 43  
44 15. Schnell O, Schafer O, Kleybrink S, *et al.* Intensification of therapeutic approaches reduces  
45  
46 mortality in diabetic patients with acute myocardial infarction: the Munich registry. *Diabetes*  
47  
48 *Care* 2004;27:455-460.  
49
- 50  
51 16. Malmberg K, Ryden L, Efendic S, *et al.* Randomised trial of insulin-glucose infusion followed by  
52  
53 subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI  
54  
55 study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995;26:57-65  
56  
57  
58  
59  
60

- 1  
2  
3 17. Malmberg K, Ryden L, Wedel H, *et al*; DIGAMI 2 Investigators. Intense metabolic control by  
4 means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2):  
5 effects on mortality and morbidity. *Eur Heart J* 2005;26:650-661  
6  
7  
8  
9  
10 18. Herrett E, Smeeth L, Walker L, *et al*; MINAP Academic group. The Myocardial Ischaemia  
11 National Audit Project (MINAP) *Heart* 2010;96:1264-67  
12  
13  
14  
15 19. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly  
16 admitted to hospital with heart failure in the United Kingdom: historical cohort study. *BMJ*  
17 2003; 327(7414):526-31  
18  
19  
20 20. Thygesen K, Alpert JS, White HD. The Joint ESC/ACCF/AHA/WHF Task Force for the redefinition  
21 of myocardial infarction. *Eur Heart J* 2007;28:2525-2538  
22  
23  
24  
25 21. Garber AJ, Moghissi ES, Bransome ED Jr, *et al*; American College of Endocrinology Task Force  
26 on Inpatient Diabetes Metabolic Control. *Endocr Pract* 2004;10:77-82  
27  
28  
29 22. Kosiborod M, Inzucchi SE, Krumholz HM *et al*. Glucometrics in patients hospitalized with acute  
30 myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation*  
31 2008;117:1018  
32  
33  
34 23. Norhammar A, Tenerz A, Nilsson G, *et al*. Glucose metabolism in patients with acute  
35 myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.  
36 *Lancet* 2002;359:2140-2144.  
37  
38  
39 24. Tenerz A, Lonnberg I, Berne C, *et al*. Myocardial infarction and prevalence of diabetes  
40 mellitus, Is increased casual blood glucose at admission a reliable criterion for the diagnosis of  
41 diabetes? *Eur Heart J* 2001;22:1102-1110  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 25. De Mulder M, Oemrawsingh RH, Stam F, *et al.* Comparison of diagnostic criteria to detect  
4  
5 undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. *Heart* 2011;  
6  
7 10.1136/heartjnl-2011-300163  
8  
9  
10 26. Melchior T, Kober L, Madsen CR, *et al.* Accelerating impact of diabetes mellitus on mortality in  
11  
12 the years following an acute myocardial infarction. *Eur Heart J* 1999;20:973-978  
13  
14  
15 27. National Institute for Health and Clinical Excellence. (2011) Hyperglycaemia in acute coronary  
16  
17 syndromes: management of hyperglycaemia in people with acute coronary syndromes. (CG  
18  
19 130). London: National Institute for Health and Clinical Excellence.  
20  
21  
22  
23 28. Deedwaniap, Kosibirod M, Barrett E *et al.* Hyperglycaemia and acute coronary syndrome. A  
24  
25 scientific Statement from the American Heart Association Diabetes Committee of the Council  
26  
27 on Nutrition, Physical activity and Metabolism. *Circulation* 2008;117:1610-9.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Review only




**FIGURE LEGENDS**

Figure 1: Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The bars represent the number of people at various glucose levels. Solid lines indicate odds ratios while dotted lines indicate 95% confidence intervals. Solid bars and black lines indicate patients with diabetes. Clear bars and red lines indicate patients without Diabetes.

For peer review only



**Figure 1:** Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The **bars** represent the number of people at various glucose levels. **Solid lines** indicate odds ratios while **dotted** lines indicate 95% confidence intervals. **Solid bars** and **black lines** indicate patients with diabetes. **Clear bars** and **red lines** indicate patients without Diabetes.

70x51mm (300 x 300 DPI)

**Supplementary Table 2A:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the survivors at discharge cohort. Data are hazard ratio (95% confidence intervals)

N= 3790	Mortality N(%)		
	30 days 106(2.80)	1 Year 363(9.60)	All 726(19.10)
<b>Admission Demographics Variables</b>			
Gender (Female vs Male)	0.585 (0.395 , 0.865)	0.520 (0.422 , 0.640)	0.577 (0.497 , 0.670)
Age (year)	1.059 (1.041 , 1.077)	1.080 (1.069 , 1.090)	1.088 (1.080 , 1.096)
SBP (mmHg)	0.985 (0.978 , 0.992)	0.995 (0.991 , 0.999)	0.998 (0.996 , 1.001)
Heart Rate (beats/min)	1.002 (0.994 , 1.010)	1.012 (1.008 , 1.015)	1.012 (1.010 , 1.015)
Total Cholesterol (mmol/L)	0.772 (0.646 , 0.922)	0.801 (0.730 , 0.879)	0.752 (0.703 , 0.803)
Admission plasma glucose (mmol/L)	1.069 (1.044 , 1.095)	1.060 (1.045 , 1.076)	1.054 (1.042 , 1.065)
eGFR (mL/min)	0.957 (0.947 , 0.967)	0.954 (0.949 , 0.959)	0.959 (0.955 , 0.963)
<b>nSTEMI vs STEMI</b>	0.558 (0.367 , 0.850)	1.015 (0.824 , 1.250)	1.213 (1.048 , 1.403)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.907 (0.551 , 1.494)	0.789 (0.590 , 1.054)	0.915 (0.757 , 1.105)
2005	0.490 (0.234 , 1.024)	0.670 (0.465 , 0.964)	0.727 (0.567 , 0.934)
2006	0.647 (0.334 , 1.252)	0.562 (0.382 , 0.827)	0.645 (0.489 , 0.850)
2007	0.402 (0.215 , 0.751)	0.517 (0.376 , 0.712)	0.560 (0.435 , 0.721)
2008	0.261 (0.115 , 0.589)	0.477 (0.333 , 0.682)	0.460 (0.331 , 0.639)
Test for Linear Trend (p-value)	0.002	<0.001	<0.001
<b>Ethnicity (South Asian vs. White European)</b>			
	1.172 (0.726 , 1.891)	0.881 (0.665 , 1.167)	0.824 (0.673 , 1.008)
<b>Medical History (Yes vs No)</b>			
Smoking	1.417 (0.945 , 2.124)	1.179 (0.950 , 1.464)	1.281 (1.101 , 1.491)
Prior Diabetes	1.363 (0.874 , 2.124)	1.736 (1.384 , 2.177)	1.782 (1.516 , 2.093)
Prior Coronary Heart Disease §	1.427 (0.848 , 2.402)	1.289 (0.965 , 1.722)	1.309 (1.071 , 1.601)
Prior Hypertension	1.987 (1.315 , 3.002)	1.752 (1.413 , 2.172)	1.646 (1.417 , 1.912)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.945 (0.633 , 1.412)	1.078 (0.865 , 1.344)	1.038 (0.889 , 1.211)
Beta Blocker	1.966 (1.306 , 2.960)	1.850 (1.484 , 2.305)	1.582 (1.348 , 1.857)
Statin	1.169 (0.759 , 1.799)	1.306 (1.042 , 1.638)	1.323 (1.125 , 1.556)
ACEI or ARB	1.174 (0.762 , 1.807)	1.708 (1.373 , 2.124)	1.833 (1.570 , 2.140)
<b>Admission treatment (Yes vs No)</b>			
Initial Reperfusion	1.154 (0.774 , 1.720)	0.570 (0.464 , 0.701)	0.449 (0.387 , 0.521)
Loop Diuretic	3.199 (2.129 , 4.806)	4.940 (3.922 , 6.221)	4.174 (3.573 , 4.877)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.165 (0.107 , 0.253)	0.582 (0.469 , 0.723)	0.908 (0.771 , 1.069)
Beta Blocker	0.138 (0.086 , 0.221)	0.557 (0.451 , 0.688)	0.729 (0.626 , 0.848)
Statin	0.166 (0.108 , 0.255)	0.458 (0.371 , 0.566)	0.624 (0.536 , 0.726)
ACEI or ARB	0.176 (0.112 , 0.276)	0.545 (0.441 , 0.673)	0.886 (0.759 , 1.036)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Supplementary Table 3A:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality subject to survival to discharge. Data are hazard ratio (95% confidence intervals)

N= 3792	Mortality, N (%)		
	30 days 106(2.80)	1 Year 363(9.60)	All 726(19.10)
<b>Admission Demographics</b>			
Gender (Female vs Male)	0.848 (0.467, 1.538)	1.026 (0.774, 1.360)	1.113 (0.912, 1.358)
Age (year)	1.077 (1.040,1.115)	1.058 (1.042, 1.075)	1.071 (1.059, 1.083)
SBP (mmHg)	0.981( 0.971, 0.990)	0.994 (0.989, 0.998)	0.996 (0.993, 0.999)
Heart Rate (beat/min)	0.998 (0.987,1.008)	1.004 (1.000, 1.009)	1.007 (1.004, 1.010)
Admission plasma glucose (mmol/L)	1.095 (1.047,1.146)	1.046 (1.017,1.077)	1.042 (1.021, 1.064)
eGFR (mL/min)	0.994 (0.977, 1.011)	0.978 (0.970, 0.987)	0.985 (0.980, 0.991)
nSTEMI vs STEMI	0.253 (0.125, 0.512)	0.643 (0.486, 0.852)	0.826 (0.679, 1.005)
<b>Year of Admission</b>	0.826 (0.701, 0.974)	0.956 (0.887, 1.030)	0.926 (0.873, 0.981)
<b>Ethnicity</b>			
(South Asian vs White European)	2.021 (0.932, 4.384)	1.118 (0.760, 1.643)	0.950 (0.718, 1.258)
<b>Medical History (Yes vs No)</b>			
Smoking	1.722 (0.934, 3.177)	0.949 (0.710, 1.270)	0.920 (0.752, 1.124)
Prior Diabetes	0.638 (0.313, 1.303)	0.907 (0.656, 1.255)	1.080 (0.860, 1.356)
Prior Coronary Heart Disease §	1.093 (0.467, 2.560)	1.117 (0.751, 1.661)	1.328 (1.015, 1.738)
Prior Hypertension	1.836 (0.985, 3.421)	1.152 (0.868, 1.529)	1.112 (0.914, 1.354)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.951 (0.509, 1.778)	1.088 (0.810, 1.462)	1.086 (0.883, 1.336)
Beta Blocker	1.707 (0.929, 3.136)	1.403 (1.045, 1.883)	1.127 (0.913, 1.392)
Statin	0.961 (0.463, 1.997)	0.974 (0.699, 1.358)	0.992 (0.782, 1.258)
ACEI or ARB	0.685 (0.351, 1.339)	1.059 (0.784, 1.429)	1.093 (0.883, 1.353)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.029 (0.568,1.867)	1.598 (1.172, 2.179)	1.484 (1.203, 1.830)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.543 (0.235,1.256)	1.027 (0.702, 1.503)	1.228 (0.925, 1.631)
Beta Blocker	0.357 (0.167, 0.763)	0.730 (0.529, 1.007)	0.795 (0.633, 0.997)
Statin	1.191 (0.448, 3.170)	0.844 (0.574, 1.240)	0.712 (0.542, 0.935)
ACEI or ARB	0.425 (0.176, 1.027)	0.673 (0.475, 0.955)	0.955 (0.734, 1.243)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial Infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Is Admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than diabetes diagnosis? : A retrospective cohort study.**

Nitin N Gholap<sup>1</sup>, Rajnikant L Mehta<sup>1</sup>, Leong Ng<sup>2,3</sup>, Melanie J Davies<sup>2</sup>, Kamlesh Khunti<sup>1</sup>, Iain B Squire<sup>2,3</sup>

1. Department of Health Sciences, University of Leicester, Leicester, UK

2. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

3. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK

**Address for correspondence:**

Professor Iain B Squire

Department of Cardiovascular Sciences

Clinical Sciences Building

Leicester Royal Infirmary

Leicester LE2 7LX

UK

Tel: +44 116 252 3125

Fax: +44 116 252 3108

e-mail: [is11@le.ac.uk](mailto:is11@le.ac.uk)

**Keywords:** Acute myocardial infarction, diabetes, glucose

**Word count:** ~~3029~~277

**ABSTRACT:**

**Objective:** To explore the relative impact/association of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI.

**Design:** Retrospective cohort study based on the Myocardial Ischaemia National Audit Project dataset.

**Setting:** Tertiary care centre.

**Participants:** 4111 (20.3% known diabetes) consecutive patients admitted with acute myocardial infarction (58.3% STEMI) between October 2002 and September 2008.

**Primary and secondary outcome measures:** All-cause mortality at 30-days and 1-year. The relative association of admission blood glucose and of antecedent diabetes with mortality was assessed using multivariate Cox regression analysis. Furthermore we compared these relationships in patients with STEMI to those with NSTEMI.

**Results:** By 30 days and 1 year, 409 (9.9%) and 677 (16.5%) of patients died. After adjusting for covariates, diabetes did not show independent association with mortality at any time point, in the entire cohort (HR 30 days 0.93 (CI 0.63 – 1.38); 1-year 1.00 (0.77 – 1.30)) or in subgroups of STEMI (HR 30days 1.03 (0.65 – 1.64); 1 year 1.08 (0.77 – 1.51)) and non-STEMI (HR 30-days 0.62 (0.26-1.50); 1-year 0.87(0.56 – 1.36)). In contrast, after adjusting for covariates, admission glucose showed robust and independent association with mortality in the entire cohort (HR: 30 days 1.07 (1.04 – 1.10); 1-year 1.05 (1.03 – 1.08)), and in the subgroup of STEMI (30-days 1.07 (1.03 – 1.10); 1-year 1.07 (1.04 – 1.10)), and NSTEMI (HR 30 days 1.07 (1.00 - 1.14); 1-year 1.02 (0.97 - 1.06)).

**Conclusion:** Admission glucose is strongly associated with mortality in all presentations of acute myocardial infarction (AMI), irrespective of established diabetes diagnosis. The increased risk is

1  
2  
3 maintained up to 1 year. Future studies are required to assess the impact of active management of  
4  
5 elevated blood glucose in improving mortality in individuals admitted with AMI.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## INTRODUCTION

For patients with acute myocardial infarction (AMI) the risk of adverse outcome is increased by the concomitant diagnosis of diabetes mellitus (diabetes).(1, 2) In addition, elevated blood glucose concentration, a common finding at admission in patients with AMI, is also associated with increased risk of adverse outcome, irrespective of prior diabetes.(1-8). In some studies (4, 9) the association between admission blood glucose concentration and adverse outcome was more powerful in patients without, compared to those with, prior diabetes. Indeed we previously reported more powerful association with 30-day and 1-year mortality after STEMI for admission blood glucose concentration, compared to the diagnosis of diabetes.(9)

While a causal relationship is unproven, there are numerous potential pathophysiological mechanisms by which hyperglycaemia may impart toxicity during myocardial ischaemia.(10, 11) Indeed, observational data suggest that elevated blood glucose may contribute directly to adverse outcome after AMI. Prognosis is worse for patients in whom hyperglycaemia persists in the 24-48 hours after AMI compared to those in whom blood glucose normalises.(12, 13) In patients without prior diabetes, insulin-based treatment of hyperglycaemia after AMI is associated with improved prognosis.(14, 15) Further, in randomised, controlled trials (RCTs) of intensive, insulin-based blood glucose management during admission with AMI, survival benefit was evident only when intervention effectively lowered blood glucose concentration.(16, 17)

While the relationship between blood glucose concentration and outcome after AMI has largely been described in patients with STEMI, the majority of acute coronary syndromes in contemporary practice are non-ST elevation AMI (NSTEMI). The aim of the current analysis was to compare the relative strength of association with 30-day, and 1-year mortality of antecedent diabetes diagnosis and admission blood glucose concentration in patients with STEMI and with NSTEMI, and in those with and without a history of diabetes, in a multi-ethnic population. We also assessed the relevance



1  
2  
3 of blood glucose concentration, recorded soon after admission to hospital with AMI, to mortality in  
4  
5 patients surviving to discharge.  
6  
7  
8  
9

## 10 11 12 13 14 **METHODS**

15  
16  
17 Data were from consecutive admissions between 1st October 2002 – 30<sup>th</sup> September 2008, to the  
18  
19 two coronary care units (CCU) of a large teaching hospital serving the population of Leicestershire,  
20  
21 UK (approximately 946,000 residents in 2004). For all patients, as part of the hospital's mandatory  
22  
23 commitment to the Myocardial Ischaemia National Audit Project (MINAP),(18) we record clinical and  
24  
25 demographic data including information on diagnosis (STEMI/NSTEMI), electrocardiographic (ECG)  
26  
27 site of infarct, medical history, coronary heart disease risk-factors, and prescribed medication. Data  
28  
29 are record-linked to mortality information (19) and include self reported coding for ethnicity, for  
30  
31 which local coverage is thorough. Approximately 10% of the local population are of South Asian  
32  
33 ethnic origin, over twice the UK national average.  
34  
35  
36

37  
38 Patients were categorised as having a diagnosis of diabetes if this was self-reported by the patient,  
39  
40 or on the basis of medication prescribed prior to admission. All patients with AMI routinely  
41  
42 underwent blood glucose measurement, in most cases within first 12 hours after admission with  
43  
44 their blood samples assayed in the hospital laboratory. We used such first recorded admission  
45  
46 glucose levels for this analysis. The blood glucose measurement used for the analysis was the first  
47  
48 recorded at the time of the index admission, assayed in the hospital laboratory as part of routine  
49  
50 investigations.—All diagnoses of AMI were verified prior to submission to the national MINAP  
51  
52 database; the diagnosis of AMI was made according to the joint ESC/ACCF/AHA/WHF definition.(20)  
53  
54  
55 Patients were categorised as STEMI or NSTEMI, according to the final discharge diagnosis recorded  
56  
57 in the MINAP database. For patients with multiple AMI admissions during the study period, we  
58  
59  
60

1  
2  
3 considered only the first event. The number of cases admitted with AMI during the study period  
4  
5 determined the sample size.  
6  
7

8 Survival was measured from the date of first admission to the date of death or of censoring at 30<sup>th</sup>  
9  
10 September 2009. Mortality data are supplied to the hospital on a monthly basis via the UK Office for  
11  
12 National Statistics. Follow-up data on mortality was available for all the patients. The pre-defined  
13  
14 primary outcome measure was 30-day, and 1-year, all-cause mortality..  
15  
16

17  
18 The study was approved by the local research ethics committee. The data used in this analysis were  
19  
20 gathered during routine care and as part of the MINAP (18) mandatory requirement for all acute  
21  
22 hospitals in England and Wales to collect data pertaining to admission with AMI.  
23  
24

### 25 **Statistical analysis**

26  
27

28 Baseline characteristics were compared between groups using independent two-sample t-tests for  
29  
30 continuous variables and chi-squared tests for categorical variables. Mortality at 30 days and at 1  
31  
32 year, in the entire cohort, and in those patients surviving to discharge, was calculated.  
33  
34

35  
36 We calculated mortality proportions for patients admitted from 1<sup>st</sup> October 2002 to 30<sup>th</sup> September  
37  
38 2008 with follow-up censored at 30<sup>th</sup> September 2009. Survival probabilities were calculated using  
39  
40 Kaplan-Meier [KM] analyses and patient groups compared using survival analysis log rank test.  
41  
42 Relative risk of mortality, as a function of clinical variables, was examined using Cox proportional  
43  
44 hazards techniques. We initially assessed the unadjusted, univariate association with outcome for  
45  
46 admission blood glucose and for diabetes, and for other potentially relevant clinical and  
47  
48 demographic variables (age, sex, ethnicity (white European, South Asian), smoking, type of AMI  
49  
50 (STEMI, NSTEMI), prior history (hypertension, any coronary artery disease, cerebrovascular or  
51  
52 peripheral vascular disease), admission systolic blood pressure and heart rate, estimated glomerular  
53  
54 filtration rate (eGFR), coronary revascularisation during index admission, pre-admission and  
55  
56 discharge drug therapy (anti-platelet, beta-blocker, statin, angiotensin converting enzyme inhibitor/  
57  
58  
59  
60

1  
2  
3 angiotensin receptor blocker), and index loop diuretic use. An interaction term representing  
4  
5 calendar year of admission was included to adjust for potential temporal changes in the  
6  
7 management of acute coronary artery disease.  
8  
9

10 Demographic and clinical covariates with univariate association ( $p < 0.10$ ) with mortality at 30 days, or  
11  
12 1 year were entered into multivariate models (Cox proportional hazards). All quantitative variables  
13 were entered as continuous variables into the model. Patients with missing data (Table 1) were not  
14 excluded but their values were set as missing. Statistical significance for all comparisons was set at  
15  
16  $p < 0.05$  (2 sided). Data are presented as hazard ratio (HR) and 95% confidence intervals (CI). We used  
17  
18 fractional polynomials to model admission glucose to account for any non-linearity and assessed its  
19  
20 independent association with mortality in subgroups with and without diabetes. Analyses were  
21  
22 carried out using SPSS version 18.  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 RESULTS

33  
34  
35 The study population was the 4111 patients admitted between 1<sup>st</sup> October 2002 – 30<sup>th</sup> September  
36  
37 2008 with discharge diagnosis of AMI (STEMI 2397, 58.3%) and for whom a minimum of 365 days  
38  
39 follow-up was available from the date of admission. For this cohort, median follow up was 912 days  
40  
41 (range 0 to 2556) days; for 3792 (92.2%) patients surviving to discharge from the index admission,  
42  
43 median follow up was 1031 (range 1 to 2556) days.  
44  
45

46 Demographic details of the study population are presented in Table 1. Prior diabetes was recorded  
47  
48 in 835 (20.3%) patients: compared to those without, patients with antecedent diabetes were on  
49  
50 average older (68.6 vs 65.8 years,  $p < 0.005$ ), more likely to be female (33.9% vs 28.9%,  $p = 0.022$ ) and  
51  
52 to have prior cardiovascular co-morbidities. Presentation with NSTEMI was more prevalent in cases  
53  
54 with (50.1%), compared to those without (39.6%), prior diabetes ( $p < 0.005$ ). Mean plasma glucose  
55  
56  
57  
58  
59  
60

1  
2  
3 was higher in patients with diabetes ( $12.0 \pm 5.5$  mmol/L) compared to those without ( $7.9 \pm 3.3$   
4 mmol/L) ( $p < 0.005$ ). Mean peak CK was lower in patients with diabetes.  
5  
6

7  
8 During the index admission administration of loop diuretic was more frequent (52.7% vs 33.4%,  
9  $p < 0.005$ ) and, for patients with STEMI, coronary reperfusion therapy less frequent (50.2% vs 60.9%,  
10  $p < 0.005$ ), in patients with diabetes. Other than for slightly less use of beta-blockers and aspirin in  
11 patients with diabetes, patterns of prescription of secondary prevention therapies at discharge were  
12 similar in the two groups.  
13  
14  
15  
16  
17

### 18 19 20 **Mortality – Univariate analysis**

21  
22  
23 Deaths during hospitalisation, over 30-days, 1-year and the entire period of follow-up numbered 319  
24 (7.8%), 409 (9.9%), 677 (16.5%) and 1041 (25.3%) respectively. Age, female sex, higher admission  
25 heart rate, higher eGFR, lower systolic blood pressure and presentation with STEMI (compared to  
26 NSTEMI), as well as prior smoking and hypertension, each showed univariate association with  
27 mortality risk over all time periods (Table 2). Loop diuretic was associated with a 3-4 fold increase in  
28 mortality during follow-up. Survival improved over the period of observation.  
29  
30  
31  
32  
33  
34  
35

36  
37 Prior diabetes showed strong univariate association with mortality risk over all time periods: HR 30  
38 days 1.40 (1.12 - 1.75); 1 year 1.58 (1.33 - 1.86); all follow-up 1.66 (1.44 , 1.90)) (Table 2). The  
39 strength of association between glucose and mortality was consistent at 30-days and at 1-year, each  
40 mmol/L increase in admission glucose concentration being associated with a 6-7% increase in hazard  
41 of mortality over all time periods.  
42  
43  
44  
45  
46  
47

### 48 49 **Post-discharge mortality**

50  
51  
52 In those surviving to discharge (N=3792), 106 (2.8%), 363 (9.6%) and 726 (19.1%) died by 30-days, 1-  
53 year and over all follow-up (Table 2A, Supplementary data). Univariate associations with mortality  
54 were similar to those in the entire population. Prior diabetes showed univariate association with  
55  
56  
57  
58  
59  
60

1  
2  
3 increased risk of death at all times, although this was not statistically significant at 30 days (HR 1.36,  
4 (0.87 - 2.12)). For admission glucose, the strength of association with post-discharge mortality was  
5 very similar to that in the entire cohort, with 5-7% increase risk per mmol/L increase in glucose.  
6  
7 (Table 2A, Supplementary Data).  
8  
9  
10

### 11 **Mortality – Multivariate analysis**

12  
13 Table 3 shows the results of multivariate analysis. Age, lower admission systolic blood pressure and  
14 higher heart rate, lower eGFR, prescription of loop diuretic, and STEMI (compared to NSTEMI) each  
15 retained independent association with mortality, as did prescription of individual discharge  
16 medications. After covariate adjustment, diabetes did not retain independent association with  
17 mortality at any time. In contrast, adjustment for covariates had little impact upon the risk of  
18 mortality associated with admission glucose concentration.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Post-discharge mortality**

30  
31 For patients surviving to discharge, associations between clinical variables and the risk of mortality  
32 were similar to those seen in the entire cohort (Table 3A, Supplementary data). While there was no  
33 association between prior diabetes and risk of mortality at any time (HR 30 days 0.64 (0.31 – 1.300);  
34 1 year 0.91 (0.66 – 1.26); all follow-up 1.08 (0.86 – 1.36)), blood glucose retained powerful  
35 association with the primary endpoint. This was evident at 30 days (HR per mmol/L 1.10, 95% CI 1.05  
36 – 1.15), 1 year (1.05, 1.02 – 1.08), and over all follow-up (1.04, 1.02 – 1.06)).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Admission glucose concentration – influence on mortality in patients with or without diabetes**

48  
49 We repeated multivariate analysis including a term for interaction between diabetes diagnosis and  
50 admission glucose concentration. While numerically greater in individuals without diabetes (Figure  
51 1), there was no conventional statistically significant difference in the association between mortality  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and admission blood glucose for patients with and without diabetes (30 days HR 1.00, (CI 0.97 –  
4  
5 1.03, p=0.95; 1 year 0.99, (0.97 – 1.02), p=0.66; entire follow-up 0.99, (0.97 – 1.01, p=0.42)).  
6  
7

### 8 **Diabetes and glucose after AMI – influence on mortality in STEMI and NSTEMI**

9

10  
11 After adjustment for covariates, diabetes showed no statistically significant association with  
12  
13 mortality at any time period, either for STEMI or NSTEMI (Table 4). The strength of association  
14  
15 between blood glucose and mortality was very similar in the first 30 days after STEMI or NSTEMI.  
16  
17 The strength of this relationship declined with time only after NSTEMI.  
18  
19  
20  
21  
22  
23

## 24 **DISCUSSION**

25

26  
27 It is well known that, both prior diabetes diagnosis, and admission blood glucose concentration, are  
28  
29 associated with adverse outcome after AMI. In this report we compared the relative association of  
30  
31 these two measures of dysglycaemia with survival after STEMI as well as NSTEMI. Irrespective of the  
32  
33 type of AMI, the univariate association with mortality risk for antecedent diabetes (40% excess at 30  
34  
35 days, 55-65% thereafter) was no longer apparent after adjustment for relevant covariates including  
36  
37 admission glucose concentration. In contrast, the excess risk associated with increasing glucose was  
38  
39 not reduced after adjustment, was similar in those with and without known diabetes, and remained  
40  
41 relevant in patients discharged alive from the index event.  
42  
43  
44

45  
46 In our previous report of over 4000 patients with STEMI, admitted in 1993-2004,(9) the 50% increase  
47  
48 in 30-day and 1-year mortality risk associated with known diabetes was attenuated by half on  
49  
50 covariate adjustment and removed completely when admission blood glucose concentration was  
51  
52 included in the analysis. The current report confirms these observations and extends them to a  
53  
54 contemporary period, and to patients with NSTEMI as well as STEMI, in whom the strength of  
55  
56 association between admission blood glucose concentration and 30-day mortality risk was similar,  
57  
58  
59  
60

1  
2  
3 and concentration dependent. Importantly, the excess risk, around 7% for each 1mmol/L increase in  
4 admission glucose concentration, was maintained up to and beyond 1 year from the index infarction.  
5  
6 Further, this phenomenon was attenuated with time only for patients with NSTEMI, and was evident  
7  
8 even in those patients who survived to discharge from hospital, two potentially important clinical  
9  
10 observations. These findings are in contrast to one previous report which reported the association  
11  
12 between admission glucose and mortality to be confined to in-hospital deaths following either  
13  
14 STEMI or NSTEMI.(8) They are however in keeping with the vast majority of reports in this area.(1-7,  
15  
16 9, 11)  
17  
18  
19

20  
21 In contrast to most previous reports,(1-9, 11) we observed no independent association between  
22  
23 diabetes and mortality risk after AMI. However, to our knowledge and unlike the present report,  
24  
25 none of these studies adjusted for admission blood glucose, and each reported individual  
26  
27 relationships between mortality after AMI and either diabetes diagnosis (1, 2, 4, 8) or blood glucose  
28  
29 concentration.(3-8, 11-13, 21) The current analysis and our previous study (9) are the only reports to  
30  
31 compare the relative association with outcome of both diabetes and blood glucose concentration.  
32  
33 Both studies demonstrate a much stronger relationship between survival and blood glucose, and the  
34  
35 loss of association between mortality and diabetes when blood glucose is considered. Due to  
36  
37 incomplete data and lack of power, we could not assess whether outcomes varied by diabetes  
38  
39 therapies. However previous studies have reported an independent association of admission blood  
40  
41 glucose with mortality regardless of diabetic therapy used.(2,5,7)  
42  
43  
44  
45

46 These observations are of potential clinical significance. While admission blood glucose  
47  
48 concentration after AMI is on average higher in patients with, compared to those without, known  
49  
50 diabetes,(4, 8, 9) there is considerable overlap, as seen in the current report (Figure 1). While many  
51  
52 patients presenting with AMI will have previously undiagnosed diabetes,(22) blood glucose at the  
53  
54 time of admission with AMI is not a reliable indicator of the subsequent diagnosis of diabetes.(23,  
55  
56 24) In routine practice, the management of hyperglycaemia after AMI is influenced by the presence  
57  
58  
59  
60

1  
2  
3 of prior diabetes diagnosis.(5) In both European(14) and North American(6) settings, the majority  
4 (>65%) of patients presenting with hyperglycaemia in the context of AMI, and not previously known  
5 to have diabetes, do not receive active management of blood glucose. In the presence of a true,  
6 direct toxic effect upon prognosis of elevated blood glucose, failure to correct hyperglycaemia may  
7 represent suboptimal clinical care, and patients without known diabetes may be particularly  
8 disadvantaged. In particular, our demonstration that the relationship between glucose  
9 concentration and subsequent outcome is evident in NSTEMI as well as STEMI is of clear clinical  
10 relevance in terms of the overall management of patients presenting with AMI.  
11  
12

13  
14  
15  
16  
17  
18  
19  
20  
21 The strength of association between diabetes and mortality risk after AMI has been reported to  
22 increase with time from the event.(25) While we observed such a trend on univariate analysis, this  
23 was attenuated in multivariate analysis, an observation which may relate to our inclusion of blood  
24 glucose as a covariate. A previous meta-analysis suggested a stronger association between  
25 admission blood glucose and adverse outcome.(4) While we could not demonstrate formal statistical  
26 evidence of such a phenomenon, our data show convincingly that the relationship between glucose  
27 and outcome is at least as powerful in patients without known diabetes. Blood glucose soon after  
28 admission represents an easily identified, clinically relevant marker of risk after AMI, which should  
29 be assessed routinely irrespective of diabetes status.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41  
42 An important observation from this study is the persisting association between admission blood  
43 glucose concentration and mortality risk in patients surviving to discharge, in both NSTEMI and  
44 STEMI. While in keeping with the possibility that blood glucose concentration at admission reflects  
45 the degree of individual physiological stress, or is a marker of the extent of infarction, our findings  
46 are as much in keeping with a direct, adverse influence on prognosis of acute hyperglycaemia. The  
47 mechanisms by which elevated glucose may be directly cardiotoxic have been summarised  
48 elsewhere (10) and include attenuation of ischaemic preconditioning, QT prolongation, increased  
49 thrombophilia, and endothelial dysfunction. Furthermore, clinical studies overwhelmingly support a  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 possible causal link between hyperglycaemia and adverse prognosis after AMI. Hyperglycaemia  
4  
5 persisting at 24 hours after admission is associated with adverse outcome,(12, 13, 17).  
6  
7

8 While observational studies show consistently the adverse association between hyperglycaemia and  
9  
10 outcomes post AMI, results of the RCTs of active management of blood glucose have been  
11  
12 inconsistent.(16,17) However, in such trials, effective reduction in blood glucose with an  
13  
14 intervention after AMI was associated with improved prognosis.(16) The guidelines from  
15  
16 professional societies in this area differ in their recommendations.(27,28) In the North American  
17  
18 guidelines, intensive glucose control is recommended in patients with AMI and significant  
19  
20 hyperglycaemia (blood glucose levels > 10.0 mmol/L) admitted in an intensive care unit.(28) In  
21  
22 contrast, the National Institute for Health and Clinical Excellence guidance recommends against  
23  
24 routine use of intensive insulin therapy to manage hyperglycaemia (blood glucose levels > 11.0  
25  
26 mmol/L) in patients with acute coronary syndrome.(27) The latter guidelines highlighted a need for  
27  
28 randomised controlled trials addressing specific gaps in knowledge this area.  
29  
30  
31  
32

33 Our report is subject to the limitations inherent in all observational cohort studies. Our results are  
34  
35 from a single-centre study. In the early years of the MINAP project, data on only STEMI were  
36  
37 collected. Furthermore, data collected for MINAP was gathered mainly from a setting of coronary  
38  
39 care unit. Selection bias could be the reason behind the overall low numbers of AMI cases (4111)  
40  
41 recruited in our study over a six year period in a catchment population of 1 million. However  
42  
43 baseline and clinical outcome parameters in our study are similar to previous studies. Selection bias  
44  
45 could also explain relatively high proportion of patients with STEMI (58.4%) compared to NSTEMI in  
46  
47 our cohort. We therefore conducted subgroup analysis for people with STEMI and NSTEMI and  
48  
49 compared their outcomes. Blood glucose concentration used in this analysis was that first recorded  
50  
51 for the index admission, and is likely to have varied in timing relative to symptom onset. Our  
52  
53 database lacks information on left ventricular (LV) ejection fraction, evidence of heart failure, and a  
54  
55 number of other potentially relevant variables. Information on body mass index, an indicator of  
56  
57  
58  
59  
60

1  
2  
3 underlying metabolic syndrome and associated dysglycaemia, was not available. Further, we have  
4  
5 no information regarding the number of patients who were given a diagnosis of diabetes during, or  
6  
7 subsequent to, the index admission. However, if elevated glucose contributes directly to prognosis,  
8  
9 active management is likely to confer greater benefit when delivered as early as possible,  
10  
11 irrespective of subsequent diabetes status. Thus we suggest the first recorded blood glucose  
12  
13 concentration to be highly relevant to guiding appropriate management in individual patients,  
14  
15 irrespective of residual LV function. While we have no information on interventions or changes to  
16  
17 therapy after discharge, it is unlikely that these impacted on outcome in a major way, as the  
18  
19 strongest association between mortality and glucose was in the first 30 days. Findings of our study  
20  
21 based on real-life practice are applicable to other populations treated in similar setting.  
22  
23  
24

25  
26 In summary, admission blood glucose concentration is a powerful, routinely available marker of  
27  
28 mortality risk after AMI. After adjustment for admission blood glucose, known diabetes is not  
29  
30 associated with adverse outcome. The association between blood glucose concentration and  
31  
32 mortality risk is of similar magnitude in patients with and without known diabetes, is evident for  
33  
34 NSTEMI as well as STEMI, and persists beyond 1 year from the index event, including in patients  
35  
36 surviving to discharge. Future studies are merited of the impact of active management of blood  
37  
38 glucose in patients with all presentations of acute coronary artery disease, irrespective of diabetes  
39  
40 diagnosis.  
41  
42  
43  
44  
45  
46

## 47 **ARTICLE SUMMARY**

### 48 **Article focus**

- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Robust associations is seen for both measures of glycaemia - the diagnosis of diabetes, and elevated blood glucose levels on admission, with poor outcomes in patients with ST elevation myocardial infarction (STEMI).

- 1  
2  
3  
4  
5  
6  
7  
8  
9
- We explored the less known, relative association of admission blood glucose levels and antecedent diabetes on early and long term survival in a contemporary UK population of patients with STEMI and NSTEMI.

10  
11

**Key Messages:**

- 12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28
- In patients with both STEMI as well as NSTEMI, admission glucose is more strongly associated with mortality than is antecedent diabetes diagnosis.
  - The increased risk associated with admission glucose is evident during the index admission, at 30 days, one year and beyond and is apparent in those surviving to discharge.
  - Conversely, after multivariate adjustment for covariates, including admission glucose is not associated with mortality.

29  
30

**Strengths and limitations of this study**

- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54
- This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary clinical practice in a tertiary care centre.
  - A statistically robust association was seen for admission glucose with both short and longer term mortality after adjusting for many important confounders.
  - Our data lacks information on glucose lowering intervention, patients with undiagnosed diabetes and other potentially relevant variables which were not considered in the analysis.

Table 1: Baseline characteristics at admission stratified by diabetes status

	All n=4111	Known DM n= 835 (20.3%)	Not Known DM n=3276 (79.7%)	P Value*	Missing Value (%)
<b>Demography</b>					
Age (years)	66.4 (13.3)	68.6 (11.8)	65.8 (13.6)	<0.005	0.0
Women (%)	1224 (29.8)	276 (33.1)	948 (28.9)	0.022	0.0
<b>Ethnicity (%)</b>					
White European	3381 (82.2%)	545 (16.1)	2836 (86.6)	<0.005	0.0
South Asian	730 ( 17.8%)	290 (39.7%)	440 (60.3%)		0.0
<b>Medical History (%)</b>					
Hypertension	2048 (50.3)	584 (70.0)	1464 (45.0)	<0.005	1.0
Current/Ex Smoker	1366 (35.7)	282 (36.8)	1084 (35.5)	0.527	7.1
Coronary Heart Disease§	491 (12.1)	149 (17.9)	342 (10.6)	<0.005	0.9
CVA	254 (6.3)	86 (10.3)	168 (5.2)	<0.005	1.2
PVD	154 (3.8)	42 (5.0)	112 (3.5)	0.041	1.2
Heart Failure	190 (4.7)	76 (9.1)	114 (3.5)	<0.005	1.2
<b>Type of Infarction (%)</b>					
STEMI	2397 (58.3)	417 (49.9)	1980 (60.4)	<0.005	0.0
nSTEMI	1714 (41.7)	418 (50.1)	1296 (39.6)		
<b>Physical Examination</b>					
Heart Rate (beats/min)	81.1 (24.3)	85.5 (25.3)	80.0 (24.0)	<0.005	1.5
SBP (mmHg)	136.5 (28.4)	137.7 (30.7)	136.2 (27.8)	0.202	1.0
<b>Biochemical Data</b>					
Peak CK (IU/L, Normal range < 200)	1113.5 (1810.4)	939.9 (1279.3)	1156.4 (1917)	<0.005	7.6
Creatinine (µmol/L)	116.4 (63.8)	128.8 (76.1)	113.1 (59.8)	<0.005	16.8
eGFR (mL/min)	63.0 (22.2)	57.7 (23.6)	64.4 (21.7)	<0.005	16.6
Total cholesterol (mmol/L)	5.1 (1.3)	4.4 (1.2)	5.2 (1.3)	<0.005	16.6
Haemoglobin (g/L)	13.7 (1.9)	13.0 (1.9)	13.9 (1.8)	<0.005	66.6
Plasma glucose (mmol/L)	8.8 (4.2)	12.0 (5.5)	7.9 (3.3)	<0.005	14.9
<b>Therapies (%)</b>					
<b>Prior to index admission</b>					
Aspirin	2671 (65.0)	622 (74.5)	2049 (62.5)	<0.005	0.0
Beta blocker	990 (25.6)	265 (33.2)	725 (23.6)	<0.005	6.0
ACEI or ARB	1097 (28.3)	407 (51.0)	690 (22.5)	<0.005	5.8
Statins	1083 (28.0)	389 (48.7)	694 (22.6)	<0.005	5.8
<b>In-hospital</b>					
Reperfusion therapy #	2414 (58.7)	419 (50.2)	1995 (60.9)	<0.005	0.0

Loop diuretics	1502 (37.4)	436 (52.7)	1066 (33.4)	<0.005	2.3
<b>At discharge</b>					
Aspirin	2701 (68.1)	529 (65.3)	2172 (68.8)	0.057	3.5
Beta blocker	2513 (63.3)	483 (59.6)	2030 (64.3)	0.013	3.5
ACEI or ARB	2493 (62.9)	495 (61.0)	1998 (63.4)	0.222	3.6
Statin	2704 (67.7)	537 (65.6)	2167 (68.2)	0.167	2.8

All values are mean (SD) or number (%). \* known diabetes vs not known diabetes. DM, Diabetes Mellitus; CVA, Cerebrovascular accidents; PVD, Peripheral Vascular Disease; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; SBP, Systolic blood pressure; CK, Creatinine Kinase; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

# thrombolysis or coronary intervention (PCI or CABG) or both

**Table 2:** Univariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals)

N=4111	Mortality, N (%)		
	30 days	1 Year	All (Median 912 days)
	409 (9.95)	677 (16.47)	1041 (25.32)
<b>Admission Demographic Variable</b>			
Gender (Female vs Male)	0.535 (0.439, 0.650)	0.515 (0.443, 0.600)	0.554 (0.490, 0.627)
Age (year)	1.068 (1.059, 1.078)	1.077 (1.069, 1.084)	1.084 (1.077, 1.090)
SBP (mmHg)	0.979 (0.976, 0.983)	0.987 (0.984, 0.990)	0.992 (0.990, 0.994)
Heart Rate (beat/min)	1.010 (1.006, 1.013)	1.012 (1.009, 1.014)	1.012 (1.010, 1.014)
Total Cholesterol (mmol/L)	0.732 (0.666, 0.806)	0.765 (0.712, 0.821)	0.744 (0.703, 0.788)
Admission plasma glucose (mmol/L)	1.072 (1.052, 1.084)	1.065 (1.055, 1.076)	1.059 (1.050, 1.068)
eGFR (mL/min)	0.956 (0.951, 0.961)	0.955 (0.951, 0.959)	0.959 (0.956, 0.962)
NSTEMI vs STEMI	0.504 (0.405, 0.627)	0.736 (0.629, 0.862)	0.939 (0.830, 1.063)
<b>Year of Admission</b>			
Oct 2002-Dec 2003	1	1	1
2004	0.909 (0.688, 1.200)	0.846 (0.681, 1.052)	0.919 (0.780, 1.082)
2005	0.591 (0.402, 0.870)	0.652 (0.491, 0.865)	0.702 (0.564, 0.873)
2006	0.830 (0.592, 1.164)	0.696 (0.529, 0.917)	0.716 (0.572, 0.897)
2007	0.759 (0.570, 1.010)	0.678 (0.541, 0.849)	0.679 (0.558, 0.826)
2008	0.485 (0.338, 0.696)	0.551 (0.424, 0.716)	0.531 (0.415, 0.680)
Test for Linear Trend (p-value)	<0.001	<0.001	<0.001
<b>Ethnicity</b> (South Asian vs. White European)	1.013 (0.786, 1.304)	0.909 (0.741, 1.114)	0.856 (0.725, 1.012)
<b>Medical History (Yes vs No)</b>			
Smoking	1.016 (0.819, 1.259)	1.049 (0.891, 1.235)	1.160 (1.019, 1.320)
Prior Diabetes	1.400 (1.121, 1.750)	1.576 (1.331, 1.865)	1.655 (1.445, 1.896)
Prior Coronary Heart Disease §	0.862 (0.628, 1.182)	0.998 (0.791, 1.258)	1.113 (0.931, 1.330)
Prior Hypertension	1.286 (1.056, 1.567)	1.437 (1.232, 1.676)	1.472 (1.300, 1.666)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.746 (0.613, 0.909)	0.869 (0.744, 1.015)	0.913 (0.804, 1.036)
Beta Blocker	1.385 (1.116, 1.719)	1.577 (1.338, 1.859)	1.489 (1.301, 1.703)
Statin	0.994 (0.795, 1.245)	1.129 (0.953, 1.338)	1.194 (1.041, 1.370)
ACEI or ARB	1.242 (1.002, 1.540)	1.467 (1.247, 1.726)	1.621 (1.423, 1.847)
<b>Admission treatment (Yes vs No)</b>			

Initial Reperfusion	0.616 (0.507 , 0.749)	0.540 (0.464 , 0.629)	0.466 (0.411 , 0.527)
Loop Diuretic	3.457 (2.807 , 4.256)	4.348 (3.681 , 5.136)	4.052 (3.556 , 4.618)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.043 (0.029 , 0.062)	0.227 (0.192 , 0.269)	0.439 (0.386 , 0.499)
Beta Blocker	0.038 (0.025 , 0.058)	0.237 (0.199 , 0.282)	0.406 (0.357 , 0.461)
Statin	0.043 (0.029 , 0.062)	0.196 (0.165 , 0.233)	0.344 (0.303 , 0.390)
ACEI or ARB	0.047 (0.031 , 0.700)	0.236 (0.198 , 0.281)	0.469 (0.412 , 0.533)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker

§ any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)

**Table 3:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the entire cohort. Data are hazard ratio (95% confidence intervals).

N=4111	Mortality, N (%)		
	30 days 409 (9.95)	1 Year 677 (16.5)	All (Median 912 days) 1041 (25.3)
<b>Admission Demographics</b>			
Gender (Female vs Male)	1.268 (0.885, 1.819)	1.094 (0.865, 1.383)	1.114 (0.931, 1.332)
Age (year)	1.059 (1.040, 1.078)	1.062 (1.048, 1.075)	1.073 (1.062, 1.083)
SBP (mmHg)	0.987 (0.981, 0.992)	0.991 (0.987, 0.995)	0.993 (0.990, 0.996)
Heart Rate (beat/min)	1.007 (1.001, 1.013)	1.006 (1.002, 1.010)	1.007 (1.005, 1.010)
Admission plasma glucose (mmol/L)	1.072 (1.042, 1.104)	1.059 (1.037, 1.081)	1.053 (1.036, 1.071)
eGFR (mL/min)	0.987 (0.978, 0.996)	0.983 (0.977, 0.990)	0.988 (0.983, 0.993)
<b>NSTEMI vs STEMI</b>	0.411 (0.282, 0.597)	0.558 (0.443, 0.704)	0.700 (0.587, 0.834)
<b>Ethnicity</b> (South Asian vs White European)	1.355 (0.893, 2.057)	1.155 (0.851, 1.568)	0.996 (0.779, 1.273)
<b>Medical History (Yes vs No)</b>			
Smoking	1.125 (0.788, 1.607)	0.953 (0.749, 1.213)	0.942 (0.786, 1.130)
Prior Diabetes	0.934 (0.631, 1.382)	1.001 (0.770, 1.300)	1.134 (0.927, 1.386)
Prior Coronary Heart Disease§	0.717 (0.402, 1.278)	0.898 (0.632, 1.277)	1.111 (0.864, 1.428)
Prior Hypertension	1.291 (0.903, 1.846)	1.155 (0.913, 1.461)	1.133 (0.949, 1.353)
<b>Pre -Admission Medication (Yes vs No)</b>			
Aspirin	0.944 (0.667, 1.335)	0.989 (0.781, 1.252)	1.010 (0.842, 1.213)
Beta Blocker	1.288 (0.898, 1.849)	1.363 (1.067, 1.742)	1.173 (0.970, 1.418)
Statin	0.863 (0.579, 1.286)	0.877 (0.668, 1.150)	0.918 (0.743, 1.135)
ACEI or ARB	0.719 (0.497, 1.042)	0.932 (0.728, 1.194)	1.017 (0.840, 1.232)
<b>Admission treatment (Yes vs No)</b>			
Loop Diuretic	1.416 (0.993, 2.019)	1.703 (1.322, 2.195)	1.532 (1.268, 1.851)
<b>Discharge Medication (Yes vs No)</b>			
Aspirin	0.297 (0.157, 0.562)	0.656 (0.479, 0.897)	0.861 (0.676, 1.097)
Beta Blocker	0.257 (0.133, 0.494)	0.564 (0.423, 0.753)	0.671 (0.544, 0.828)
Statin	0.628 (0.295, 1.339)	0.683 (0.484, 0.963)	0.629 (0.490, 0.808)
ACEI or ARB	0.470 (0.229, 0.968)	0.610 (0.443, 0.839)	0.850 (0.668, 1.081)

1  
2  
3  
4  
5 SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST  
6 elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme  
7 inhibitor; ARB, angiotensin receptor blocker

8  
9 § any of angina/ myocardial infarction; / percutaneous Intervention (PCI)/ coronary artery bypass grafting (CABG)  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 4:** Multivariate association of clinical variables with 30-day, 1-year, and total mortality in the subgroups of patients with STEMI and NSTEMI. Data are hazard ratio (95% confidence intervals)

N=4111		Mortality, N (%)					
STEMI	NSTEMI	30 days		1 Year		All	
2397	1714	STEMI	NSTEMI	STEMI	NSTEMI	STEMI	NSTEMI
<b>Admission Demographics</b>							
Age (year)		1.055 (1.033 - 1.077)	1.073 (1.031 - 1.116)	1.061 (1.044 - 1.078)	1.056 (1.035 - 1.079)	1.077 (1.062 - 1.091)	1.061 (1.046 - 1.077)
SBP (mmHg)		0.988 (0.982 - 0.994)	0.983 (0.970 - 0.995)	0.992 (0.987 - 0.997)	0.988 (0.982 - 0.995)	0.993 (0.989 - 0.997)	0.994 (0.990 - 0.998)
Heart Rate (beat/min)		1.008 (1.001 - 1.015)	1.008 (0.997 - 1.02)	1.008 (1.002 - 1.013)	1.007 (1.001 - 1.013)	1.008 (1.004 - 1.012)	1.007 (1.002 - 1.011)
eGFR (mL/min)		0.986 (0.975 - 0.997)	0.987 (0.969 - 1.005)	0.982 (0.974 - 0.991)	0.978 (0.968 - 0.989)	0.986 (0.979 - 0.993)	0.987 (0.979 - 0.995)
Admission plasma glucose		1.070 (1.034 - 1.107)	1.074 (1.005 - 1.148)	1.071 (1.042 - 1.10)	1.021 (0.979 - 1.066)	1.076 (1.051 - 1.10)	1.014 (0.983 - 1.047)
Prior Diabetes		1.035 (0.652 - 1.641)	0.629 (0.264 - 1.502)	1.083 (0.772 - 1.518)	0.878 (0.566 - 1.36)	1.189 (0.907 - 1.559)	1.055 (0.773 - 1.44)
<b>Admission treatment (Yes vs No)</b>							
Loop Diuretic		1.330 (0.890 - 1.989)	1.66 (0.759 - 3.629)	1.706 (1.248 - 2.333)	1.988 (1.283 - 3.081)	1.365 (1.068 - 1.745)	2.03 (1.496 - 2.756)
<b>Discharge Medication (Yes vs No)</b>							
Aspirin		0.301 (0.135 - 0.672)	0.308 (0.088 - 1.076)	0.499 (0.322 - 0.773)	0.869 (0.523 - 1.433)	0.697 (0.501 - 0.970)	1.052 (0.711 - 1.557)
Beta Blocker		0.208 (0.095 - 0.455)	0.337 (0.094 - 1.207)	0.469 (0.320 - 0.687)	0.77(0.485 - 1.222)	0.520 (0.393 - 0.698)	0.939 (0.674 - 1.308)
Statin		1.046 (0.375 - 2.918)	0.255 (0.066 - 0.992)	0.551 (0.334 - 0.908)	0.745 (0.449 - 1.237)	0.615 (0.429 - 0.880)	0.65 (0.444 - 0.951)
ACEI or ARB		0.392 (0.153 - 1.006)	0.451 (0.121 - 1.673)	0.903 (0.545 - 1.496)	0.541 (0.348 - 0.841)	1.041 (0.712 - 1.523)	0.857 (0.616 - 1.194)

SBP, Systolic blood pressure; eGFR, estimated Glomerular filtration rate calculated using the MDRD formula; STEMI, ST elevation myocardial infarction; nSTEMI, non-ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker



1  
2  
3 **Contributors:** NG, IS, KK conceived the idea of the study and were responsible for the design of the  
4  
5 study. NG, RM were responsible for undertaking for the data analysis and produced the tables and  
6  
7 graphs. IS, KK, MJD provided input into the data analysis. The initial draft of the manuscript was  
8  
9 prepared by NG and IS and then circulated repeatedly amongst all authors for critical revision. IS was  
10  
11 responsible for the acquisition of the data and IS, NG, RM, KK and MJD contributed to the  
12  
13 interpretation of the results.  
14

15  
16  
17 **Funding:** This research received no specific grant from any funding agency in the public, commercial  
18  
19 or not-for-profit sectors. The work in this paper is part of the research portfolio supported by the  
20  
21 Leicester NIHR Biomedical Research Unit in Cardiovascular Disease. NG has received support by the  
22  
23 National Institute for Health Research, Collaboration for Leadership in Applied Health Research and  
24  
25 Care - Leicestershire, Northamptonshire and Rutland (NIHR CLAHRC for LNR) project for a PhD.  
26  
27

28  
29 **Competing interests:** None  
30

31  
32 **Ethical approval:** The study was approved by the local research ethics committee.  
33  
34

35 **Copyright/licence for publication:** The Corresponding Author has the right to grant on behalf of all  
36  
37 authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for  
38  
39 government employees) on a worldwide basis to the BMJ Group and co-owners or contracting  
40  
41 owning societies (where published by the BMJ group on their behalf), and its Licensees to permit this  
42  
43 article (if accepted) to be published in the Heart edition and any other BMJPG products and to  
44  
45 exploit all subsidiary rights, as set out in our licence.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Malmberg K, Yusuf S, Gerstein HC, *et al.* Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry. *Circulation* 2000;102:1014-1019.
2. McGuire DK, Emanuelsson H, Granger CB, *et al.* Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO IIb study. *Eur Heart J* 2000;21:1750-1758
3. Svensson A-M, McGuire DK, Abrahamsson P, *et al.* Association between hyper- and hypoglycaemia and 2-year all-cause mortality risk in diabetic patients with acute coronary events. *Eur Heart J* 2005;26:1255-1261
4. Capes SE, Hunt D, Malmberg K, *et al.* Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000;355:773-778
5. Wahab NN, Cowden EA, Pearce NJ, *et al.* Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? *J. Am. Coll. Cardiol* 2002;40:1748- 1754
6. Kosiborod M, Rathore SS, Inzucchi SE, *et al.* Admission glucose and mortality in elderly patients hospitalised with acute myocardial infarction. *Circulation* 2005;111:3078-3086
7. Cao JJ, Hudson M, Jankowski M, *et al.* Relation of chronic and acute glycaemic control on mortality in acute myocardial infarction with diabetes mellitus. *Am J Cardiol* 2005;96:183-186

- 1  
2  
3 8. Sinnaeve PR, Steg G, Fox KAA, *et al.* Association of fasting glucose with increased short-term  
4 and 6-month mortality in ST-elevation and non ST-elevation acute coronary syndromes. *Arch*  
5  
6  
7 *Int Med* 2009;169:402-409  
8  
9
- 10 9. Squire IB, Nelson CP, Ng LL, *et al.* Prognostic value of admission blood glucose concentration  
11 and diabetes diagnosis on survival after acute myocardial infarction; Results from 4702 index  
12 cases in routine practice. *Clin Sci (London)* 2010;118:527-535  
13  
14  
15  
16
- 17 10. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. *Eur Heart J*  
18 2001;26:328-331  
19  
20  
21  
22
- 23 11. De Caterina R, Madonna R, Sourij H, *et al.* Glycaemia control in acute coronary syndromes:  
24 prognostic value and therapeutic options. *Eur Heart J* 2010;31:1557-1564  
25  
26  
27
- 28 12. Ghoyal A, Mahaffey KW, Garg J, *et al.* Prognostic significance of the change in glucose level in  
29 the first 24h after acute myocardial infarction: results from the CARDINAL study. *Eur Heart J*  
30 2006;27:1289-1297  
31  
32  
33  
34  
35
- 36 13. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for  
37 long-term prognosis after myocardial infarction even in non-diabetic patients. *Diabetes Care*  
38 1999;22:1827-1831  
39  
40  
41  
42
- 43 14. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for  
44 hyperglycaemic patients without known diabetes who present with an acute coronary  
45 syndrome. *Heart* 2007;93:1542-1546  
46  
47  
48  
49
- 50 15. Schnell O, Schafer O, Kleybrink S, *et al.* Intensification of therapeutic approaches reduces  
51 mortality in diabetic patients with acute myocardial infarction: the Munich registry. *Diabetes*  
52 *Care* 2004;27:455-460.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Malmberg K, Ryden L, Efendic S, *et al*. Randomised trial of insulin-glucose infusion followed by  
4  
5 subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI  
6  
7 study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995;26:57-65  
8  
9
- 10  
11 17. Malmberg K, Ryden L, Wedel H, *et al*; DIGAMI 2 Investigators. Intense metabolic control by  
12  
13 means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2):  
14  
15 effects on mortality and morbidity. *Eur Heart J* 2005;26:650-661  
16  
17
- 18  
19 18. Herrett E, Smeeth L, Walker L, *et al*; MINAP Academic group. The Myocardial Ischaemia  
20  
21 National Audit Project (MINAP) Heart 2010;96:1264-67  
22
- 23  
24 19. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly  
25  
26 admitted to hospital with heart failure in the United Kingdom: historical cohort study. *BMJ*  
27  
28 2003; 327(7414):526-31  
29
- 30  
31 20. Thygesen K, Alpert JS, White HD. The Joint ESC/ACCF/AHA/WHF Task Force for the redefinition  
32  
33 of myocardial infarction. *Eur Heart J* 2007;28:2525-2538  
34  
35
- 36  
37 21. Garber AJ, Moghissi ES, Bransome ED Jr, *et al*; American College of Endocrinology Task Force  
38  
39 on Inpatient Diabetes Metabolic Control. *Endocr Pract* 2004;10:77-82  
40
- 41  
42 22. Kosiborod M, Inzucchi SE, Krumholz HM *et al*. Glucometrics in patients hospitalized with acute  
43  
44 myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation*  
45  
46 2008;117:1018  
47
- 48  
49 23. Norhammar A, Tenerz A, Nilsson G, *et al*. Glucose metabolism in patients with acute  
50  
51 myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.  
52  
53 *Lancet* 2002;359:2140-2144.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 24. Tenerz A, Lonnberg I, Berne C, *et al.* Myocardial infarction and prevalence of diabetes  
4  
5 mellitus, Is increased casual blood glucose at admission a reliable criterion for the diagnosis of  
6  
7 diabetes? *Eur Heart J* 2001;22:1102–1110  
8  
9  
10 25. De Mulder M, Oemrawsingh RH, Stam F, *et al.* Comparison of diagnostic criteria to detect  
11  
12 undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. *Heart* 2011;  
13  
14 10.1136/heartjnl-2011-300163  
15  
16  
17 26. Melchior T, Kober L, Madsen CR, *et al.* Accelerating impact of diabetes mellitus on mortality in  
18  
19 the years following an acute myocardial infarction. *Eur Heart J* 1999;20:973-978  
20  
21  
22  
23 27. National Institute for Health and Clinical Excellence. (2011) Hyperglycaemia in acute coronary  
24  
25 syndromes: management of hyperglycaemia in people with acute coronary syndromes. (CG  
26  
27 130). London: National Institute for Health and Clinical Excellence.  
28  
29  
30 28. Deedwaniap, Kosibirod M, Barrett E *et al.* Hyperglycaemia and acute coronary syndrome. A  
31  
32 scientific Statement from the American Heart Association Diabetes Committee of the Council  
33  
34 on Nutrition, Physical activity and Metabolism. *Circulation* 2008;117:1610-9.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE LEGENDS**

Figure 1: Unadjusted odds of 30-day mortality according to admission blood glucose concentration in people with and without diabetes.

The bars represent the number of people at various glucose levels. Solid lines indicate odds ratios while dotted lines indicate 95% confidence intervals. Solid bars and black lines indicate patients with diabetes. Clear bars and red lines indicate patients without Diabetes.

For peer review only